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“Omnis cellula a cellula“ (every cell comes from a cell)
Rudolf Virchow
“La vraie generosite envers I'avenir consiste a tout donner au present”
Albert Camus
“They are shallow animals, having always employed their minds about 
Body and Gut, they imagine that in the whole system of things there is 
nothing but Gut and Body” (on doctors)
Samuel Taylor Coleridge (1796)
ABSTRACT
The fundamental question of how restriction of differentiation potential and 
activation of lineage-specific gene expression in progenitor cells are regulated is 
at the heart of research into the molecular mechanisms of biology. The basic 
helix-loop-helix (bHLH) transcription factor SCL/TAL-1 serves as a paradigm for 
a transcription factor with pivotal roles in haematopoietic stem cell (HSC) 
specification, maturation of haematopoietic lineages as well as T-cell 
leukaemogenesis. Interestingly, it has been described as both a transcriptional 
activator and a repressor. However, the molecular mechanisms conferring these 
opposing functions are currently unknown.
As a first step towards characterising the role of SCL in haematopoiesis and 
leukaemogenesis, we performed a gain-of-function study using a transgenic 
mouse model over-expressing SCL. Although no leukaemia was observed, 
constitutive expression of SCL or a mutant lacking the DNA binding domain in 
HSCs and early progenitors caused a severe defect in T- and B-lymphopoiesis. 
This was likely due to an interaction with the important lymphoid regulator and 
SCL heterodimerisation partner E2A.
Then, we set up a proteomics strategy to identify protein partners of SCL in 
haematopoiesis. We isolated SCL-containing protein complexes in erythroid cells 
and megakaryocytes using a novel purification strategy based on in vivo 
biotinylation of SCL. Mass spectrometry analysis led to the identification of 
several previously unknown candidate partners including ETO-2, a member of
the ETO family of co-repressor proteins and SSDP2, a partner of LDB-1. Using 
several different approaches, we validated the SCL/ETO-2 interaction in cell lines 
as well as primary erythrocytes and megakaryocytes. We then identified Gfi-1 b, a 
critical regulator of erythropoiesis with repressive function and the co-repressor 
mSin3A as additional partners of SCL and ETO-2 in erythroid cells, but not 
megakaryocytes. Further characterisation in transactivation experiments and 
during in vitro differentiation of primary fetal liver cells led us to hypothesise that, 
in early erythropoiesis, ETO-2 might confer a repressive function to SCL.
In conclusion, this study gives a first insight into how the composition of the 
multimeric protein complexes including SCL might modulate haematopoietic 
differentiation and cell fate decision.
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CHAPTER I : GENERAL INTRODUCTION 
1 Haematopoiesis as a model for cell commitment and 
differentiation
During development and adult life, commitment and differentiation from a 
pluripotent progenitor cell to a lineage-restricted mature cell are modulated by the 
microenvironment, cellular interactions and the combined action of numerous 
signaling molecules and transcription factors. These processes involve progressive 
restriction of the differentiation potential of the progenitor cells and acquisition of 
lineage-specific patterns of gene expression by their progeny.
The haematopoietic system serves as an ideal model for studying the 
molecular and genetic basis of such a differentiation process. Blood lineages, 
which all derive from a pluripotent progenitor called the haematopoietic stem cell 
(HSC), are divided into two main groups : the myeloid and the lymphoid 
compartments (figure 1.1, differentiation). The former group consists of the red 
cells, megakaryocytes/platelets, granulocytes, basophils, eosinophils and 
monocytes/macrophages. The latter group comprises the T, B and NK (natural 
killer) cells. The haematopoietic system has to sustain high productivity and high 
diversity and needs to adapt to physiopathological conditions in order to keep the 
number of blood cells constant. The analysis of this tightly regulated process called 
haematopoiesis has been instrumental in elucidating the mechanisms underlying 
cell fate decision and cellular maturation.
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1.1 Haematopoiesis and ontogeny
Haematopoiesis is a highly conserved process in vertebrates1 and invertebrates 
and occurs at distinct anatomical sites during development. Studies of 
haematopoiesis in mammals (mouse), birds (chicken, quail) as well as lower 
vertebrates (zebrafish and xenopus) and insects (drosophila) have greatly 
contributed to our understanding of haematopoietic development and it has 
become apparent that there are two phases of haematopoiesis during ontogeny in 
these organisms (figure 1.2). Below, I have chosen a few examples that illustrate 
the high degree of conservation of haematopoietic development during evolution.
Blood cells are specified from mesodermal precursors and are produced 
through a first wave of primitive (embryonic) haematopoiesis, which begins in the 
extra-embryonic yolk sac (YS) blood islands in higher vertebrates and consists 
mainly of nucleated red cells2 (figure 1.1 and 1.2). The equivalent region in 
zebrafish (reviewed in3) is located intraembryonically and is known as the 
intermediate cell mass (ICM)3. In drosophila (reviewed in4), this embryonic phase 
of haemopoiesis is initiated by a population of hemocytes originating from the head 
mesoderm and by crystal cells near the anterior region of the gut5.
The first evidence suggesting that there was an independent intra- 
embryonic site for generation of definitive (adult) haematopoietic cells came from 
experiments performed by F. Dieterlen-Lievre and colleagues on chicken-quail 
chimeric embryos6. They showed that YS progenitors failed to produce definitive 
haematopoiesis but that an intra-embryonic region contained haematopoietic 
precursors able to generate blood cells found throughout life. These observations 
were then confirmed in other species. In mice, for example, before circulation is
Mouse
Embryo Adult
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AGM
.Bone marrow
A Schematic presentation of murine blood cell ontogeny
Primitive haematopoiesis is initiated in the yolk sac at 7.5 dpc and progressively replaced by 
by 9.5 to 11.5 dpc by definitive haematopoiesis arising from the AGM and by 12.5 dpc 
the fetal liver. In the adult animal, the main site of haematopoiesis is the bone marrow. 
AGM= aorta-gonad-mesonephros region
B Schematic presentation of Zebrafish blood cell ontogeny
In Zebrafish, the primitive sites of haematopoiesis starting from 12 hpf are the intermediate cell mass 
(ICM) and the rostral blood islands. Around 24 hpf this site is replaced by the AGM equivalent in the 
dorsal aorta. Adult haematopoiesis is initiated 4 dpf in the head kidneys. 
h/dpf= hours/days post fertilisation
Drosophila
C Schematic presentation of Drosophila blood cell ontogeny and haematopoiesis
In Drosophila, the first site of embryonic haematopoiesis is the head mesoderm. In early larval 
development haematopoiesis shifts to the lymph glands (left panels). Similar to the hierarchy of 
blood cell development in higher organisms, Drosophila blood cells arise from early precursors 
called hemocytes that will give rise to various haematopoietic lineages.
Zebrafish
Embryo
Rostral blood islands intermediate cell mass
primitive myelopoiesis primitive erythropoiesis
head kidneys
Plasmatocytes
phagocytosisEmbryo Larva
hemocytesHead
mesoderm [ ) )  Lamellocytes 
encapsulation
Crystal ceils 
wound-healing
Figure 1.2 Overview of the ontogeny of haematopoietic cells
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established, YS progenitors do not generate multipotent haematopoietic cells in in 
vitro assays whereas cells produced in the intra-embryonic aorta-gonado- 
mesonephros region (AGM, also called paraaortic splanchnopleura (PAS) at earlier 
developmental stages) do so7,8. It is now generally accepted that the transient 
wave of primitive erythropoiesis occurring at around 7.5 dpc (days post-coitum) is 
progressively replaced, by 9.5 to 11.5 dpc, by the second wave of definitive 
haematopoiesis first developing within the PAS/AGM and ensuring the generation 
of adult myeloid and lymphoid cells. As primitive haematopoiesis declines and 
circulation is established, cells produced in the the AGM are thought colonize the 
fetal liver (and to a much lesser extent the yolk sac) at around 11 dpc, which 
becomes the main site of blood production in mid- to late-gestation embryos9. 
Towards the end of gestation, another shift occurs and the bone marrow becomes 
the predominant site of definitive adult haematopoiesis (figure 1.2, top). Studies of 
haematopoietic development in Xenopus have confirmed the dual origin of 
embryonic and adult blood. In Xenopus embryos, the ventral blood island region 
(VBI, the YS equivalent) and the dorsal lateral plate (DLP) (aorta-gonad- 
mesonephros region (AGM) equivalent) derive from different blastomeres. In an 
elegant study involving lineage tracing, Ciau-Uitz et al. have shown that aortic 
clusters (or adult HSCs) derive from the blastomere that gives rise to the DLP10. In 
zebrafish, haemopoiesis moves from the ICM to the ventral wall of the dorsal aorta 
(AGM equivalent) before establishing itself in the adult kidney (figure 1.2, middle 
panel). In drosophila, the lymph glands become the main site of haemopoiesis at 
the late larval stages (figure 1.2, bottom panel).
15
1.2 Origin of the haematopoietic stem cell: search for the haemangioblast
In recent years, considerable effort has been put into trying to define the 
origin of the haematopoietic stem cell (HSC). The close spatial relationship 
between haematopoietic cells and angioblasts in both the extra-embryonic and 
embryonic mesoderm and the fact that endothelial and haematopoietic precursors 
share a number of transcription factors and surface markers suggest the existence 
of a common progenitor, the putative haemangioblast11,12(Figure 1.1, 
development). Indeed, targeted disruption of an endothelial marker in the mouse 
(vascular endothelial growth factor (VEGF) receptor-2, f l k l13) and mutation of the 
zebrafish cloche locus affect development of both blood and endothelial lineages14. 
Besides, several groups15'17 were able to show in in vitro differentiation assays that 
an embryonic stem (ES) cell-derived progenitor (called blast-colony forming cell) 
can produce adherent endothelial cells, as well as primitive and definitive erythroid 
cells, macrophages and neutrophils, thus confirming in vitro the existence of a 
common endothelial-haematopoietic precursor. However, until recently, the 
haemangioblast had not been isolated in vertebrate embryos, although several 
studies suggested that endothelial cells isolated from the lining of dorsal aorta and 
the AGM region possessed haematopoietic stem cell activity18'21. Since then, 
Huber et al have demonstrated the existence of cells displaying both vascular and 
haematopoietic activity in the embryo proper22. It is now generally accepted that 
clusters of HSCs appear on the floor of the dorsal aorta by budding from a 
hemogenic endothelium. In zebrafish, overlapping expression patterns of blood 
and endothelial genes in the posterior lateral mesoderm (PLM) also suggest the 
existence of haemangioblast-like cells23'25.
16
1.3 Functional and phenotypic analysis of HSCs
The earliest cell to be defined in the highly hierarchised haematopoietic 
system is the pluripotent HSC (Figure 1.1). This cell has been characterised both 
functionally in transplantation experiments and immunophenotypically using cell 
surface markers and dyes. Thus, it was defined by its long-term reconstitution 
capacity of all haematopoietic lineages in serial and competitive bone marrow 
transplantation experiments using tertiary recipients26,27. Only definitive HSCs 
originating from the PAS/AGM, but not primitive HSCs produced in the YS, can 
reconstitute bone marrow haematopoiesis in adult recipients28.
In addition, the phenotypic specification of this earliest adult haematopoietic 
stem cell has become more and more sophisticated. The murine c-kit+Lin'Sca+ 
(KLS) population clearly contains most of the cells with HSC potential. This KLS 
population can be further devided into CD38+CD34+ and CD38+CD34|0W cells. 
CD38+CD34+ are responsible for the immediate radioprotection of lethally 
irradiated mice, whereas CD38+CD34l0W cells have long-term reconstitution 
capacity for both myeloid and lymphoid cells29 and constitute the bone marrow 
stem cell pool. Besides, this HSC population effectively exports the vital dye 
Hoechst and represents the side population in the flowcytometric forward-sideward 
scatter30.
1.4 The precursor compartment and mature blood cells
The HSC gives rise to partially committed multipotent precursors, also called 
common lymphoid progenitor (CLP) and common myeloid progenitor (CMP). The 
CLP generates B, T and NK cells whereas the CMP give rises to the 
megakaryocyte-erythrocyte progenitor (MEP) and the granulocyte-monocyte
17
(GMP) progenitor at the origin of the macrophage/monocyte, 
granulocyte/neutrophil, basophilic and eosinophilic lineages (see Figure 1.1).
In the following paragraph, I wish to briefly outline the steps involved in the 
differentiation of the CLP and the MEP into their respective lineages. 
Lymphopoiesis
Lymphocyte development occurs through a common lymphoid progenitor 
(CLP), which has restricted lineage potential. Thus, isolation of CD10+/CD19- 
lymphoid progenitors from bone marrow revealed that these cells were capable of 
developing into T, B, and NK, or lymphoid dendritic cells, but not into myeloid or 
erythroid cells31. Moreover, Kondo et al showed convincingly that a single cell of a 
rare population of interleukin 7 receptor expressing bone marrow cells can give rise 
to T and B, but not myeloid cells32. CLPs develop into three distinct cell types : B 
and T lymphocytes and NK cells. Beginning with lineage commitment and 
continuing throughout differentiation, both B and T lymphocytes develop through 
stages that can be defined by the rearrangement of antigen receptor genes, the 
acquisition or loss of cell surface and intracellular proteins, and responses to 
growth and survival factors (see chapter III and figure 3.1).
A fundamental difference between mammalian B and T cell development 
lies in the anatomical site in which it occurs. B cell development can be divided into 
two stages : an antigen-independent stage that occurs primarily in fetal liver and 
bone marrow, and an antigen-dependent stage that occurs in secondary lymphoid 
organs. T cell development on the other hand consists of an essential progenitor 
migration step from fetal liver or bone marrow to the thymus. The precise 
phenotype of this migratory progenitor is unknown and relatively little is known 
regarding the mechanisms that attract marrow lymphoid progenitors to the thymus,
18
but chemotactic factors produced by the thymic microenvironment probably play a 
role33. Although historical views have assumed that the thymus only functions in 
young humans and mice because of its well-known involution, this viewpoint has 
been seriously challenged and it now appears that the T cell pool is replenished via 
a functional thymus throughout life34.
Erythropoiesis
The existence of a common megakaryocyte/erythroid precursor was first 
suggested upon study of erythroleukaemic and megakaryoblastic cell lines 
showing co-expression of erythroid and megakaryocytic markers35-37. 
Subsequently, bipotent progenitors were characterised in culture assays38 and 
isolated by virtue of their cell surface phenotype39-41.
Erythropoiesis is a complex multistep process encompassing the 
differentiation of the MEP to mature erythrocytes42 (figure 1.5 A, B). The steps 
involved in this process include the differentiation to early erythroid progenitors 
(burst-forming units-erythroid, BFU-E), then to late erythroid progenitors (colony- 
forming units-erythroid, CFU-E) and finally to the morphologically recognisable 
erythroid precursors. A key event of the late stages of erythroid differentiation is 
nuclear condensation, followed by extrusion of the nucleus to produce enucleated 
reticulocytes and finally mature erythrocytes. As differentiation proceeds, 
haemoglobinisation of the cells increases, cells express Ter119 and downregulate 
the surface marker molecule CD 71.
A modei to study erythroid differentiation
The Murine Erythroid Leukaemia (MEL) cell line serves as a practical model 
for erythroid differentiation. It was first derived from murine proerythroblasts 
transformed with the Friend leukaemia virus43. Morphologically, these cells have
19
some of the characteristics of immature erythroblasts, but they can be induced to 
initiate erythroid differentiation by the addition of dimethylsulfoxide (DMSO) to the 
culture medium44. Globin mRNA can be detected after 2 days of induction with a 
maximum peak after 4 days. Around this time, cells that stain positive for haem
45appear .
Megakaryocytopoiesis
The study of megakaryocytopoiesis has been particularly difficult because 
of the relative infrequency of megakaryocytes in the bone marrow and their fragility 
in vitro. However, it is now generally accepted that megakaryocytes derive from the 
MEP (see above). This is also supported by the close relationship between early 
erythroid and megakaryocyte differentiation at the molecular level46. The transition 
between multipotent precursor and megakaryocyte-restricted progenitors involves 
expression of the c-mpl oncogene or thrombopoietin receptor47,48. The earliest 
definable committed progenitor, the megakaryocytic burst forming cell (BFU-MK) 
gives rise to the GPIIbGPIIIa positive megakaryocytic colony forming cell (CFU- 
MK), which eventually stops mitosis and enters endomitosis leading to production 
of polyploid precursors with scant cytoplasm (figure 1.6 A, B). These cells produce 
Platelet factor 4 (PF4) and von Willebrandt Factor (vWF). Upon completion of 
endomitosis, the cells have acquired a DNA content of up to 128N (where 2N is the 
DNA content of a somatic cell), develop a mature cytoplasm and eventually start to 
release platelets. An individual mature megakaryocyte produces in the order of 
2000 to 3000 platelets.
A model to study megakaryocyte differentiation 
L8057 is a murine megakaryoblastic cell line derived from irradiated mice. 
This cell line can be induced to differentiate along the megakaryocyte/platelet
20
lineage expressing increased levels of the megakaryocyte specific enzyme 
acetylcholinesterase, megakaryocytic/platelet-specific surface antigens such as 
GPIIb, and showing increased ploidy following incubation with phorbol diester49. 
Thus, L8057 cells provide a cellular model for studying the characteristics of 
megakaryocytic differentiation.
2 MOLECULAR EVENTS UNDERLYING THE PROGRESSIVE 
DIFFERENTIATION PROGRAM OF HAEMATOPOIETIC CELLS
Haematopoietic cells face at least four choices during their differentiation 
process (Figure 1.3). They can self-renew or proliferate, differentiate to more 
committed precursors, undergo apoptosis or enter quiescence. Clearly, the 
regulators and molecular events that can influence these decisions are likely to 
play critical roles during normal haematopoietic differentiation.
2.1 Differentiation of the haematopoietic stem cell: instructive or
stochastic model ?
It is now generally accepted that the proliferative and self-renewal capacity 
of the adult HSC declines with differentiation. At the same time, lineage choice 
becomes more and more restricted as highly specialised transcriptional programs 
are switched on. Thus, the modern concept of « sternness » implies that, in 
contrast to terminally differentiated cells, the haematopoietic stem cell is still 
receptive to multiple fate decisions. Although much progress has been made, the 
molecular mechanisms underlying the progressive commitment and differentiation 
of haematopoietic cells remain to be fully elucidated. Two contrasting lines of 
thought dominate the current view of what directs cell fate decisions: the
21
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stochastic and the instructive hypothesis. The stochastic model implies that 
lineage choice is a cell-intrinsic process that occurs at random whereas the 
instructive hypothesis stresses the importance of external signals from the bone 
marrow environment or haematopoietic niche for lineage choice of the HSC. 
Therefore, one of the central questions of ancient and modern philosophy, namely 
the role of randomness and determination for the direction of life has entered the 
haematopoietic field50.
Low levels of lineage specific gene expression have now clearly been 
demonstrated in purified stem cells51'53 suggesting the concept of multilineage 
priming. This has led to the hypothesis that loss of multipotency may be a 
stochastic event characterised by a decrease in both the diversity of molecules 
found in the cell and in the complexity of cellular dynamics54. However, there is 
also increasing evidence of the importance of the bone marrow microenvironment 
and cell-to-cell communication for cell fate decision52
Taking into account the experimental evidence, it now seems that fate 
determination of haematopoietic cells is the result of both stochastic and instructive 
events occuring within the crosstalk between signaling pathways, cytokine 
responses and transcription factors50.
2.2 Signaling pathways
It has been proposed that mechanisms regulating haematopoietic stem cells 
elaborate on those that establish morphogenesis during embryonic development. 
Indeed, several signaling pathways that determine cell fate in model organisms 
have been shown to expand HSCs. These include Wnt55, Notch 156, Sonic 
Hedgehog57 and bone morphogenetic protein (BMP)58. Besides, a survey of gene 
expression in stem cells identified genes involved in cell-cell communication52,
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indicating that these cells are responsive to environmental signals. Indeed, 
haematopoietic cells require constant input from their environment for their survival 
and in the absence of signals such as c-kit and the JAK-STAT pathway undergo 
apoptosis59. However, these signals do not appear to regulate cell differentiation60. 
It is therefore plausible to postulate that commitment to differentiation occurs 
spontaneously and that signals from the environment are required to maintain 
sternness. This is illustrated by the fact that LIF and the STAT-3 pathway61 or the 
down-stream acting homeodomain protein Nanog62 are required to maintain 
totipotency of the embryonic stem cells in vitro. Finally, as HSCs undergo further 
lineage restriction and the cells are faced with a two-lineage choice instead of a 
multilineage option, the extrinsic signals that govern the initial decision between 
self-renewal and commitment to differentiation are recycled for other functions. 
This is exemplified by the decisive role of Notch 1 at several early and late branch 
points of lymphoid lineage development (for review 63). Taken together, these 
observations indicate that evolutional conserved signaling pathways important 
during embryonic development are reutilized in the adult to regulate HSC numbers 
and to sustain cell type diversification.
2.3 Cytokines
In addition to these conserved pathways, a network of cytokines only found 
in vertebrates transmits external signals to the cell. Two of these cytokines, 
erythropoietin (EPO) and thrombopoietin (TPO), are essential for the production of 
erythrocytes and megakaryocytes. Interestingly, they share a high degree of 
homology and both act via the Janus family tyrosine kinase 2 (JAK2) -Signal 
transducer and activator of transcription (STAT) 5 pathway. Epo-receptors are 
maximally expressed on erythroid cells at the CFU-E and proerythroblast stage
and the main function of Epo signaling appears to lie in the prevention of 
apoptosis. TPO on the other hand acts via its receptor c-mpl on expansion of 
megakaryocyte precursors and terminal differentiation. The debate over the role of 
cytokines in cell fate determination has focused on the question whether they are 
permissive or instructive, similar to the question of stochastic versus deterministic 
mechanisms of lineage choice. Several lines of evidence suggest a permissive role 
for cytokines in allowing the survival of cells that are already committed to one fate. 
This is best exemplified by the fact that erythroid colony formation is observed in 
EPO receptor deficient cells that are stimulated via other types of receptors64, 
suggesting that erythroid cell differentiation is intrinsically determined and that EPO 
is required only to sustain cell survival. However, several approaches also provide 
evidence in support of a more active role of cytokines in cell differentiation. For 
example, thrombopoietin (TPO), was found to be a specific factor that controls 
megakaryocytic cell proliferation and maturation65,66. Abrogated expression of its 
receptor Mpl in transgenic mice results in thrombocytopenia and an 85% decrease 
in the number of megakaryocytes in the bone marrow67. Moreover, GM-CSF is 
required for the generation of granulocytes and macrophages in vitro and skews 
the output of multipotent cells towards these lineages60. Besides, it seems that 
cytokines can also regulate the expression levels of transcription factors, ie G-CSF 
induces granulocyte differentiation through up-regulation of C/EBPe and 
C/EBPa,thus altering ratios beween C/EBPa and another transcription factor 
called PU.1 essential for myeloid development68. In addition, c-kit signaling 
downregulates the E12 transcription factor and prevents progression of the B 
lineage at the pro-B to pre-B transition. This indicates that cytokines can alter 
transcription factor dosage, thereby shifting the transcription network towards a
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particular path, and thus supporting a more instructive role for cytokines in 
regulating haematopoietic cell differentiation.
2.4 Transcriptional control of haematopoiesis
The molecular machinery responsible for controlling transcription by RNA 
polymerase II (RNA pol II) is considerably more complex than previously 
anticipated. Over twenty years of transcription biochemistry and genetics have 
identified a battery of proteins that aid or abate RNA pol II access to specific 
regulatory DNA sites, the promoters. The first of these regulatory proteins to be 
discovered were the sequence-specific DNA binding transcriptional factors. Next to 
be characterised were the general transcription factors, a set of highly conserved 
proteins responsible for escorting RNA pol II to the promoter. The more recent 
regulators to be characterised are the co-activators, co-repressors and chromatin 
remodelling complexes69.
In the ensuing section, I wish to delineate our current understanding of how 
sequence-specific haematopoietic transcription factors and their co-factors direct 
the differentiation of the HSC into erythroid, megakaryocyte and lymphoid lineages. 
Our current understanding of the role of sequence specific transcription factors in 
the establishment of the haematopoietic hierarchy is summarised in figure 1.4.
2.4.1 Sequence-specific transcription factors
Clearly, one of the key elements in the process of haematopoietic 
differentiation and progressive lineage restriction is the control of gene expression 
via sequence-specific transcription factors. These proteins are multimodular and 
belong to different families. Expression of these factors can be ubiquitous or 
lineage-specific and binding to DNA is mediated directly or indirectly via specific
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DNA sequences. Interestingly, with the exception of GATA-2, all key 
regulators of haematopoietic differentiation are involved in the pathogenesis of 
leukaemia.
Haematopoietic transcription factors have been discovered through 
promoter studies (ie. GATA-170,71, NF-E272), because of their involvment in 
leukaemias (see below) or, more recently, through genetic screens in Drosophila, 
C. elegans or zebrafish.
As most of transcription factors important for haematopoiesis in mammals 
have orthologues in lower vertebrates, these genetic studies have been very 
informative. As an example, more than 50 mutants with defective haematopoiesis 
were isolated from large scale mutagenesis screens in zebrafish73,74.
For some mutants, the underlying mechanisms producing the phenotype remain 
unclear. This is illustrated by the zebrafish cloche mutant which was first dicovered 
as a spontaneous mutation in fish from an Indonesian fish farm and was named 
after its bell-shaped heart (cloche=french for bell). It is characterised by an almost 
complete absence of primitive haematopoietic activity in the ICM and the rostral 
blood islands and cardiac abnormalities. This is thought to be due to a disruption of 
the specification of haematopoietic and endothelial systems (for review3,75). 
Clearly, the characterisation of the function of the proteins encoded by cloche and 
other mutants will give invaluable information to dissect the molecular mechanisms 
involved in haematopoiesis.
On the other hand, some mutants are defined by a specific defect in one single 
transcription factor gene. For example, the zebrafish loss-of-function mutant vlad 
tepes harbors mutations of the critical haematopoietic regulator GATA-176 and the 
severely anaemic mutant « kugelig » (named after the German word for spherical),
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which was identified in a mutagenesis screen in Tubingen, was recently shown to 
carry a mutation of the Hox gene regulator cdx4 77.
Loss-of-function studies in mammals have been of invaluable help in trying 
to define the role of key transcriptional regulators. Conventional knock-outs have 
greatly increased our understanding of the transcriptional mechanisms underlying 
cell fate decisions. Thus, analyses of mouse knock-out models have identified 
some of the lineage-restricted transcriptional regulators that play an active role in 
the specification and biology of the HSC. More recently, conditional knock-out 
strategies have overcome the limitations of conventional approaches and allowed 
the examination of the role of these regulators in more differentiated 
haematopoietic cells. Thus, it has become apparent that all of them also fulfill 
important roles later on in the differentiation to specific lineages (figure 1.4). 
Specification and biology of HSCs
A paradigm of such a transcription factor involved both in HSC specification, 
subsequent blood lineage differentiation and leukaemia is the bHLH oncoprotein 
SCL/TAL-1. As such, SCL is a key player in the specification of the primitive and 
definitive HSC, but not for the biology and maintenance of HSCs78,79.
Besides SCL, other nuclear proteins, LMO-2 and Runx1/AML-1/CbF-|3 have been 
shown to play pivotal roles in the early stages of haematopoietic development. 
LMO-2 inactivation results in failure of erythropoiesis at the yolk sac stage80 as well 
as in a block in definitive haematopoiesis in the adult81, whereas Runx-1 is 
absolutely required for the development of definitive haematopoiesis at the fetal 
liver stage82. However, it is no longer indispensable once haematopoietic stem 
cells are formed83. In addition, the GATA family of zinc finger proteins plays a 
critical role in haematopoietic development. Loss of GATA-2 offers a clear example
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of a factor crucial for the maintenance and proliferation of the HSC, and GATA-2 
null cells exhibit a broad haematopoietic deficit84. Gfi-1 on the other hand, restricts 
proliferation and preserves functional integrity of haematopoietic stem cells in 
competitive repopulation and serial transplant assays85. Besides, the Ets 
transcription factor Tel/ETV6 has recently been identified as the first transcriptional 
regulator that is selectively required for the survival of adult HSCs through a 
conditional knock-out strategy86.
Progenitor cells
In addition to their role at the HSC level, all transcription factors or their 
homologues mentioned above are also implicated in the differentiation of 
haematopoietic progenitors.
SCL, for example, is required for the differentiation of erythroid progenitors and 
megakaryocytes at the colony forming unit stage87'89. Loss of GATA-1 impedes 
survival of erythroid progenitors as well as terminal differentiation of erythroid cells, 
although the consequences for definitive cells are blunted by partial redundancy 
with GATA-290. GATA-1 is essential for primitive and definitive erythropoiesis and 
GATA-1 deficient mice die by 12.5dpc due to inefficient erythropoiesis in the yolk 
sac91. Besides, in vitro and chimeric analyses of the knock-out92,93 and knock 
down94,95 models of GATA-1 resulted in arrested embryonic erythropoiesis and a 
maturation arrest of definitive haematopoiesis at the proerythroblast stage. Loss of 
GATA-1 expression in megakaryocytes also leads to defects in maturation in this 
lineage96,97.Likewise, mice missing the lymphoid factor Ikaros lack T- or B lymphoid 
cells, and their precursors98. PU. 1-null mice lack cells of disparate haematopoietic 
lineages, namely myeloid and lymphoid cells99. More surprisingly, loss of some 
broadly expressed factors results in lineage-selective deficits. For example,
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targeted disruption of the E2A gene blocks B-lymphopoiesis, but does not interfere 
with development of other tissues in which it is normally expressed100,101.
Terminal differentiation
Conversely, some cell-restricted transcription factors appear to be required only 
after lineage commitment. For example, in terminal myeloid differentiation, Gfi-1 is 
required for neutrophil differentiation102 and the CCAAT/enhancer-binding-protein-a 
(C/EBP-cx) coordinates cellular differentiation with growth arrest in neutrophils103. In 
erythro-megakaryocytic adult hematopoiesis, loss of p45 NF-E2 and FOG-1 
expression impairs maturation of both the erythroid and megakaryocytic 
lineages104'106, and EKLF deficiency produces a stage-specific, gene selective 
defect: failure of adequate transcription of the adult p globin gene107.
Taken together, these data illustrate that a complex interplay between external 
signaling pathways and transcription factors gives rise to the progressive lineage 
restriction and differentiation of the HSC and establishes the hierarchy of all blood 
cell lineages including the erythroid (figure 1.5) and megakaryocyte (figure 1.6) 
compartment.
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2.4.2 Leukaemogenic transcription factors
As mentioned above, many of these transcription factors were originally 
cloned from chromosomal translocations in human leukaemia. Indeed, transcription 
factor genes constitute the most frequent target of leukaemic translocations, 
emphasizing the critical role of these « master » regulatory proteins in the control 
of blood cell development108. Activation of transcription factor genes by 
chromosomal translocations takes two main forms. In T- or B- cell progenitors, 
such genes are frequently mobilised into the vicinity of genes encoding discrete 
chains of the T-cell receptor (TCR) or immunoglobulin (Ig) molecules, resulting in 
inappropriate expression of the translocated proto-oncogenes. More commonly, 
the coding exons of genes disrupted by a reciprocal translocation are incorporated 
into a single fusion gene, which generates a chimeric protein with unique 
properties including loss-of-function or dominant negative alterations.
Translocations that inappropriately activate transcription factor genes in 
acute lymphoblastic leukaemia and acute myeloblastic leukaemia show remarkable 
specificity for haematopoietic cells blocked at defined stages of differentiation. This 
property suggests that the different oncoproteins produced by these chromosomal 
changes specifically interfere with the transcriptional networks that normally 
function in concert with growth factors and their receptors to regulate 
haematopoiesis109. The progression to leukaemia then depends on additional 
mutations that promote the survival of developmentally arrested cells (two-hit 
theory).
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2.4.3 Mechanisms of action
In recent years, it has become clear that the principles governing the 
transcription factor network are far more complex than previously thought.
Dosage
One of the most important realisations was that transcription factor dosage 
plays a central role in the determination of cell fate as exemplified by the E2A 
gradient in lymphoid differentiation110,111 and the PU.1 dosage effects regulating B 
cell versus macrophage development112.
Protein-protein interactions: antogonism versus cooperation
Transcription factors commonly exert their function via protein-protein 
interactions. In this molecular crosstalk, different nuclear proteins can both 
antagonise each other or cooperate together in multimeric protein complexes.
As exemplified by the GATA-1/PU.1 interaction, specific transcription factors 
may be able to antagonise each other by inactivating DNA-binding domains113 or 
by blocking protein interaction domains114 thereby determining cell fate.
Besides, these factors cooperate as part of multimeric large molecular 
weight protein complexes with activating or repressing functions. The molecular 
mechanisms by which the same sequence-specific transcription factor can activate 
or repress gene expression are poorly understood, but it seems that co-factor 
exchange is commonly used to regulate levels of transcriptional activation. Thus, it 
has been shown that different classes of transcription factors can recruit both co­
repressors and co-activators115,116 as recently exemplified by NF-E2p18/MafK 
whose dimerisation partner switches from co-repressor to co-activator during MEL 
cell differentiation117. These data illustrate the importance of protein-protein 
interactions between transcription factors and their co-factors for haematopoietic
35
cell fate determination. They also suggest that the classical view of haematopoietic 
lineage determination via positive activation of unique gene expression programs is 
too simplistic. Instead, it seems that lineage-specific transcription factors 
simultaneously exert inhibitory effects on alternate lineage gene programs by either 
directly antagonizing other transcription factors or by recruiting inhibitors of 
transcription to large multimeric complexes.
As illustrated in the next paragraph, the mechanism through which co-factors of 
sequence specific transcription factors confer activation or repression frequently 
involves epigenetic processes such as histone modifications or DNA methylation.
2.4.4 Transcription co-factors and the context of chromatin 
A general and very much simplified schematic overview of the mechanisms 
surrounding the chromatin modifications involved in directing gene expresssion is 
shown in figure 1.7 (for review118'121).
The eukaryotic genome is packaged into the compact state of chromatin that forms 
the scaffold from which the fundamental nuclear processes of transcription, 
replication and DNA repair occur. Chromatin is composed of nucleosomes that are 
comprised of 145-147 base pairs of DNA wrapped around an octameric core 
containing two molecules each of histones H2A, H2B, H3 and H4. The H1 linker 
stabilizes the assembly of the octameric core into higher order structures. The N- 
terminal portion of the core histones is the site for post-translational modifications 
such as methylation, phosphorylation, ubiquitylation and acetylation. These post- 
translational histone modifications have been implicated in replicational and 
transcriptional activity122. Chromatin remodeling via ATP-dependent hydrolyses of 
the Swi/SNF family of co-activators (for review123) and modifications by histone 
acetylases (HAT, like p300/CBP, PCAF) or histone deacetylases (HDAC)
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represent a fundamental mechanism of transcriptional regulation. It has been 
proposed that histone acetylation or specific methylation at histone 3 lysine 4 
weakens the interactions of histones with DNA and induces alteration in 
nucleosome structure, enhancing accessibility of targeted promoters to 
components of the transcriptional machinery124.
Conversely, decreased histone acetylation due to the action of HDACs or 
acetylation at histone 4 lysine 12 is thought to lead to less accessible chromatin 
conformation, resulting in repression of transcription125,126. Unlike activation 
complexes, in which co-activators have intrinsic HAT activity, one of the functions 
of co-repressors, including N-CoR127, SMRT128 and mSin3A129, is it to recruit 
HDACs to large multi-protein repression complexes. These complexes also contain 
sequence specific transcription factors and other molecules such as the ETO 
family of co-repressor proteins130,131.
Deacetylation might then prompt methylation of histone tails by histone 
methyl transferases like Su-var leading to condensation of the chromatin structure 
and subsequent recruitment of DNA methyl transferases. Methylated DNA is bound 
by methyl CpG binding proteins such as MeCP and HP1, which induces higher 
order formation of heterochromatin. At this stage, the DNA is compacted and 
unaccessible. However, to which extent this degree of heterochromatin formation is 
irreversible remains unknown.
In summary, it now seems plausible that, analogous and complementary to 
the genetic code identified 40 years ago, the different histone and chromatin 
modifications described above, encode for a « histone code », that further defines 
transcriptional regulation118.
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2.4.5 The role of co-repressors in leukaemia
Inappropriate repression of genes required for cell differentiation has been 
linked to several forms of cancer, particularly to acute leukaemia. For example, in 
acute promyelocytic leukaemia (APL), the retinoic acid receptor (RAR) fusion 
proteins (e.g. PML-RAR or PLZF-RAR) can interact with components of a co­
repressor complex containing HDACs132. Additionally, it has now become apparent 
that the fusion protein AML1/ETO acts in an analogous way by recruiting HDAC 
containing repressor complexes to AML-1 DNA binding sites, thereby 
inappropriately inactivating genes important in haematopoietic 
differentiation130,131,133,134. Therefore, molecules inhibiting the activity of HDACs 
have gained much interest as possible new therapeutic agents in the management 
of acute leukaemia135'138. More recently, it has been shown that expression of the 
AML/ETO fusion protein (or ETO on its own) in haematopoietic cells impedes 
binding of the co-activator p300 to E2A139, suggesting that repression of gene 
activation might be mediated by blocking the interaction between co-activator and 
transcription factor. However, the exact role of ETO proteins in normal and 
malignant haematopoiesis remains to be elucidated.
3 THE ONCOPROTEIN AND bHLH TRANSCRIPTION 
FACTOR SCL/TAL-1
3.1 History of discovery
The story begins with a case report of a 16-year old boy who presented with acute 
lymphoblastic leukaemia (ALL) of an early T-cell phenotype and resistant to
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standard therapeutic agents140. Surprisingly, after receiving the adenosine 
deaminase inhibitor 2’deoxycoformycin, the leukaemic cells underwent 
transformation into myeloid cells. Unfortunately, the patient died due to extensive 
tissue infiltration with cells of a promyelocyte morphology. Both before and after the 
transformation, leukaemic blasts carried a translocation between chromosome 
1p32-33 and the T-cell receptor locus on chromosome 14q11. The investigators 
established a cell line called DU.528 carrying the same cytogenetic abnormality 
and recapitulating the stem cell phenotype in vitro141. However, since then, there 
have been no further reports that leukaemias carrying this type of translocation 
behaved in a similar way after treatment. When the breakpoint was isolated, it 
became apparent that as a result of the translocation a new gene on chromosome 
1 was abberantly activated under the control of the TCR locus. The gene was 
cloned independently by several groups and given the name STEM CELL 
LEUKAEMIA (SCL, also called Tal-1 and Tcl5)142_146. Although we now know that 
abberant expression of SCL leads to leukaemia of the early T cell type and not to 
stem cell leukaemia, this name remains very appropriate, given SCL’s pivotal 
function in fate determination of the early haematopoietic stem cell.
3.2 Expression profile
During embryogenesis, SCL is first expressed in the presumptive 
haemangioblast147. Then, SCL is present in the HSC and the most immature 
progenitors, but becomes downregulated as differentiation proceeds into most 
lineages40,148'151. However, SCL remains expressed in erythroid cells, 
megakaryocytes and mast cells152'156.
Outside the haematopoietic system, SCL expression has been observed in 
endothelial and neurogenic tissues157'159.
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3.3 Regulation of sc/gene expression
Two promoters in alternative 5’ exons have been identified in both the human and 
murine scl gene160,161 together with a third promoter within the gene whose function 
remains to be elucidated162. The two 5’ promoters exhibit lineage restricted activity. 
Promoter 1a is regulated by GATA-1, SP1 and SP3 and is active in transient 
reporter assays in erythroid and mast cells, but not in T-cells. Promoter 1b is 
regulated by PU-1, SP1 and SP3, and is active in mast cells and early CD34+ 
myeloid precursors163-166. In addition, multiple enhancer elements have been 
identified allowing expression of the scl gene in a chromatin context167'170. Thus, 
reporter assays in transgenic mice have demonstrated a role for the upstream 
enhancers in directing scl gene expression to neurogenic and endothelial tissue 
whereas the downstream enhancer elements targeted scl gene expression to the 
haematopoietic and endothelial systems171-173. Furthermore, it was shown in 
rescue experiments that stem cell specific enhancer elements are able to re­
establish the formation of haematopoietic progenitors in a scl-/- background174,175. 
In the same experimental approach, the scl+18/19 stem cell enhancer directs 
transcription to both haematopoietic precursors and endothelial cells through 
binding of Fli-1 and Ets factors170.
In view of the discordant protein and mRNA levels of SCL in erythroid 
differentiation, it has been postulated that other mechanisms in addition to these 
c/s-regulatory elements must be responsible for fine tuning of protein turn over176, 
although these post-transcriptional regulatory events remain to be uncovered.
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3.4 Structure
SCL is a member of the bHLH family of transcription factors
These transcription factors share a common basic helix-loop-helix (bHLH) domain 
which mediates sequence-specific interaction with DNA through the basic 
domain177,178 and promotes homo- or heterodimerization and protein-protein 
interaction through the HLH domain179,180. bHLH proteins have been subgrouped 
into seven different classes181. Of these, class I includes the ubiquitously 
expressed E proteins represented by the E2A gene products E12/47, HEB and E2-
2. All members of this group share a significant homology in their two 
transactivation domains and are conserved throughout evolution.
Class II bHLH proteins are tissue specific and include MyoD182 or Neuro D183. 
Class V members are represented by the Id proteins. They lack the DNA binding 
domain and act as dominant-negative regulators of class I and class II proteins184.
SCL belongs to the family of class II bHLH transcription factors and 
heterodimerizes with the class I bHLH proteins E2A 181-185-186. These heterodimers 
recognize a specific nucleotide motif, CANNTG, termed the E-box and were initially 
thought to function in transcriptional regulation via direct DNA-binding.
Core region; bHLH domain
Although important domains have been mapped to the Nt and Ct regions of SCL in 
transactivation assays in heterologous cells167,187, a structure-function study 
performed in SCL-null ES cells has shown that the bHLH domain is the core region 
of the protein. This study convincingly demonstrated that a construct containing the 
minimal bHLH region of SCL was fully active in generating primitive and definitive 
haematopoiesis188.
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« To bind or not to bind DNA «
The classical view that transcription factors act via direct binding to DNA has 
recently been challenged by the observation that transcription factors act in the 
context of multi-subunit protein complexes and do not necessarily require a DNA- 
binding domain to exert their function. The structure-funotion study of SCL has 
given further proof that transcription factor function can be divided into DNA- 
binding dependent and independent actions.
In this context, it has been shown in SCL-/- ES cells and in the zebrafish 
mutant cloche (see chapter 2.4.1) that DNA-binding defective mutants are able to 
specify HSC and restore primitive haematopoiesis. However, these mutants were 
unable to rescue maturation of definitive erythroid cells and megakaryocytes188. In 
accordance to this data, at a molecular level, Lecuyer et al demonstrated that 
direct DNA-binding of SCL on the c-kit promoter is not necessary for activation of 
c-kit expression in a progenitor cell line189, whereas maximal activation of the GPA 
promoter in mature erythroid cells requires SCL DNA-binding190.
As far as T-ALL is concerned, two mouse models have now convincingly 
shown that the DNA-binding activity of SCL is not required to reproduce a 
preleukaemic or leukaemic phenotype191,192.
Therefore, it is likely, that, to specify HSC and in leukaemogenesis (as will 
be described below), SCL acts through its HLH domain by protein-protein 
interaction.
The HLH region
In order to define residues within the SCL HLH domain necessary for the 
haematopoietic function of SCL, a detailed mutational analysis of this region was 
performed193. This study showed that most of the amino acids in the loop and a
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phenylalanine residue in helix two are crucial for SCL function in haematopoietic 
specification (summarised in figure 1.8). Importantly, introduction of these residues 
is sufficient to convert the muscle-specific HLH domain of Myo-D into one capable 
of rescuing haematopoiesis from SCL-/- ES cells. It is very likely that some if not all 
the residues thus defined mediate protein-protein interactions.
Post-translational modifications
Post-translational modifications of SCL influence both its function as a regulator of 
erythroid-megakaryocytic differentiation and its DNA-binding affinity.
As a result of multiple transcription initiation sites within the scl gene, the SCL 
protein exists in several different forms containing different N-terminal portions of 
the full length protein while retaining the bHLH domain142,160,161. The distribution of 
these SCL isoforms is cell type specific, suggesting that they may influence cell 
fate depending on their ability to transactivate downstream target genes194. In this 
context, it has recently been demonstrated that SCL isoform production is 
controlled by a small open reading frame which is responsive to signaling 
pathways that modulate translation initiation factors. This study concluded that 
different isoforms may direct differentiation towards the erythroid or 
megakaryocytic lineages195.
Further posttranslational modifications include phosphorylation of serine 
residues and acetylation. Thus, phosphorylation of serine residues 196'197 can 
influence the DNA-binding activity of SCL. Acetylation of SCL by the histone 
acetyltransferases p300/CBP and p/CAF promotes erythroid differentiation198,199.
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3.5 SCL function
In normal haematopoiesis, SCL plays crucial roles at different stages of 
development.
SCL is indispensable for generation of primitive and definitive 
haematopoietic stem cells
Different approaches convincingly show that SCL is required for the commitment of 
the haemangioblast to a haematopoietic fate148'200'205. Gain-of-function studies in 
zebrafish also suggest that SCL can specify the haemangioblast from early 
mesoderm24 and together with LM02 induces early blood and endothelial genes all 
along the anterior-posterior axis206.
Besides, SCL knock-out mice die at 9.5 dpc due to the complete absence of 
primitive haematopoietic cells, revealing that SCL is absolutely required for 
primitive haematopoiesis87,88.
Further studies using SCL-/- ES cells, both in in vitro differentiation cultures and in 
vivo in chimeric mice, showed that lack of SCL activity also induces a complete 
absence of all definitive haematopoietic lineages and concluded that SCL was 
indispensable for the generation of both primitive and definitive blood cells89,207. 
These findings have been further substantiated by a study using a conditional 
knock-out strategy, which revealed that although SCL is required for the generation 
of haematopoietic stem cells, its inactivation does not impair stem cell maintenance 
or function in serial transplantation experiments78. A second study, equally making 
use of a conditional knock out, but following a different Cre-recombinase induction 
protocol, found a two-fold reduction in primitive progenitors, such as CFU-S1279
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and a similar reduction in short term repopulating cells after transplantation 
whereas the number of long term repopulating stem cells remained the same208. 
SCL is a critical regulator of adult erythroid and megakaryocyte 
differentiation
In addition to its crucial role at the earliest stages of primitive and definitive 
haematopoiesis, SCL is also thought to act as an important transcription factor for 
the differentiation of erythroid and megakaryocytes. The first clue to this came from 
antisense experiments showing that SCL regulates proliferation and self-renewal of 
the multipotent progenitor cell line K562209. Its ability to promote erythroid 
differentiation was then investigated by forced expression in induced MEL cells210, 
TF-1 cells155 and the K562 cell line210. In all of these studies, SCL was shown to 
enhance differentiation into the erythroid lineage. Further over-expression studies 
of SCL using retroviral transfer into haematopoietic CD34+ progenitor cells have 
given evidence that SCL might promote erythroid and megakaryocyte 
differentiation at the expense of myelocyte differentiation211,212. Recently, genetic 
evidence has emerged clearly demonstrating that SCL is required for the 
maturation of erythroid and megakaryocytic lineages78,79,188.
In the past few years, it has become obvious that in order to exert these functions 
in primitive and definitive haematopoiesis, SCL interacts with other nuclear proteins 
in multiprotein complexes.
3.6 SCL partners
As mentioned above, the tissue specific class II bHLH protein SCL is able to form 
heterodimers with ubiquitous class I bHLH proteins such as the E2A gene products 
E12 and E47, HEB and E2.2. In addition, SCL has been shown to interact with 
other proteins (figure 1.9).
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The first SCL partners to be identified by co-immunoprecipitation in a T-ALL cell 
line213 or by mammalian two hybrid assay214 were the LIM domain proteins LMO- 
1/2. LMO-1 and LMO-2 share a high degree of homology and, like SCL, have been 
implicated in the pathogenesis of T-ALL215. LMO-2 is also essential for normal 
blood cell formation80,81. Besides, there is increasing evidence for both physical 
and functional interaction between bHLH heterodimers, LIM-domain proteins and 
LIM-domain binding proteins such as LDB-1216,217. Targeted deletion of the mouse 
LDB-1 locus causes a severe patterning defect during gastrulation and 
abnormalities within the mesoderm derived extraembryonic structures including the 
blood islands of the yolk sac218, thus indicating a role for this protein in blood cell 
formation. Using casting experiments, Wadman et al revealed the presence on 
DNA of a pentameric complex in induced MEL cells consisting of the SCL/E2A 
heterodimer together with LMO-2, LDB-1, and the critical haematopoietic regulator 
GATA-1219. Besides, Valge Archer described a similar complex consisting of SCL, 
LMO-2, LDB-1 and the GATA family member GATA-3 in T-ALL213.
Interestingly, interactions of SCL with the histone acetyl transferases CBP/p300 
and pCAF198,199 as well as with the co-repressor mSin3A and associated HDACs 
220 have been reported.
3.7 SCL target genes
Despite the fact that SCL is an essential regulator of haematopoiesis, only few 
target genes have been identified so far. Until recently, the evidence for these 
potential candidates was mostly based on the presence of an E box within their 
promoter or enhancer regions and the outcome of reporter assays rather then 
direct evidence for the in vivo presence of a protein complex including SCL. In this 
context, a DNAase hypersensitive site (HS1) upstream of the GATA-1 gene
49
containing an E-box-GATA motif, has been shown to direct reporter gene 
expression to erythroid cells and megakaryocytes in transgenic mice221. Similarly, 
EKLF and Flk-1 genes have been described as potential candidate targets in 
erythroid and endothelial cells, respectively222,223. Besides, using chromatin 
immunoselection, SCL was found to bind to the regulatory sequences of a gene of 
unknown function with homology to ontogelin224. Among the first direct target 
genes described for SCL was the c-kit gene, which encodes an essential tyrosine 
kinase receptor required for the maintenance of HSC and progenitors189,225. Using 
chromatinimmunoprecipitation (ChIP) assays, Lecuyer et al showed that a SCL 
multiprotein complex consisting of E47, LMO-2, LDB-1, GATA-1/2 and Sp1 can 
assemble on the c-kit promoter and that the presence of all these proteins was 
necessary for transactivation of the gene in a pluripotent CD 34+ cell line. 
However, c-kit gene expression was not affected in SCL-/- ES cells induced to 
undergo haematopoietic differentiation148. In addition, Vitelli et al demonstrated that 
retinoblastoma protein can associate with SCL, E12, LMO-2 and LDB-1 in more 
mature erythroid cells and leads to repression of c-kit expression226. Finally, the 
pentameric complex including SCL is believed to positively regulate expression of 
late erythroid genes such as glycophorin A (GPA) and protein 4.2 genes190,227.
3.8 SCL: activator and repressor
Functionally, SCL is considered as both a positive and a negative regulator. First, 
because SCL/E2A heterodimers are less potent activators than E2A homodimers, 
it was postulated that SCL could exert repressor effects228,229. Second, as 
mentioned above, SCL positively regulates erythroid differentiation when 
overexpressed in MEL cells210, but is a repressor of erythroid differentiation of the 
human cell line K562 in antisense experiments209 and blocks differentiation when
ectopically expressed in normal and leukemic myeloid precursors230. Finally and as 
indicated before, the pentameric complex is believed to positively regulate 
expression of glycophorin A (GPA) and protein 4.2190,227, and to activate or repress 
expression of the c-kit gene depending on the cellular context and nature of 
additional partners189,226. In addition to their functional activity observed in 
transcriptional assays, members of the pentameric complex have been shown to 
co-occupy in vivo regulatory sequences of GATA-1, a-g lobin and GPA 
genes190'231,232. Although we are now beginning to understand how a 
haematopoietic-specific multiprotein transcriptional complex might form on 
regulatory regions of tissue-specific genes, so far, the composition of the complex 
does not account for its function. Activation and repression of gene expression are 
achieved through multiple mechanisms including recruitment of chromatin 
remodelling factors and histone-modifying proteins like acetyltransferases (HATs) 
and deacetylasetransferases (HDACs). As mentioned above, interaction of SCL 
with HATs CBP/p300 and pCAF 198'199 as well as with the co-repressor mSin3A 
and associated HDACs220 have been reported, thereby reinforcing the hypothesis 
that SCL might have a dual function, as an activator or a repressor.
3.9 SCL and T-cell leukaemogenesis
The t(1; 14) translocation is the most frequently observed chromosomal 
rearrangement in acute T-cell leukaemia and leads to overexpression of SCL in 
early T-cells, where it is normally downregulated144,146,162,233,234. Ectopic expression 
of SCL also occurrs without obvious chromosomal rearrangement, but due to a 
deletion of about 90kb of DNA from chromosome 1 which brings the sci gene 
under the control of the ubiquitously activated s/7 promoter, thus leading to 
constitutive expression of SCL235'239. This deletion is believed to result from
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illegitimate recombinase activity. Recently, a third mechanism of SCL RNA 
overexpression in T-ALL has become apparent involving the biallelic expression of 
SCL240,241, but the underlying molecular mechanisms and their impact on protein 
levels remain to be elucidated. The incidence of these different abnormalities was 
defined by gene expression data from microarray and quantitative RT-PCR on 59 
children with T-ALL and normal thymocyte controls showing that within this 
population SCL over-expression occurred in 49% of all cases. None of the 29 SCL 
positive samples carried the t(1;14). Intrachromosomal deletions occurred in 31 % 
of case. In the remaining 69%, no cytogenetic or molecular evidence of 
rearrangements affecting the SCL locus could be detected242.
The oncogenic properties of SCL have been studied using transgenic mouse 
models with a variety of different promoters and mouse backgrounds191,243'246. It is 
now clear that the oncogenicity of SCL alone in these mouse models is weak. 
Dependent on the mouse strain and the promoter used, mice either failed to suffer 
from leukaemia or developed the disease only after a long latency period. This led 
to the conclusion that either levels and/or the precise timing of SCL expression in 
T-cell development may be critical for leukaemogenesis. Moreover, additional 
oncogenic events are required to enhance the leukaemic potential of SCL. One 
potential candidate partner of SCL in this setting could be the LIM domain proteins 
LMO-1/2, which are also involved in human T-cell leukaemogenesis247. Moreover, 
microarray data on T-ALL samples confirmed that LMO-1/2 are over-expressed 
together with SCL in a high proportion of cases242 and, using biochemical assays, 
Wadman et al showed that LMO-1/2 and SCL can associate in extracts of 
leukaemic blasts214. In addition, transgenic mouse models expressing both LMO-
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1/2 and SCL in thymocytes develop aggressive leukaemia and T-cell lymphoma 
with low latency244,245,248,249.
The LIM proteins are unable to bind to DNA and the LIM domain of LMO-2 
is regarded as a protein-protein interaction domain. This implies that LMO proteins 
may serve as adapters allowing the proper assembly of larger multi-protein 
complexes250,251. Hence, LMO-2 and SCL together with E47 and LDB-1 were found 
in an aberrant complex in a leukaemic T cell line252. These aberrant complexes 
might interfere with normal differentiation of T cells by deregulating gene 
expression through multiple possible ways. First, SCL-containing complexes could 
lead to abnormal gene activation. Thus, when expressed in a SCL/LM02-negative 
T-ALL cell line, SCL or its DNA binding mutant, and LMO-2 form a complex with 
GATA-3 and specifically induce expression of the TALLA-1 and RALDH2 
genes253,254, although the relevance of the expression of these genes for the 
leukemogenic process remains to be clarified. Second, SCL heterodimerisation 
partners, the E-proteins, are essential regulators of T-cell differentiation and their 
inactivation leads to T-cell leukaemia111,255. It has been long hypothesised that SCL 
might prevent the function of E-proteins in T cells through simple 
sequestration149,228,229. In addition to sequestering E proteins, SCL could recruit 
repressor complexes to genes normally switched on in differentiating T cells. Two 
papers now suggest that both these mechanisms may be operative. Herblot et al 
demonstrated that in mice, SCL and LMO-2 are normally expressed in the double 
negative thymocyte population, but progressively downregulated up to the CD4+ 
CD8+ stage. However, in the leukaemic setting, SCL is over-expressed in the late 
double negative and in the double positive stage. SCL and LMO-2 over-expression 
in mice leads to inhibition of E2A/HEB function and repression of the pre-Ta gene
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expression, essential for normal T cell development149. Consistent with this, O’Neil 
et al showed that expression of a SCL transgene in an E2Aor HEB heterozygous 
background promotes development of leukaemia. Using ChIP assays, they 
demonstrated that the SCL/E2A heterodimer recruits the co-repressor complex 
mSin3A/HDAC1 to enhancer elements of genes important for thymocyte 
differentiation, such as CD4 and pre-Ta256.
Taken together, these data indicate that, in T-ALL, SCL may form aberrant 
protein complexes, therefore perturbing expression of genes essential for normal 
T-cell differentiation.
However, these aberrant SCL-containing complexes remain to be fully 
characterised and their exact molecular mechanism of action elucidated. Moreover, 
their relevance in human leukaemogenesis needs to be investigated.
4 SUMMARY OF THE INTRODUCTION
In summary, the haematopoietic system is an ideal model to begin to study some 
of the molecular mechanisms underlying the progressive restriction of the 
differentiation potential of stem cells and their progeny leading to production of 
lineage-specific mature cells.
Sequence specific transcription factors such as SCL play a pivotal role in this 
process. Their main function is to mark genes for either activation, through 
recruitment of co-activators like the chromatin modifying or remodelling complexes 
HAT and SWI/SNF, or repression, through recruitment of co-repressor complexes 
containing HDACs. They can also synergise with or directly antagonise the activity 
of other transcription factors.
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Lineage specification requires the fine balance between activator and repressive 
functions of these regulators. Transcriptional programs essential for differentiation 
of a given lineage and leading to cell cycle arrest and production of structural and 
tissue-specific proteins, need to be activated in a timely fashion. Other programs, 
important for alternate lineage specification, have to be constitutively repressed. 
These different levels of regulation are likely to be achieved through the same set 
of tissue-specific transcription factors.
SCL has been described both as an activator and repressor of gene transcription in 
normal and malignant haemopoieis. The molecular mechanisms conferring SCL 
function are largely unknown, but most likely involve interaction with protein 
partners. Therefore, the main part of my thesis work (Chapters IV, V and VI) deals 
with the identification and characterisation of SCL-containing multiprotein protein 
complexes to further elucidate the role of this transcription factor in lineage 
maturation.
5 STRUCTURE, HYPOTHESIS AND AIMS OF THIS THESIS
The results of this thesis are divided into four chapters (chapters III to VI). Chapter 
III describes work which was performed at the INSERM Unit 474 in Paris, France, 
under the direction of Paul-Henri Romeo. It describes the characterisation of a 
transgenic mouse model over-expressing SCL or its DNA-binding mutant under the 
control of a haematopoietic specific promoter, sea-7.
The aim of this first part of our work was to address three central questions 
surrounding SCL:
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1. What is the role of SCL at the haematopoietic stem cell level ?
2. What exactly is its role in T-cell leukaemogenesis ?
3. Is the DNA binding activity essential for SCL function ?
When I arrived at INSERM Unit 474, work on this project had already started and 
transgenic mice had been generated. Possible perturbations in the stem cell pool 
were under investigation, but it soon became apparent that this transgenic model 
did not have any significant phenotype at the level of the adult haematopoietic 
stem cell. My project was to characterise transgene expression and abnormalities 
observed in B and T cell development. Unexpectedly, there was a severe defect in 
B lymphopoiesis. Besides, mice over-expressing SCL or its DNA-binding mutant 
did not develop T-cell leukaemia, but presented with a pre-leukaemic thymocyte 
phenotype. These results suggested that SCL over-expression under control of the 
sca-1 promoter was not sufficient to cause leukaemia. This could have been due to 
inappropriate levels of SCL in the leukaemic target cell. Alternatively, SCL 
overexpression by itself may be insufficient and represent only the first step in the 
leukaemogenic process. Besides, DNA binding was dispensable for SCL’s function 
in this setting, thus stressing the importance of protein-protein interactions for SCL 
function.
A logical progression ensuing from this work was therefore to try and identify 
protein partners of SCL.
Chapter IV to VI describe the work subsequently performed at the 
Molecular Haematology Unit, WIMM, Oxford. During this second and more 
significant part of my thesis, we aimed at identifying protein partners of SCL in 
definitive haematopoiesis.
56
As mentioned in the introduction, current data suggests that in definitive 
haematopoiesis the pentameric complex consisting of SCL/E2A, GATA-1, LMO-2 
and LDB-1 can exert both repressor and activator functions dependent on cellular 
context and target genes involved. We therefore hypothesised that co-factors had 
to interact with this core complex to confer its function.
In an attempt to identify some of the proteins interacting with SCL, we established 
two different protein purification strategies using either conventional pre-purification 
followed by immunoprecipitation (chapter IV) or biotin/streptavidin-affinity 
purification whereby SCL was biotinylated in vivo and SCL-containing complexes 
pulled down by streptavidin-affinity (chapter V and VI). These protein complexes 
were subsequently identified by mass spectrometry. We have performed our 
analysis in both erythroid and megakaryoblastic cell lines as a first step towards 
the characterisation of protein complexes in two related but distinct haematopoietic 
cell types. This approach has allowed us to identify several new potential partners 
of SCL. So far, our work has focused on the validation and functional analysis of 
the interaction between SCL and one of these partners, the co-repressor ETO-2.
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CHAPTER II : MATERIALS AND METHODS 
1 MOUSE GENETICS PROCEDURES
This part of the work was performed in France. All procedures done on mice were 
authorized by the French authorities.
1.1 Mouse handling and breeding procedures
Mice were housed in a barrier facility with precautions to avoid introduction of 
pathogens (Hopital Henri Mondor, Creteil). Mice were bred in trios and offspring 
were weaned at 3-4 weeks after birth. The tip of the tails were removed for 
genotyping. Mice from 6-8 weeks of age were bred in groups of 2 or 3 females and 
1 male. Timed mating was assessed by the presence of a vaginal plug, 
corresponding to 0.5 dpc (days post coitum).
1.2 Generation of DNA constructs and SCL and Ab SCL heterozygous mice
Ly-6E. 1-hscl and Ly-6E. 1-Abhscl constructs were obtained by inserting the human 
(h) scl or Abhscl c-DNA followed by the bovine growth hormone gene polyA into 
the poly llli vector (pL6Cla)257'259. The 14 kb Ly-6E.1-hscl and the 14kb Ly- 
6E.1 -Abhscl fragments were obtained by BamH1 digestion. DNA fragments were 
purified by agarose gel electrophoresis and microinjected into the pronuclei of 
fertilised oocytes from a cross of B6D2F1 animals (C57BL/6 x DBA/2). Southern 
blot analysis of tail DNA was used to identify transgenic animals, to determine copy 
number and to assess integration patterns.
1.3 Genotyping of mice
Mice were genotyped by PCR. To obtain the genomic DNA, tails were lysed 
overnight at 55 °C in 500 ^il of lysis buffer containing 100 mM
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Tris/200mMEDTA/0.5%SDS/proteinase K. DNA was extracted using Phenol- 
Chloroforme. Amplicates were electrophoresed on a 1.2% agarose gel.
2 CELL BIOLOGY PROCEDURES
2.1 Cell culture conditions and cell lines 
Standard cell lines
MEL 585 (mouse erythroleukaemia cell line)43, NIH 3T3 cells and the acute T cell 
leukaemia cell line Jurkat167 were maintained in RPMI 1640 supplemented with 
10% heat inactivated fetal calf serum (FCS), 2.0 mM L-glutamine, 100 units/ml 
penicillin, and 100 units/ml streptomycin.
MEL cell were induced to differentiate in 2% dimethyl sulphoxide (DMSO) for 3 to 5 
days.
L8057 cells (murine megakaryoblastic cell line260) were grown in 50% IMDM, 50% 
RPMI 1640 with 15% FCS using the same supplements as described above.
All cells were cultured in a humidified atmosphere of 5% CO2 at 37 °C.
ES cell in vitro differentiation assay
In vitro haematopoietic differentiation was performed as described89,261 and a 
general scheme of the rescue assay is described in figure 5.6. Briefly, SCL-/- ES 
cells were expanded on STO feeder cells. SCL'/_ ES cell clones expressing 
biotinylated SCL were subjected to the first step of in vitro differentiation and 
permitted to form embryoid bodies (EB). To generate primitive erythroid colonies, 
day 6 EBs were disaggregated and replated into methylcellulose media containing 
erythropoietin (Epo, 2 U/ml). For definitive haematopoiesis, day 8 EBs were 
replated in methylcellulose in the presence of Epo (2 U/ml) and c-kit ligand (100
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ng/ml) ; Interleukin (lL)-3 (1 ng/ml), IL-6 (5 ng/ml), granulocyte colony stimulating 
factor (G-CSF, 30 ng/ml) and granulocyte-macrophage-CSF (GM-CSF 3 ng/ml); or 
c-kit ligand (100 ng/ml) and thrombopoietin (Tpo, 5 ng/ml) for definitive 
erythropoiesis, myelopoiesis and megakaryocytopoiesis, respectively. Colonies 
were scored on day 5 (primitive and definitive erythropoiesis) or day 7 
(myelopoiesis and megakaryocytopoiesis). Colonies were then picked for analysis 
of cell morphology by May-Grunwald-Giemsa staining (according to the 
manufacturer’s instructions) or RNA extraction.
2.2 Transfections
All transfections were performed using a BioRad Gene PulserElectroporator 
(BioRad, UK).
Stably transfected cells were selected in their respective medium containing 
puromycin (Sigma) 0.5 ^g/ml (Jurkat) or 2 [xg/ml (MEL and L8057) and zeocin 
(Invitrogen) 100 ng/ml (MEL and L8057), 200 ng/ml (SCL-/-) or 400 ng/ml (Jurkat). 
MEL
Stably transfected clones were obtained by electroporating 1x 107 cells in 1 ml 
PBS 1X together with 15 mg of linearized cDNA. Electroporation conditions were : 
220 V, 960 nF. Cells were replated in RPMI 10%FCS for 48 hours before selection 
with the appropriate selection medium. Macroscopically visible clones were picked 
after one to two weeks and expanded.
L8057
5x106 L8057 cells were electroporated in 80 ml of PBS 1X with 15 mg of linearized 
cDNA using 0.2 mm electroporation cuvettes (EquiBio). Electroporation conditions 
were 250 nF and 160 V. After 10 min of incubation on ice, cells were replated in 6
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well plates for 48 hours before transfer into 50% methylcellulose (Methocult 
M3434, Stem Cell Technologies, Vancouver) containing the appropriate antibiotic. 
ES cells
Undifferentiated ES cells were trypsinized and passed through a 19.5 Gauge 
syringe to obtain a single cell suspension. 1x107 cells were transfected with 
20 pg of linearized DNA in 1 ml of PBS. Electroporation conditions were : 800 V, 3 
p,F. Cells were incubated at room temperature for 10 min and replated on feeder 
cells. After 48 hours, transfected cells were transferred onto gelatin coated dishes 
for selection. 9-10 days later, colonies of ES cells showing no sign of differentiation 
were picked and expanded.
2.3 Transactivation assays
NIH3T3 cells were transfected using the Lipofectamine 2000 reagent (Invitrogen) 
24 hours after plating in 24-well plates at a density of 7 104 cells/well. Amounts of 
transfected DNA/well were as follows : 750 ng of luciferase reporter gene, 75 ng of 
SCL, E2A and GATA-1 and 375 ng of LM02 and LDB-1 expression plasmids as 
previously described 189, and 75 to 300 ng of ETO-2 expression vector. 50 ng of 
CMV-bGal was added to serve as transfection efficiency control. Total amounts of 
DNA were kept at 2 mg/well using pBluescript. 24 hours after transfection, cells 
were lysed and luciferase and bGal activities measured using standard procedures 
(kits from Roche). Each transfection was performed in duplicate and data 
presented are the results of 3 to 5 independent experiments.
2.4 Purification of mouse primary haematopoietic cells
Ter119+ splenocytes : C57BI/6 mice were treated with phenylhydrazine (Sigma, 
0.04 mg/g body weight). Three successive intraperitoneal injections were 
performed at 12 hour intervals. Spleens were harvested 6 days after the first
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injection. Ter119+ cells were isolated after labelling the splenocytes with biotin- 
conjugated rat anti-mouse Ter119 antibodies (BD Pharmingen) and subsequent 
incubation with anti-biotin microbeads (Miltenyi Biotec). The positive fraction was 
recovered on AUTOMACS (Miltenyi Biotec). Purity was assessed by May- 
Grunwald-Giemsa staining.
Primary megakaryocytes
C57BI/6 mice were treated with 5-fluorouracil (5-FU, 150 mg/kg, intraperitoneal). 
Eight days post-injection, mice were sacrified, bone marrow cells harvested and 
replated at a density of 5x106 cells/ml in serum-free medium StemPro 34 
(Invitrogen) in presence of Thrombopoietin (TPO, conditioned supernatant, 1/100 
dilution. After 3 days of culture, megakaryocytes were isolated by negative 
selection. The culture was immunodepleted from Ter119-, Mac1-, Gr1- and B220- 
positive cells by labelling with the corresponding biotin-conjugated rat anti-mouse 
antibodies (BD Pharmingen), subsequent incubation with streptavidin microbeads 
(Miltenyi Biotec) and separation of the positive and negative fractions on MACS 
columns for large cells, according to manufacturer’s instructions (Miltenyi Biotec). 
Purity of the negative fraction was assessed by May-Grunwald-Giemsa staining 
and flow cytometry (data not shown). The cell population was estimated to contain 
at least 95% of CD61+ megakaryocytes (data not shown).
Expansion and erythroid differentiation of wt fetal liver cells 
After obtaining a single cell suspension, 1x106 cells/ml of fetal liver cells from day 
12.5-13.5 mouse embryos were resuspended in serum-free stem cell expansion 
medium (StemPro-34™ Life Technology Gibco BRL) supplemented with human 
recombinant erythropoietin (2 U/ml), murine recombinant stem cell factor (100 
ng/ml), dexamethasone (Sigma) (1 mM) and insulin-like growth factor 1 (IGF-1,
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Biovalley, France) (40 ng/ml). The culture medium was changed daily for 3 days. 
On day 4, cells were resuspended in PBS 1X, EDTA, BSA at a concentration of 
100 ml/107 cells and incubated with rat anti-Ter119 antibody (Becton Dickinson 
Pharmingen). After incubation on ice, cells were washed, incubated with anti-rat 
MACS beads (Miltenyi Biotec) and rotated at 4 °C. Separation of the positive and 
negative fractions on MACS columns was achieved according to manufacturer’s 
instructions (Miltenyi Biotec). Purity of the negative fraction was assessed by May- 
Grunwald-Giemsa staining and flow cytometry. Ter119 negative cells were used to 
prepare nuclear extracts. A fraction was induced to differentiate into erythroid cells 
using serum-free stem cell expansion medium (StemPro-34™ Life Technology 
Gibco BRL) supplemented with human recombinant erythropoietin (10 U/ml), 
insulin-like growth factor 1 (IGF-1, Biovalley, France) (40 ng/ml), human transferrin 
(Sigma) (1 mg,ml), Mifipristone (1 mM), FCS 10%, Biotin (Sigma) (0.1 mg/ml) and 
Hypoxanthine (Sigma) (5 mg/ml). Cells were harvested after 24 hours and 48 
hours for preparation of nuclear extracts.
2.5 FACS analysis
Peripheral blood was taken from the tail vein and washed 3 times in PBS buffer. 
After incubation with the relevant antibodies, ready-made FACS lysis solution 
(Becton Dickinson) was added. Thymus, spleen and bone marrow were dissected 
out and homogenised in RPMI 1640 containing 1% fetal calf serum, 50 pM p- 
mercaptoethanol, 1% penicillin and streptomycin. Anucleated cells were lysed by 
osmotic shock in lysis buffer (NH4CI 155 mM, KHCO3 10 mM, EDTA 0,1 mM) and 
washed twice with complete medium. Non-dissociated cells and tissue debris were 
filtered on a Cell strainer (70 pm nylon) (Falcon, 35-2350). Cells were 
immunophenotyped using conjugated monoclonal antibodies and standard
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techniques. The following antibodies were used: anti-CD4-FITC, CD8-PE, CD45R 
(B220)-FITC, CD45R (B220)-PE-Cy5, CD19-PE, IL-7Rcx-biotin, c-kit-APC, CD11b 
(MAC-1 )-APC, CDHb-FITC, Sca-1-FITC and streptavidin-Cy-Chrome complex. 
All antibodies used were purchased from PharMingen. 10000 events were 
analysed on a FACScalibur (Becton Dickinson) permitting four-colour analysis.
2.6 Activation of B splenocytes
Splenic cells were depleted of T cells using anti-CD4 and anti-CD8 microbeads 
(Miltenyi Biotec) and activated for 3 days in aMEM containing 10% fetal calf serum, 
50 mM |3-mercaptoethanol, 1% penicillin and streptomycin and Lipopolysaccharide 
(25 i^g/ml).
2.7 Transplantation in NOD/SCID mice
Grafts were enriched for haematopoietic stem cells by treating transgenic and 
littermate control donors with 150 mg/kg of 5- Fluorouracil. On day 5 after 
treatment BM cells were harvested and depleted of CD4 or CD8 positive cells 
using a-CD4 and a-CD8 antibodies and magnetic beads (Miltenyi) to prevent graft 
versus host disease (GvHD). 5 x 104 cells were injected into the tail vein of 
NOD/SCID mice previously sublethally irradiated with 2.5 Grays. Weekly full blood 
counts were obtained starting at 6 weeks. BM cells were harvested from recipients 
8 weeks after transplantation and haematological reconstitution was assessed by 
flow cytometry.
2.8 Cytology and Histology procedures
Thymus paraffin-embedded sections were prepared in the histopathology 
department of Henri Mondor Hospital. Sections were dewaxed and microwave
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treated. HSCL protein was revealed using the mouse monoclonal antibody BTL-73 
and the Mouse-on-Mouse Iso-IHC Kit (Inno Genex TH).
3 DNA PROCEDURES
3.1 Enzymatic modification of DNA
Restriction digestion of DNA was carried out using restrictions enzymes and 
corresponding buffers from New England Biolabs or Roche according to the 
manufacturer’s instructions. In general, 5 units of enzyme were used to digest 2-10 
\ig of DNA in a volume of 50-100 \i\ for 1 hour to overnight.
When necessary, DNA ends of cloning vectors were phophatised with shrimp 
alkaline phosphatase (Roche).
DNA used for cloning or as probes for northern blotting was resolved on 1% 
agarose gels, and purified from the excised agarose slice using the QIAGEN Gel 
Extraction Kit according to the manufacturer’s instructions.
3.2 Ligation and transformation of competent bacteriae
Vectors and inserts were ligated in a molar ration of 1:3 or 1:5 using the Rapid 
Ligation kit (Roche) according to the manufacturer’s instructions. For 
transformation of purified plasmid vectors and freshly ligated DNA, 106 
chemocompetent DH5a bacteria were gently mixed with 200 pg of plasmid DNA or 
10 |nl of the ligation reaction and incubated on ice for 30 minutes. The mixture was 
then exposed to 42 °C for 45 seconds and re-placed on ice for 2 minutes before 
adding 900 jxl of LB medium. The bacteria were incubated at 37 °C on a rocker for 
30 minutes, pelleted and spread on LB agar plates supplemented with 50 ng/ml of 
ampicillin. The cultures were then allowed to grow for 14 hours.
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3.3 Constructs
The Escherichia coli BirA biotin ligase gene262 was inserted as a PCR fragment 
(see primers xba-cla-birA 5’ and xba-birA-R Table 2.1) into the human EF1a 
promoter expression vector bearing a puromycin resistance gene. This antibiotic 
cassette was cloned into the vector using a polylinker (see Table 2.1). The SCL (wt 
and mutant) cDNAs were tagged in 5’ with an oligonucleotide sequence encoding 
for the 23 amino acid biotinylation tag262 using a PCR strategy. To do this, the first 
fragment, consisting of the biotag, was generated using oligo 2 and 3 (Table2.1). 
The second fragment, SCL or mutant, was generated with oligo 1 and 4. The two 
fragment were then mixed, denatured and reamplified with oligos 3 and 4 and the 
PCR product cloned into the pEF1a vector bearing a zeocin resistance gene. The 
mouse SSDP2 263, mouse ETO-2 264 and rat E2A 265 (wt and mutants) cDNAs were 
subcloned into the pEF1a-biotag vector in replacement of the SCL sequence using 
a PCR-based strategy. All PCR fragments were generated using the proof-reading 
Pfu-polymerase (Stratagene) and verified by sequencing.
3.4 Preparation of plasmid DNA
To obtain 5-50 pg of plasmid DNA, a small-scale preparation of DNA was carried 
out using the QIAGEN Plasmid Mini Kit according to the manufacturer’s 
instructions. To obtain 100-1000 \ig of plasmid DNA, a large-scale preparation of 
plasmid DNA was performed using the QIAGEN Plasmid Maxi Kit according to the 
manufacturer’s instructions.
3.5 DNA sequencing
Automated DNA sequencing using the 3100 Genetic Analyser (Applied 
Biosystems) was carried out by the MHU Sequencing Facility (MHU, WIMM).
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3.6 Polymerase chain reaction
PCR reactions were carried out in order to genotype mice, to generate constructs 
and to obtain specific DNA probes for Northern blotting. For primers : see table 1. 
In general, PCR reactions were carried out in a total volume of 50 pi, containing 5 
ng of template, 5 pi of DMSO, 5 pi of 10X enzyme buffer, 10 mmol of each 
nucleotide, 25 pmol of each oligonucleotide and 1 unit of AmpliTaq Gold DNA 
polymerase (Applied Biosystem) or Pfu (Stratagene). Conditions for PCR of SCL 
cDNA were as follows : 94 °C for 3 minutes, 95 °C for 1 minute, 58 °C for 1 minute, 
72 °C for 1 min, 20 cycles, 72 °C for 10 min.
4 RNA PROCEDURES
4.1 Preparation of total RNA
Total RNA of spleen, thymus, kidney, liver were prepared with TRIZOL (Gibco, 
BRL). Total RNA of cell lines or ES cell derived haematopoietic colonies was 
obtained using the QIAGEN Rneasy Kit according to the manufacturer’s 
instructions.
4.2 Northern Blotting
For Northern Blots, 10-15 pg of total RNA in RNA loading buffer were separated on 
a 1% formaldehyde agarose gel containing ethidiumbromide in 1X MOPS running 
buffer at constant 100 V and transferred to a Nitrocellulose Hybond N+ membrane 
(Amersham Biosciences) by capillary transfer using 20X SSC buffer (0.3 M sodium 
citrate, 3 M NaCI; pH 7.0) overnight. The membrane was cross-linked using a 
Stratalinker UV Crosslinker (Stratagene).
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The membrane was pre-hybridised for 30 minutes in ExpressHyb(Clontech) 
containing denatured salmon DNA (Invitrogen). Hybridisation was performed using 
the same buffer containing the denatured radioactive probe for 1 hour at 65 °C in a 
rotary oven. Membranes were then washed three times at room temperature with 
2X SSC containing 0.1% SDS for 15 minutes, followed by 2 washes at 50 °Cfor 20 
minutes in 0.1X SSC with 0.1% SDS. Probes used for northern blotting were 
excised from cDNA plasmids (SCL) or were generated by PCR using cDNA 
plasmids as a template and sequence specific PCR primers (Bir A) (Table 2.1). 
Radioisotope labelled DNA probes were prepared by random hexamer method 
using the Megaprime DNA labeling kit according to the manufacturer’s instructions 
(Amersham Biosciences).
Membranes were exposed to autoradiographic films at -80 °C overnight.
4.3 Semi-quantitative RT-PCR
SCL expression was quantitated by RT-PCR on RNA isolated from haematopoietic 
colonies derived from wt ES cells and SCL-/- ES cells transfected with Bir A and 
biotagged SCL and cDNA prepared according to standard protocols. One-tenth of 
the synthesized cDNA was used for PCR (same protocol as described above). 
Each PCR reaction contained 0.1 piCi a-32P dCTP. Two sets of primers were 
added : one designed to amplify 570bp of the SCL sequence (see table 2.1) and 
one designed to amplify 249bp of the constitutively expressed hypoxanthine 
phosphoriosyl transferase (HRPT) transcripts90. Aliquots were analysed on a 4% 
PAGE after cycles 18-24 for HPRT and SCL sequences. Quantification was carried 
out using the Phosphorimager (Storm, Molecular Dynamics). Control experiments 
without reverse transcriptase in the cDNA synthesis reactions did not show specific 
PCR products.
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4.4 Quantitative real-time PCR
For quantification of transgene expression in different haematopoietic lineages and 
animal lines, bone marrow cells and thymocytes were sorted by flow cytometry 
using anti-B220-PE-Cy5 (CD45R), anti-TER-PE, anti-CD11b-FITC (MAC), anti- 
CD4-FITC and anti-CD8-PE antibodies (all from PharMingen). After TRIZOL 
extraction of total mRNAs and standard reverse transcription, quantitative PCR 
was performed with the LC FastStart DNA Master SYBR Green I reaction kit 
(Roche Diagnostics, cat no: 2239264). The primers used are indicated in Table 
2.1. MgCb was used at a final concentration of 4 jxM. The annealing temperature 
was 60°C. All samples were run in duplicates. Melting Curve analysis and 
quantification calculation was performed using fluorimetric online detection with the 
LightCycler (Roche Diagnostics).
5 PROTEIN PROCEDURES
5.1 Preparation of nuclear extracts
Small scale preparation of nuclear extracts
107 cells were washed in 1 ml of PBS 1X and pelleted into an eppendorf tube. 
After resuspension in 10 times the pellet volume of buffer A (10 mM Hepes pH 7.9,
1.5 mM MgCb, 10 mM KCI, 0.5 mM PMSF or a protease inhibitor cocktail 
(Complete EDTA-free, Roche) and 0.5 mM DTT) cells were kept on ice for 10 min 
and vortexed. Nuclei were pelleted for 10 sec at maximum speed and resuspended 
in 5 times the pellet volume of buffer C (20 mM HEPES pH 7.9, 25% glycerol, 420 
mM NaCI, 1.5 mM MgCfe, 0.2 mM EDTA, 0.5 mM PMSF or protease inhibitor
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cocktail (Complete EDTA-free, Roche) and 0.5 mM DTT). After incubation on ice 
for 20 min and centrifugation, supernatants were kept for protein analysis.
Large scale preparation of nuclear extract
40 ml of confluent cells were aliquoted into 20 flasks containing 100 ml of medium 
each. 48 hours later, a further 150 ml of medium was added. 72 hours later, a 5 ml 
cell pellet corresponding to approximately 2x109 cells was harvested by spinning 
for 15 min at 3000 rpm and washed once in PBS1X. After measuring the packed 
cell volume pellets were resuspended in 10 pellet volumes of buffer A (see above). 
Cells were spun down immediately at the same conditions, resuspended in buffer 
A and transferred into the loose Dounce homogenizer. After spinning the 
homogenate for 1 hour at 20000 RPM and 4 °C in the ultracentrifuge using the 
SW28 rotor, the nuclear pellet was resuspended in 8 ml of 150 mM Heng buffer 
(150 mM KCI, 20 mM Hepes, 20% Glycerol, 0.25 mM EDTA, 0.05% NP40). 1 ml of
2.2 M KCI Heng buffer was added dropwise to achieve a final salt concentration of 
420 mM KCI and nuclei were homogenized using the tight Dounce homogenizer. 
The homogenate was spun at 40000 RPM for 1 hour at 4 °C, the supernatant 
aliquoted and protein concentration dosed with Bradford reagent (Biorad).
5.2 Sodium dodecyl-sulphate polyacrylamide gel electrophoresis (SDS- 
PAGE)
For home made gels, 30% (w/v) acrylamide : 0.8 (w/v) bis-acrylamide stock 
solution (BioRad) was mixed with the separating (375 mM Tris-CI pH 8 .8 , 
0.1%SDS) and stacking (125 mM Tris-CI pH 6 .8 , 0.1% SDS) gel buffers to obtain a 
final concentration of 10% versus 3%, respectively. Gels were polymerized by the 
addition of 0.05% ammonium persulphate (APS) and 1% of N.N.N’.N’- 
tetramethylethylenediamine (TEMED) for 30 minutes at room temperature.
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Electrophoresis was performed in Tris-glycine running buffer (25 mM Tris-base, pH 
8.3, 190 mM glycine, 1 mM EDTA, 0.1% SDS) at constant 80 V. Gel 
electrophoresis was performed using the Mini gel electrophoresis system (Hoeffer) 
under denaturing conditions. Protein samples were mixed in 2X Laemmli sample 
buffer and 0.5 mM DTT and boiled at 95 °C for 5 minutes just before loading. 
Precast gel electrophoresis using 4-12% Bis-Tris and 7% Tris-Acetate gels was 
performed in the NuPage electrophoresis system (Invitrogen) according to the 
manufacturer’s instructions. The molecular weight in kD was estimated using the 
See Blue Marker from InvitroGen.
5.3 Western Blotting
Proteins resolved by SDS-PAGE were electrotransferred onto Hybond-P 
membranes (Amersham Biosciences) using a wet blotting method. Transfer was 
performed in 25 mM Tris, 192 mM Glycine, 20% Methanol at constant 25 V 
overnight at 4 °C. Subsequently, membranes were incubated for 1 hour at room 
temperature in TBST (50 mM Tris, 150 mM NaCI, 0.1% Tween 20) containing 5% 
semi-skimmed milk in order to block non-specific protein binding sites. Next, 
membranes was incubated for 2 hours at room temperature with primary 
antibodies diluted in TBST containing 5% semi-skimmed milk. Primary antibodies 
and dilutions are indicated in Table 2.2.
After incubation with primary antibodies, membranes were washed 3 x 20 minutes 
in TBST before incubation with HRP-conjugated secondary antibodies diluted in 
TBST (Table 2.2). After washes, immunoblots were developed using enhanced 
chemiluminescence (ECL, Amersham, UK). If indicated, filters were stripped in 
0.5M Tris pH 6 .8 , 20% SDS, 14.3 M (3-mercaptoethanol for 30 minutes at 50 °C
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and washed twice at room temperature for 10 min in TBS, 0.1% Tween-20. Filters 
were stored at 4 °C.
5.4 Quantitative Western Blots
Nuclear extracts were prepared as described. Total protein in nuclear extracts from 
transfected clones and wild type cells was dosed after the Bradford method and 
loaded onto a 10% SDS-Page gel. After transfer, the membrane was cut into two 
horizontal parts. The upper part containing molecular sizes above 30 kD was 
incubated with anti-SCL polyclonal rabbit serum, the lower part with anti-Grb-2 as a 
loading control. After washing in TBST and incubation with a HRP-conjugated 
secondary antibody, signals were revealed by chemoluminescence (Amersham). 
Signal intensities were quantitated using the Quantity One software (Biorad).
5.5 Gel filtration
Crude nuclear extracts (25 mg total protein) were precipitated with 55% saturated 
ammonium sulphate, and the precipitated proteins redissolved in 20 mM Tris pH 8 , 
200 mM NaCI, Glycerol 10%, 0.05% Triton. The concentrated nuclear extracts 
were fractionated on a Superose 6 H/R column (Amersham Biosciences) in the 
same buffer. Fractions of 0.5 ml were collected at a flow rate of 0.4 ml/min. 
Individual fractions were then subjected to western blotting.
5.6 Affinitypurification of anti-SCL antibodies
Polyclonal rabbit SCL antibodies were raised against the C-terminal and the N- 
terminal regions of the protein186,188. For affinitypurification of these antibodies, 
cDNAs coding for these regions were subcloned into the pGEX2TK GST 
expression vector using a PCR-based strategy. The constructs were transformed 
into DHIaand expression of the fusion proteins was achieved by adding 0.2 mM 
IPTG to 500 ml of bacterial culture. After 4 hours, bacteriae were pelleted and
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lysed in lysis buffer containing 50 mM Tris HCI pH 8 , 1 mM EDTA, pH 8%, 50 mM 
NaCI and 10 mg/ml lysozyme. Lysates were sonicated, spun at 10000 RPM for 10 
min and the supernatants were incubated with Gluthathione-Sepharose 4b slurry to 
allow adherence of the peptide to the beads.
Covalent binding
Sepharose beads were resuspended in 0.2 M Sodium Borate pH 9 and covalent 
binding of the GST fusion proteins was achieved upon incubation for 30 min in 20 
mM dimethylpimelimidate (DMP). Reactions were quenched with 0.2 M 
ethanolamine for 2 hours. Beads crosslinked to the Ct and Nt peptides were loaded 
separately onto two columns (BioRad 64775, cat no : 731-1550, 0.8x4 cm Polyprep 
chromatography column) and stored in 0.02% Sodium Acide/PBS.
Prior to affinitypurification, antisera were precleared from anti-GST antibodies 
using immobilized GST columns (Pierce, cat no : 20505). Briefly, after equilibration 
of the column with PBS1X, 4 ml of each antiserum were mixed with 4 ml of PBS1X 
and loaded onto the column. An additional 10 ml of PBS1X were applied and 
fractions collected and pooled according to their UV absorbance at 280nm.
For affinitypurification, columns containing the Ct and Nt antigens were washed in 
10 mM Tris pH 7.5, 100 mM Glycine pH 2.5, 10 mM Tris pH 8 .8 , 100 mM 
Triethylamine pH 11.5 and 10 mM Tris pH 7.5 until the pH reached 7.5. Antisera 
depleted from anti-GST antibodies were applied to the column, which were then 
washed with 10 mM Tris pH 7.5 and 10 mM Tris/500 mM NaCI. Antibodies were 
eluted using 100 mM Glycine pH 2.5 and neutralized with 1 M Tris pH 8 containing 
1 mg/ml BSA. The samples were concentrated on a CENTRIPLUS YM 10 spin 
column (Centricon).
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5.7 Immunopurification of SCL-containing complexes
25 pi of protein G beads (P3296 Fast Flow, Sigma) were washed twice in 100 mM 
Sodium Borate pH 9 prior to saturating them with 20 pi of Ct or Nt immunopurified 
antibodies for 1 hour at room temperature. The antibodies were crosslinked to 
beads as described above using DMP and ethanolamine. Crosslinked beads were 
washed twice in Tris/Saline pH 8 , 0.05% Triton, once in 100 mM Glycine pH 2.5 to 
remove unbound antibodies and three more times in Tris/Saline pH 8 , 0.05% 
Triton.
Subsequently, beads were incubated overnight with 100 pi of gelfiltration fraction 
on a rotating wheel at 4 °C.
Beads were washed four times in Tris/Saline pH 8 , 0.05% Triton, 0.5 mM PMSF, 
0.5 mM DTT and elution of SCL containing complexes was carried out with 100 
mM Glycine pH 2.5 neutralized by 1 M Tris pH 9.
Eluates were diluted in Laemmli buffer and 0.5 mM DTT and loaded on a 4-12% 
SDS-Page gel for Western Blot and Silverstain.
5.8 Affinitypurification of SCL-containing complexes
Maxi pull downs were achieved by incubating 5 mg of crude nuclear extract with 
100 p,l of paramagnetic streptavidin beads (Dynabeads M-280, Dynal (Great Neck, 
NJ). Beads were washed prior to use with TBS1X and 200 pg/ml of ovalbumin 
(Sigma). Nuclear extracts were diluted in binding buffer containing TBS1X, 0.3% 
Nonidet P-40 to obtain a final salt binding concentration of 150 mM NaCI. After 
incubation overnight on a rotating wheel at 4 °C beads were washed 6 times in 
washing buffer (TBS1X, 0.3% Nonidet P-40, 250 mM NaCI) and then boiled to
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elute the complex. Samples were resolved on a 4-12% SDS Page gradient gels for 
Coomassie stain and Western Blots.
5.9 Protein staining procedures
Silverstaining was performed using a kit (Invitrogen) according to the 
manufacturer’s instructions. Bands were destained immediately after cutting.
Sypro Ruby Protein gel staining (BioRad) and Colloidal Coomassie staining 
(Invitrogen) were used according to the manufacturer’s instructions.
5.10 Mass Spectrometry
Proteins eluted from the beads were separated on a 4-12% SDS PAGE gel and 
stained with Colloidal blue (Invitrogen). The entire lane was cut into at least 25 
slices and subjected to trypsin digestion using either a MWG Roboseq 4204 or a 
Qiagen 3000 robot. Analysis of tryptic digests was performed on a MicroMass Q- 
TOF Global with a capillary HPLC system with a nanospray probe. 5 \x\ of sample 
were run on a long column to separate out the peptides. Database searches were 
performed with MASCOT using the following settings: fixed modifications: 
Carbamidomethyl (C), variable modifications: Oxidation (M), peptide charge 2+ and 
3+. The data format was pkl www.matrixscience.com.
5.11 Co-immunoprecipitation and Depletion Experiments
Nuclear extracts were diluted in TBS 1X/0.3% Nonidet P-40 to obtain a final 
concentration of 150 mM NaCI and precleared for 30 min at 4 °C with 2 p,g of 
normal IgG (Santa Cruz: rat sc-2026, rabbit sc-2027, goat sc-2028) together with 
25 pi of Protein G beads (Fastflow, Sigma). Beads were pelleted and kept as a 
control. The supernatant was incubated overnight at 4 °C with primary antibody 
and 25 \x\ of Protein G beads. For immunoprecipitation with anti-GATA-1 N6
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antibody, a rabbit anti-rat bridging antibody (Jackson Immunodiagnostics) bound to 
beads was used. After completion of immunoprecipitation, IgG control and sample 
beads were washed 4 times in TBS 1X, 0.3% Nonidet P-40, 250 mM NaCI and 
boiled in 2x Laemmli buffer. For depletion experiments, the supernatant of the first 
immunoprecipitation was subjected to a second round of immunoprecipitation. 
Protease inhibitors (Complete EDTA-free (Roche)) were present throughout these 
procedures.
5.12 Immunolabelling and colocalisation
MEL and L8057 cells on coverslips were fixed in 4% paraformaldehyde and 
antigens indirectly immunolabelled with monoclonal mouse antibodies directed 
against SCL (1/100 dilution) and SC35 ( 1/100 dilution), rabbit polyclonal Ldb1 
antibodies (1/100 dilution)), or goat anti-ETO-2 antibodies (1/20 dilution). 
Secondary antibodies used were Alexa Fluor 488-conjugated donkey anti-mouse 
(Molecular Probes), Alexa Fluor 546-conjugated donkey anti-goat (Molecular 
Probes) and Cy-3-conjugated donkey anti-rabitt (Jackson Laboratory). Nucleic 
acids were counterstained with 1 jxg/ml DAPI (data not shown), monochrome 
images collected using a Radiance 2000 MP confocal microscope (BioRad), 
intensities over the nucleoplasm and equivalent areas of the slide measured using 
the metamorph software and data exported to Excel for background subtraction 
and analysis266. Images were exported to Adobe Photoshop, contrast stretched 
and pseucolored images were generated.
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CHAPTER III: CHARACTERISATION OF A TRANSGENIC MOUSE 
MODEL OVER-EXPRESSING SCL OR ITS DNA BINDING MUTANT 
UNDER THE CONTROL OF THE SCA-1 PROMOTER 
1 INTRODUCTION
1.1 The sca-1 promoter
The Ly-6E.1 and Ly-6A.2 genes are highly homologous strain-specific alleles of the 
mouse belonging to the Ly-6 multigene family and encode 876 and 830 base 
transcripts, respectively, and a 10-12 kD GPI-linked cell surface glycoprotein called 
Sca-1267. The proteins are identical in sequence except for two aminoacids. Little is 
known about Ly-6E/A expression during mouse embryonic development. Yolk sac 
cells from embryos at 10-11 dpc have been shown to be negative for sca-1 
expression as measured by RT-PCR and flow cytometry, however, the 
intraembryonic AGM region expresses Ly-6E/A2. During adult haematopoiesis, the 
Ly-6E/A gene is expressed in the haematopoietic stem cells (HSCs) of mouse 
bone marrow and fetal liver as well as in multipotent progenitors and mature T and 
B lymphocytes258,259. However, the expression pattern is complex and allele- 
specific in inbred strains of mice. For example, Ly-6A.2 strains express Sca-1 on 
99% of stem cells with repopulating activity, whereas Ly-6E.1 strains express Sca- 
1 on only 25% of these cells257. Transgenic mice studies, using a Ly-6E.1-LacZ 
construct, have shown that a 14 Kb Ly-6E.1 genomic fragment is sufficient to 
recapitulate endogenous sca-1 gene expression257. We therefore used these sca-1 
gene regulatory sequences to study the effects of forced hSCL expression on
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lymphocyte development and to understand how ectopic expression of hSCL or its 
DNA-binding mutant causes T cell leukaemia.
1.2 T cell lymphopoiesis
The characterisation of T cell developmental stages is based on the rearrangement 
status of the TCR loci and the expression of the CD4 and CD8 co-receptors (see 
figure 3.1). The earliest T cell progenitors in the thymus are present within the CD4 
and CD8 double negative (DN) population. In murine models, this DN population 
can be further subdivided into four developmental stages DN1 to 4 according to 
CD44 and CD25 surface marker expression. CD44+ and CD25- still have the 
ability to mature into NK and T lineage cells. Commitment to the T lineage is 
largely associated with activation of CD25 expression and downregulation of CD44 
and is followed by initiation of gene rearrangements at the TCR p, yand 5 loci. 
Formation of a functional TCR p gene product allows expression of the pre-TCR 
complex, which includes the TCR p chain as well as the pre-Ta protein and the 
CD3 assembly of signaling molecules. Signaling mediated by the pre-TCR complex 
results in developmental progression, also referred to as p selection. This transition 
is characterised by inhibition of gene rearrangement, initiation of cellular 
expansion, and maturation into CD4 and CD8 double positive (DP) thymocytes. DP 
cells then exit the cell cycle and begin TCR a gene rearrangement. The expression 
of an apTCR allows DP cells to undergo major histocompatibility complex (MHC) 
mediated positive or negative selection. Positively selected DP thymocytes 
downregulate either CD4 or CD8 expression to become single positive (SP) mature 
T lineage cells 268.
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Important transcription factors involved in the differentiation of T cells are the bHLH 
proteins encoded by the E2A gene, E12 and E47. Whereas DN1 thymocytes 
express little or no E2A, it is upregulated during the transition of the DN2 to DN4 
stage. However, upon pre-TCR mediated signaling, E47 DNA-binding activity is 
significantly down regulated. As compared to DN thymocytes, DP cells express 
lower levels of E47 proteins, which are decreased further during the transition from 
DP to SP cells These observations indicate, that a gradient of E47 expression is 
present during thymocyte development and that down regulation of this protein is 
required to promote the maturation of DN cells to the DP stage and further to the 
SP stage259.
1.3 B lymphopoiesis
As T cells, B cells develop from the CLP. The different stages of B cell 
differentiation can be subdivided according to surface marker expression and 
rearrangement of Immunoglobulin chains (figure 3.1). CLP and early pro-B cells 
express interleukin 7 receptor (II-7R) a and c-kit on their surface. Subsequent 
expression of the B cell marker B220 initiates pro-B cell differentiation marked by 
CD19 expression and completion of Dh-Jh rearrangement. Productive V h-D Jh 
recombination in late pro-B cells results in cell surface expression of the Ign 
proteins as part of the pre-B cell receptor (pre-BCR). Signaling through the pre- 
BCR promotes light-chain gene recombination and subsequently leads to the 
emergence of immature IgM positive B cells that emigrate from the bone marrow to 
the peripheral lymphoid organs (reviewed in270). Precursor commitment and 
progression through all stages of B lineage development as delineated above is 
dependent on specific gene expression programs as well as environmental cues.
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The analysis of genetically altered mice has led to the identification of a number of 
transcription factors, including E2A, EBF and Pax 5, that regulate many B lineage 
specific genes. These transcription factors act in a cascade and in synergy to 
establish and maintain the expression of target genes that promote the B 
lymphocyte maturation program from the common lymphoid progenitor up to the 
isotype switching of activated B lymphocytes. In the following I would like to focus 
on the role of E proteins in B cell development.
Considering that E2A proteins are components of heterodimers that are important 
for the development of many lineages, it was surprising that the targeted deletion 
of the E2A gene did not lead to any defects in these lineages, suggesting that the 
alternative class I bHLH proteins HEB and E2.2 are able to compensate for the 
loss of E2A100,101. However, in B cell development where E2A proteins form 
homodimers, a severe defect was observed in E2A deficient mice100,110. 
E2A-deficient mice display a complete block in B lineage development prior to the 
onset of IgH DJ rearrangement100,101. Early B lineage specific transcripts, including 
Igp,, IgK, RAG1 and Pax5, are lacking in E2A-null mutant bone marrow cells. Two 
other E protein members, E2-2 and HEB, also play a role in B lineage 
development. Mice deficient for these proteins generate mature B cells but contain 
50% fewer pro-B cells in the fetal liver, and mice that are transheterozygous for 
any two of the four E proteins display fewer pro-B cells than mice heterozygous for 
any E protein alone271. Restoration of E protein expression in an E2A null 
background allows for B cell development albeit at varying degrees. Expression of 
both E12 and E47 transgenes in E2A-deficient mice promotes B lineage 
development better than either transgene alone110. Furthermore, expression of two, 
but not one, copies of the HEB gene introduced into the E2A locus results in a
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partial rescue of B cell development272. Mature B cells are generated, but wild-type 
numbers are not achieved. Therefore, the overall timing and dosage of E protein 
activity may be a key determinant in B lineage progression rather than the activity 
of a specific E protein. More recent work using an affinity-tagged E2A knock-in 
allele and ChIP experiments has identified a number of critical early B-lineage 
genes as direct targets of E2A273,274.
In addition to this pivotal role in B cell commitment and early differentiation, E 
proteins have also been implicated in the initiation of V(D)J recombination and 11-7 
dependent expansion and survival of pro-B lymphocytes275 as well as pro-B to pre- 
B cell transition. Besides, E2A protein expression is high in activated mature B 
cells and cells present in the dark zone of germinal centres276,277, where they 
undergo clonal expansion, affinity maturation and immunoglobulin isotype 
switching. Although loss of E2A activity in the germinal centre does not interfere 
with proliferation and survival, it abolishes completely isotype switch 
recombination276.
2 OUTLINE OF EXPERIMENTS
The aim of the experiments presented in this chapter was to further establish the 
role of ectopic SCL and its DNA binding mutant /to SCL in lymphopoiesis and 
leukaemogenesis. Using a transgenic mouse model expressing SCL under the 
control of the Ly-6E 1 promoter we hoped to address the hypothesis that over­
expression of wt or Ab SCL in the stem cell compartment and in early thymocytes 
would perturb the stem cell pool and generate a pre-leukaemic or leukaemic 
phenotype.
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We established a transgene expression profile using RNA and protein prepared 
from various haematopoietic and non-haematopoietic organs. Besides, we 
immunologically labelled histological sections of the thymus to assess ectopic SCL 
expression. To quantitate transgene levels, we undertook real-time PCR analysis 
of bone marrow cell.
Next, we described the haematopoietic phenotype by performing blood films, full 
blood counts and FACS analysis of peripheral blood, bone marrow and thymus. 
Moreover, we obtained histology of peripheral lymphoid organs.
In order to characterise the defect observed in T-and B-cell differentiation more 
closely, we sorted progenitor populations from thymus and bone marrow and 
performed RT-PCR of genes critical for normal T- and B-cell differentiation. 
Furthermore, we extended our analysis to mature B-cells and induced isotype 
switching in vitro. Besides, we performed transplantation experiments in 
NOD/SCID mice with subsequent FACS analysis of peripheral blood and bone 
marrow to confirm that the defects observed were cell-intrinsic.
The results of this analysis indicate that over-expression of SCL or Ab SCL driven 
by the Ly-6E.1 promoter does not lead to T-cell leukaemia, but induces a profound 
defect in T lymphopoiesis. Surprisingly, we also found a block in B lymphopoiesis 
leading to a severe reduction in immature and mature B cells and a defect in 
isotype switch recombination. Mice expressing the SCL DNA-binding mutant 
developed the same phenotype as wild-type SCL in T- and B-cells, implying that 
the underlying mechanism of action in this setting was DNA-binding independent. 
Taken together, these data indicate that SCL or Ab SCL under the control of the Ly- 
6E 1 promoter leads to an arrest of normal lymphoid differentiation, suggesting that
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they may sequester or repress important lymphoid transcription factors such as the 
E proteins.
3 RESULTS
In the ensuing result section, I will present the T-and B cell phenotype.
3.1 Phenotype of Ly-6E. 1-hscl and Ly-6E.1- Abhscl transgenic mice
Transgenic constructs were made by inserting the human SCL (hscl) cDNA or the 
human SCL cDNA lacking the DNA binding domain (Abhscl) followed by the bovine 
growth hormone gene polyA sequence into the Cla I site of the 14 Kb Ly-6E.1 
cassette (fig. 3.2A)258,259 The Abhscl mutant was kindly given to us by Dr E 
MacIntyre (Hopital Necker-Paris) and was derived using oligonucleotide-mediated 
mutagenesis to delete the basic domain containing the amino acids 187 to 199 as 
previously described210,278. The Ly-6E. 1-hscl or the Ly-6E. 1-Abhscl fragments were 
microinjected into the pronuclei of fertilised (C57BL/6 x DBA/2) F1 oocytes. Two 
transgenic lines were generated with the Ly-6E.1-hscl construct, line 6 (L6) and 
line 8 (L8). Southern blot analysis of tail DNA showed that L6 contained 10 copies 
of the transgene while L8 contained 2 copies (data not shown). While the L6 
females were infertile, making it impossible to generate a homozygous line 6, we 
could obtain, at low frequency, homozygous descendants for line 8. Generation of 
Abhscl transgenic mice was difficult because of low transgene transmission. One 
founder did not transmit while another passed on the transgene to only one out of 
40 offspring. The third founder transmitted the transgene to 10 out of 68 
descendants establishing the transgenic line Ab L3 containing 6 copies of the 
transgene (data not shown). As we could only generate one Abhscl transgenic
86
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animal line, the conclusions regarding the DNA-binding domain must be guarded, 
as possible integration effects cannot be ruled out. While the general physical 
appearance of the transgenic lines was normal, an obvious kinking and short 
length of the tail was observed in 100 % of the high copy L6 mice, 70 % of the two 
copy heterozygous L8 and 100 % of the homozygous four copy L8 mice (fig. 3.2B). 
Ab L3 trangenic mice did not have kinked tails. Taken together with the known 
expression pattern of the Ly-6EA cassette in the Mullerian ducts and tail during 
embryogenesis, these results suggest that ectopic expression of hSCL induces 
female infertility, tail growth and bone abnormalities and that the severity of this 
phenotype is, in part, SCL dose- dependent.
3.2 Expression of hscl and Abhscl transgenes
As expected from previous analysis of the expression pattern of the Ly-6E. 1 
cassette, hscl mRNA was present in thymus, spleen and kidney and not detected 
in the squeletal muscle and the heart (fig. 3.2C). In these organs, the mRNA 
expression pattern of hscl in the heterozygous L8 and of Abhscl in the Ab L3 
transgenic mice was the same as in L6 animals, but the expression level was lower 
(data not shown). We next performed real time RT-PCR on total bone marrow of 
the 10 copy L6, the heterozygous 2 copy L8 and of wild type littermates. This 
assay revealed that the hscl/hprt mRNA ratio of the L6 animals was 6 times the 
expression level ratio of the L8 mice (Table 3.1). Thus, the transgene copy 
numbers in the two animal lines correlated well with their hscl mRNA expression 
level. In order to assess the transgene expression in different haematopoietic 
lineages we quantified hscl mRNA of FACS sorted bone marrow cells and 
thymocytes of L6 mice and their wild type littermate controls. Real time RT-PCR
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Table 3.1 Quantification of hscl mRNA levels in different 
animal lines
Animal lines mean hscl 
mRNA
mean hprt 
mRNA
mean scl/hprt 
ratio
10 copy L6 1.137 x 10'1 1.065 x 10‘1 1.068
2 copy L8 8.144 x 10‘3 4.572 x 10'2 0.178
Wild type 0 4.943 x 10'4 0
Real-time RT-PCR using Lightcycler technology (Roche) of unsorted 
bone marrow cells of L6, L8 and wild type animal lines was performed 
to show correlation beween transgene copy number and mRNA 
expression. Scl mRNA was quantified relative to hprt mRNA levels. All 
samples were run in duplicate and the mean scl/hprt ratio of 2 
experiments is shown.
Table 3.2 Effects of hSCL expression on peripheral blood 
cells
Animal
lines
B220+ CD4+ CD8+ MAC-1 + Sca-1 + 
Mac-1+
L6 19+/-10.9 22+/- 3.4 26+/- 3.2 27+/- 4.5 19+/-4 .8
Wild type 48+/- 7.2 13+/-1.8 11+/-1.2 24+/- 4.5 < 2+/-1
Peripheral blood cells from hscl L6 mice and their age and sex 
matched wild type controls were stained with anti-CD4 and anti-CD8 
antibodies for T-lymphocytes, anti-B220 antibody for B lymphocytes 
and anti-Sca-1 and anti-Mac-1 antibodies for myeloid cells and 
analysed by FACS. Mean percentages and SD values of 6 experiments 
are shown and refer to the total white cell count. They do not exactly 
equal 100% because several stains were necessary.
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showed a hscl/hprt mRNA ratio of 1 for B220 positive bone marrow cells and a 
ratio of 2 for the Mac positive population. The overall ratio in total thymocytes was
0.4 (data not shown). Real-time RT-PCR on DN, DP, CD4+ SP and CD8+ SP cells 
showed that the transgene was expressed in all thymocytes subsets in increasing 
order: DP, DN, SP cells. There was no significant difference in the mRNA 
expression level of CD4 and CD8 SP cells (data not shown). Hence, hscl mRNA 
expression was present in all the haematopoietic lineages studied and is in 
accordance with previously published data on the expression pattern of Ly-6E.1257. 
To examine whether the expression of hSCL protein was correlated with the 
expression of hscl mRNA, protein extracts from different organs were analysed by 
Western blot. A correlated expression between the hscl mRNA and the hSCL 
protein levels was found in all the positive organs tested, except for the kidney 
which expressed a high level of mRNA, but did not express the hSCL protein (fig. 
3.2D). A comparative study of SCL protein expression was performed using spleen 
nuclear extracts of the 10 copy L6 and the 2 copy heterozygous L8 mice. The 
protein level detected in L6 animals was 5 times the level of L8 mice, thus showing 
the correlation between transgene copy numbers and protein expression level in 
the spleen (fig. 3.2E). A faint hSCL expression was found in the total bone marrow 
by Western blotting and immunohistochemical staining of bone marrow paraffin- 
embedded sections showed the presence of positive mononuclear cells in this 
organ (data not shown).
3.3 Peripheral blood FACS analysis of transgenic mice reveals abnormalities 
in circulating lymphocytes and myeloid cells
To determine whether ectopic expression of hscl or Abhscl under the control of the 
Sca-1 regulatory sequence induces a defect in haematopoiesis, blood of 12 weeks
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old transgenic and non-transgenic age and sex matched littermates was collected 
and subjected to full blood counts. This analysis showed an increase in the total 
number of white blood cells (WBC) in the transgenic versus non-transgenic mice 
(3000/mm3 +/- 200 versus 2200/mm3 +/- 200, respectively) while the erythroid 
compartment, assessed by haemoglobin measurements and red blood cell 
numbers was not significantly altered (data not shown).
FACS analysis, performed on 12 weeks old L6 mice and their age and sex 
matched wild type controls revealed alterations of the peripheral blood cell 
distribution (Table 3.2). After gating on the total WBC, we found a 1.7 and 2.4 fold 
increase in CD4 and CD8 positive cells, respectively, leading to an alteration of the 
CD4/CD8 ratio of 1.2 vs 0.8 in non transgenic versus transgenic animals. 
Additionally, there was a 60% reduction in the absolute number of B cells identified 
by anti-B220 antibody. Interestingly, FACS analysis with anti-CD11b showed that 
the majority of L6 CD11b positive cells continued to express the cell surface 
marker Sca-1, whereas wild type CD11b positive cells were negative for this 
antigen in the peripheral blood (data not shown). All full blood counts and FACS 
analysis were performed on 6 transgenic and non-transgenic littermates.
Thus, abnormalities were only found in haematopoietic cells, which normally do 
not express SCL leading us to investigate haematopoietic and lymphopoietic 
organs.
3.4 The Sca-1 antigen expression persists on granulocytes and monocytes
After gating on the myeloid population, 100% of CD11b positive cells in the 
peripheral blood of L6 transgenic mice expressed the cell surface antigen Sca-1. In 
the bone marrow, we found a moderate increase of transgenic CD11b positive 
bone marrow cells. To define the mechanism underlying this moderate expansion
of the myeloid pool more closely, we performed methylcellulose cultures of total 
bone marrow and showed that the GM colony number was similar using transgenic 
or wild type bone marrow, while the size of the transgenic colonies appeared 
larger, thus indicating an increase in the proliferation potential of the transgenic 
granulo-macrophagic precursors (data not shown). Looking at the cell surface 
antigen, we found that, while only 5 % to 10 % of the CD11b+ cells expressed the 
Sca-1 antigen in the wild type mice and the low copy L8 line, more than 50 % of 
the CD11b+ cells were positive for Sca-1 in the high copy L6 and Ab L3 line (data 
not shown). As the bone marrow Sca-1 negative cells corresponded partly to 
macrophages (identified by the F4-80 specific antibody) and as the Sca-1 antigen 
is normally expressed on immature haematopoietic progenitors, the persistence of 
Sca-1 expression could indicate a block in granulocytic differentiation. This 
phenomenon has already been observed in granulopoietic cells that constitutively 
and inappropriately expressed SCL 228. We therefore performed cytospins of 
CD11b positive peripheral blood cells and of Sca-1/CD11b positive bone marrow 
cells and showed that their morphological stage of differentiation was similar to wild 
type CD11b positive cells (data not shown). Looking at the transgene expression 
using the BTL-73 anti SCL antibody we found that the transgene was extinguished 
in mature monocytes and granulocytes, indicating why we did not see a block in 
granulocytic differentiation.
3.5 Ectopic hSCL or AbhSCL expression under the control of the sca-1 
regulatory sequences alters thymic cellularity but does not lead to leukaemia
No T cell leukaemia developed in 150 transgenic mice during an observation 
period of one year. We first determined the type of cells that express hSCL protein 
in the thymus by performing immunohistochemical staining on paraffin-embedded
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sections of this organ using a monoclonal antibody that recognised the hSCL 
protein and not the mSCL protein. A nuclear staining was found in most of the cells 
in the medulla and in a minority of cells in the cortex (fig. 3.3A). Examination of the 
thymus of wild type, L6 and Db L3 mice of different ages showed that the 
transgenic animals presented with a smaller thymus (fig 3.3B) and a decrease of 
absolute thymocytes numbers (160 x 106 +/-10 x 106 versus 110 x 106 +/-10 x 106 
at 4-8 weeks; 80 x 106 +/- 10 x 106 versus 40 x 106 +/- 10 x 106 at 12 weeks in wild 
type and transgenic mice, respectively). FACS analysis of the total thymic 
population did not show, in the younger animals, any significant alterations in 
thymocyte subset distribution. In contrast, 12 week old transgenic mice presented 
a 50% decrease of the DN cell population, a 30-50 % decrease in the absolute 
number of DP cells whereas the same absolute number of single positive (SP) 
CD4 or CD8 cells was observed in transgenic and non-transgenic mice (fig. 3.3C). 
Hence, taken together, these data indicate a relative increase in the number of SP 
cells with regards to the more immature cell populations. In order to investigate the 
causes for this relative increase further we performed FACS analysis on the CD8 
SP cells which consist of two distinct type of cells: CD8 immature single positive 
cells (ISP) expressing low level of TCR-p and representing cells undergoing 
differentiation just before the double positive stage and CD8 mature single positive 
cells characterised by high level of TCR-p expression and representing 
differentiated cells. The expression level of TCR-p was analysed in CD8 SP cells, 
showing a 2 to 3 fold decrease of ISP cells in transgenic animals (data not shown) 
and indicating that the relative increase in the CD8 SP cells was not due to an 
increase in ISP cells.
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As signaling by the pre T-cell receptor (pre-Ta) and T-cell receptor (TCR) regulates 
cell proliferation and differentiation of DN and DP thymocytes, we studied 
expression of these genes. Real-time RT-PCR analysis was performed on DN, DP, 
CD4+ SP and CD8+ SP cells purified from L6 transgenic mice and their wild type 
littermates. These experiments did not show any significant deregulation of pTa or 
ter a gene expression in DN, DP or SP transgenic thymocytes (data not shown). 
The absence of T cell leukaemia in transgenic mice may be related to low hSCL 
expression in transgenic T cells. Thus, we compared the hSCL expression level in 
Jurkat and L6 transgenic thymocytes by western blotting and showed that the 
hSCL protein level in Jurkat was at least 4 times higher compared to the L6 
transgenic thymocytes (data not shown). Thus, assuming that the level of SCL 
expression in Jurkat cells represents the minimal threshold to cause tumors, ly- 
6E. 1 promoter weakness may be one reason why no T cell neoplasia occurred in 
our mouse model. Alternatively, other the variables such as mouse strain, 
transgene integration site or copy number have to be considered.
3.6 Ectopic hSCL expression leads to a significant reduction of early B-cell 
precursors
As blood analysis showed a significant reduction in B-lymphocytes, we performed 
FACS analysis on the lymphoid gate of the bone marrow of 12 weeks old L6 
transgenic mice and age and sex matched littermate controls and showed a 40 to 
50% reduction in the relative and absolute number of B220+ CD19+ cells. These
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results were independent of the copy number and were also observed in the Ab L3 
transgenic mice (fig. 3.4A).
To define the stage of a possible block in B cell differentiation, we performed 
multicolour fluorescent staining on the bone marrow of L6 and wild type animals 
using anti-B220, anti-CD19, anti-IL-7Ra and anti-c-kit specific antibodies. B220+ 
CD19+ cells were divided into two distinct entities: one B220high CD19+ population 
representing the more mature cells and one B220low CD19+ subset consisting of 
immature B cells. Together with the IL-7Raantibody, we observed a 4 fold 
decrease of pre-B and late pro-B cells (B220low IL-7Ra+ CD19+) in transgenic mice 
(fig. 3.4B). Additionally, using c-kit antibody to target the most immature B cell 
progenitors, we observed a three-fold reduction in the intermediate pro-B stage 
(B220low IL-7Ra+ c-kit+) (fig. 3.4C).
To further characterise the defect in B cell lymphopoiesis, bone marrow cells of L6 
and L8 transgenic and non-transgenic animals were subjected to in vitro pre-B 
colony formation assays. After 7 days of culture on methylcellulose we obtained 2 
to 3 (L6, L8) and 12 (Wt) pre-B colonies, indicating that B cell differentiation was 
not only reduced in vivo, but also in vitro and suggesting an intrinsic defect within 
the lymphoid compartment. As fetal B cell development has been described to 
differ from the adult setting, we analysed the B cell population in days 16.5 to 18.5 
fetal livers by FACS and found that, as in the adult bone marrow, the B cell 
compartment was affected by the ectopic expression of SCL protein at least up the 
pro-B cell stage (data not shown).
To analyse SCL effects on the expression of genes previously described as being 
important for B cell differentiation, we sorted B220+ CD19+ IL-7Ra+ (pro-B) and
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B220+ CD19+ IL-7Ra' (pre- B) cells from the bone marrow of transgenic and wild 
type mice and performed RT-PCR analysis. We demonstrate that, in cells escaping 
the defect in B cell differentiation, neither pax. 7, lef-1 nor pu.1 genes were affected 
by hSCL expression in either of these cell populations (data not shown), implying 
that B-cell differentiation in these cells does not seem to be impaired.
3.7 Ectopic hSCL expression in B cells leads to a defect in isotype class 
switch recombination
We then studied the effects of ectopic hSCL expression on splenic B cell 
maturation. Morphology of the spleen of transgenic animals revealed a 
disorganisation of the germinal centre (fig. 3.5A). Absolute splenocyte numbers of 
transgenic and wild type littermate were similar and FACS analysis showed a 30 to 
50% reduction of B220+ CD19+ and B220+ lgM+ cells in the spleen (fig. 3.5B and 
data not shown). In order to assess antigen dependent maturation further, we 
analysed the ability of transgenic splenocytes to undergo isotype class switch 
recombination upon activation with T cell independent antigen. As 
lipopolysaccharide (LPS) induces murine B cells to switch from IgM to lgG3 and 
lgG2b, we used LPS activation on sorted transgenic and non-transgenic B 
splenocytes. After exclusion of B220 negative cells, splenocytes derived from the 
high copy number transgenic mice showed a 4.5 fold reduction in lgG2b and lgG3 
isotypes (fig. 3.5C and data not shown) after 72 hours, indicating an effect of 
ectopic hSCL expression on antigen dependent B cell differentiation. B220 positive 
splenocytes derived from the low copy number transgenic mice showed a 
reduction in lgG3 of only 1.9 fold thus implying that SCL induces an isotype switch 
recombination defect in a dose dependent manner (data not shown).
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As E2A is involved in class switch recombination and heterodimerizes with SCL we 
performed electrophoretic mobility shift assays (data not shown) on nuclear 
extracts of LPS activated B splenocytes of transgenic L6, heterozygous L8 and 
wild type littermates. This analysis showed specific binding of a SCL/E2A complex 
to scl oligonucleotides, which is supershifted by a hSCL specific antibody. The 
same complex, however much weaker, is present in splenocytes of L8 animals. 
Thus, a complex containing SCL/E2A is present in activated B splenocytes of 
transgenic mice and its expression correlates with the transgene copy number in 
each line. Together with previously published data228'230,279, these results indicate 
that SCL protein may sequester E2A in these cells.
3.8 NOD/SCID mice transplanted with transgenic bone marrow display 
features of hSCL transgenic mice
B-cell differentiation has been shown to depend on the interaction of lymphoid 
precursor cells with the surrounding bone marrow stroma and microenvironment. 
We therefore aimed to exclude that the reduction in the B cell compartment was 
secondary to an extrinsic, cell non-autonomous phenomenon by performing 
transplantation experiments of transgenic and non-transgenic bone marrow into 
sublethally irradiated NOD/SCID mice.
At week 6 and 7 after transplant, blood was collected and FACS analysis 
performed. 75% of NOD/SCID mice injected either with transgenic or non- 
transgenic bone marrow, successfully engrafted. In NOD/SCID mice transplanted 
with transgenic bone marrow the Sca-1 antigen persisted on 30% to 50% of 
myeloid cells, indicating their transgenic origin. 11% versus less than 1% of 
peripheral blood lymphocytes of NOD/SCID mice transplanted with non transgenic
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versus transgenic bone marrow, respectively, were B220+ lgM+ cells (fig. 3.6A). 
Analysis of the bone marrow of all transplanted animals at 8 weeks post transplant 
showed that the population of B220hl9h CD19+ cells in transgenic grafts was 
severely reduced compared to wild type grafts. Non-transplanted NOD/SCID mice 
normally show an accumulation of pro B (B220low) cells (fig. 3.6B, first scatter) 
These cells disappeared in transplanted NOD/SCID mice irrespectively of the 
transgenic or nontransgenic origin of the bone marrow as shown in the second and 
third scatter of fig 3.6B. This absence of pro B cell accumulation in the transgenic 
transplants indicates that a possible block in B cell differentiation may be prior to 
this stage.
Thus, this data shows that in contrast to nontransgenic transplants hscl grafts 
failed to re-establish early and late primary B cell lymphopoiesis and that the 
effects of ectopic hSCL expression on myelo- and lymphopoiesis are intrinsic to the 
cell populations and not secondary to an epiphenomenon of the transgenic 
microenvironment.
4 DISCUSSION
This work was designed to assess (1) the effects of ectopic hSCL expression on 
the lymphoid compartment and (2) to determine the importance of the DNA binding 
domain for some of SCL’s functions. For these purposes, we generated two hscl 
transgenic models: L6 and L8 Ly-6E.1-hscl lines expressing different levels of the 
full length hscl transcription factor. Additionally, we examined the L3 Ly-6E. 1- 
Abhscl line encoding for a mutant hSCL protein devoid of the basic domain which 
allows DNA binding. However, because we were able to obtain only one single 
animal line, statements regarding this domain must be made with caution.
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Non-haematopoietic disorders
Transgenic mice presented haematopoietic and non-haematopoietic disorders. 
Apart from infertility, the most characteristic abnormality was the presence of 
kinked tails in 100% of high copy and 70% of low copy animals whereas they were 
absent in the Abhscl mutant suggesting that these phenomena were dose 
dependent and required hSCL DNA-binding. Dose dependency of bone related 
abnormalities and infertility has been observed previously in the sil/scl transgenic 
model248; in this model, the hSCL transactivation domain was not required to 
generate the phenotype. Our findings indicate that the DNA binding domain may 
be necessary to produce these ectopic non haematopoietic disorders and imply its 
potential importance for some SCL functions, although, due to reduced fertility of 
the mutant, we could investigate only one Abhscl animal line.
Transgene expression levels
Using real-time RT-PCR we showed a correlation between transgene copy 
numbers and mRNA expression level in the different animal lines. We could also 
establish a correlation between hscl mRNA and protein levels in different organs 
except for the kidneys which expressed high levels of transgene mRNA, but no 
protein. This discrepancy is in accordance with previously published observations 
on lacZ reporter gene expression under the control of Ly-6E.1 showing high mRNA 
but no protein expression in the kidneys257 and could be due to tight control of 
translation or protein degradation in this organ.
The stem cell pool is not affected
Despite its essential role in haematopoietic stem cells (HSCs), Ly-6E. 1-hscl did not 
lead to major quantitative alterations of these cells neither under normal conditions 
nor after 5-fluorouracil treatment (data not shown). Furthermore, methylcellulose
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colony forming assays did not show any significant difference in the number and 
morphology of colony forming units between transgenic and wild-type BM (data not 
shown). These results suggest that the expression level of hSCL in the Ly-6E.1- 
hscl transgenic HSCs might not be sufficient to increase the self-renewal potential 
of the HSC compartment or that the microenvironment may counterbalance hSCL 
action to ensure the homeostasis of the HSC pool.
Effects on the myeloid compartment
In contrast to previously published work212,230,245, we did not observe a block in 
myeloid or monocytic differentiation, neither in vivo nor in vitro, in the transgenic 
mice. Instead, there was a moderate increase in myeloid cells and a subpopulation 
of transgenic CD11b (Mac-1) positive cells expressed the Sca-1 antigen; this 
phenotype was dose-dependent but DNA-binding independent indicating that its 
generation may need a threshold of hSCL expression in myeloid cells. This 
suggests that sca-1 gene expression might be repressed during terminal myeloid 
differentiation and that the repressor might be sequestered by hSCL. Further 
investigations to address this question are necessary.
The defects observed in the lymphoid compartment may be due to
sequestration of E proteins
T-cells
Importantly, ectopic hSCL did not induce T cell leukaemia in any of the transgenic 
lines in over 150 offspring during their first year of life. This is in contrast to data 
published on the single transgenic Ick/SCL and on the double transgenic SCUcklla 
or SCL/lmo-2 and SCL/lmo-1 mice244'246,248,249. However, the onset of T-cell 
tumours in Ick/SCL transgenic mice was characterised by low penetrance and long 
latency244. In contrast, Ick/SCL mice with a p53 +/- background or double
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transgenic mice developed the disease earlier and with a significantly higher 
penetrance. Thus, the ability of SCL to generate T-cell tumours in transgenic 
mouse models is likely to depend not only on the regulatory sequences used to 
mediate SCL expression in mice and on variables such as mouse strain, transgene 
integration site and copy number, but also on additional oncogenic events or co­
expression of other oncogenic transgenes.
In our model, we observed a decrease in the number of immature DN, ISP CD8+ 
cells and DP subsets which was not due to increased apoptosis (data not shown). 
However, compared to non transgenic mice, the number of mature SP cells 
remained unchanged indicating an increased differentiation capacity from the DP 
to the SP cell stage or a proliferation ability of the transgenic SP cells. T cell- 
specific E box complexes are largely composed of E2A/HEB heterodimers; 
however, their DNA-binding activity is decreased upon transition from the DP to the 
SP cell subset111,280. Thus, ectopic expression of SCL could perturb this balance 
and induce an increase in the differentiation rate of the DP cells. A recent study 
using standard RT-PCR followed by Phosphorlmaging quantification showed a 
significant reduction in pTa expression in DN cells and in tcra expression in the DP 
population in scl/lmo1 transgenic mice which went on to develop leukaemia149. 
Using real-time PCR we could not detect a down-regulation of these genes in DN, 
DP or SP cells of hscl single transgenic mice thus indicating that the decrease in 
DP cells is not due to a deregulation of these genes. Besides, we did not detect 
lmo2 mRNA in DP nor SP thymocytes (data not shown). Thus, our results suggest 
that ectopic SCL expression during T-lymphopoiesis alters cell proliferation and 
differentiation via pTa and tcra gene expression independent mechanism and may
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represent a state in which additional events like LMO-1/2 expression are necessary 
to lead to the leukaemic phenotype.
B-cells
The most striking characteristic of Ly6E. 1-hscl and Ly6E. 1-Abhscl transgenic mice 
was their reduction in B cells. This phenotype has not been described so far in 
neither in vivo nor in vitro studies and is certainly due to a specific SCL activity as, 
in contrast to our results, transgenic mice generated using the Ly-6E.1-bcl2 
cassette present an increase of the B cell compartment in spleen and bone marrow 
(unpublished data, Dzierzak E.). Although SCL has not been directly implicated in 
normal or malignant B-cell biology, bHLH dosage plays a critical role in B-cell 
differentiation. Because SCL is able to heterodimerize with E2A in vitro, we further 
investigated its effects on B-cell development. The hscl transgene induced a 
reduction in the fetal and adult B cell compartment including the most immature 
stages. However, antigen independent maturation of B cells escaping this effect 
seemed to be normal. Finally, by transplanting transgenic bone marrow cells into 
NOD/SCID mice we showed that the B cell defect induced by SCL was cell 
autonomous.
The B cell deficiency observed may be due to a differentiation block, similar to the 
one described in various gene inactivation studies such as Pax-5-7' knock out 
mice280. As pax-5 has recently been described as a target gene for E2A281, titration 
of E2A by hSCL in pro and pre B cells should alter pax-5 gene expression. 
However, in pro and pre B cells escaping the defect in B cell differentiation, we did 
not detect any alteration in pax-5 gene expression, implying that SCL does at least 
not completely sequester E2A in pro and pre B cells. Additionally, in contrast to the 
Pax-5-7- knock out experiments, we could not detect an accumulation of immature
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pro B cells. This may suggest that if there is indeed a block in differentiation it must 
be early before the pro B cell stage. The effect observed occured at low and high 
copy transgene numbers, implying that even low levels of SCL expression are 
sufficient to perturb the transcriptional balance of B-lymphopoiesis. In addition, the 
same B-cell defect was also observed in the Ab mutant, supporting the idea that 
hSCL may exert transcriptional activity via a DNA binding independent mechanism 
by forming part of a large multi protein complex. This is consistent with previous 
data on hSCL acting as a co-factor of GATA-3 in a complex containing LM02254 
and particularly with the rescue of primitive and definitive haematopoiesis by 
AbSCL188.
We also found disorganisation of the germinal centre and defect in isotype class 
switch recombination of mature B cells. Similar morphological features have been 
found in mice lacking OBF-1, a transcription factor involved in class switching282. 
As E2A is required in class switch recombination276 we performed EMSA on 
nuclear extracts of LPS activated B splenocytes and showed that the heterodimer 
SCL/E2A was present in these cells and that its level correlated with the transgene 
copy number. Additionally, the class switch recombination defect observed was 
dependent on the expression level of SCL protein indicating that it is most likely 
due to titration of E2A. This is in contrast to the reduction in the B cell 
compartment, which was dose-independent and thus suggests other possible 
mechanisms of SCL action on B cell differentiation. Taken together, ectopic SCL 
expression sheds further light on the critical role of E-proteins in B-cell 
development.
In conclusion, we have shown that overexpression of hSCL alone in a transgenic 
scenario does not only lead to an imbalance in thymocyte maturation but also to a
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most unexpected block in B lineage differentiation. Here, we have indicated both 
DNA-binding independent and dependent functions of SCL and show that the SCL 
gene extinction observed during myelopoiesis and B and T lymphopoiesis is 
necessary for the normal development of these haematopoietic lineages.
5 ANNEX TO DISCUSSION
This first project allowed me to become familiar with some of the important 
techniques used in molecular and cellular biology. However, it had severe 
limitations directly linked to the transgenic approach used. With hindsight, it seems 
to me that an over-expression model using a non-inducible system may not be the 
ideal approach to further define the role of SCL in haematopoiesis and leukaemia. 
Besides, the detailed characterisation of its effects on B cells, where SCL is not 
normally expressed, is questionable and the results obtained simply strengthen the 
importance of E proteins in B cell development.
I have come to the following five main conclusions:
1. The Sca-1 cassette is not suitable to drive expression of SCL in the HSC 
compartment. This may be due to insufficient levels of transgene expression in 
each cell. Besides, the mouse strain used expresses Sca-1 in only 25% of 
stem cells with repopulating activity. If these cells have a survival 
disadvantage, they may be substituted by HSC that do not express the 
transgene. Moreover, recent evidence from conditional knockout studies 
suggests that SCL is dispensible for normal function and maintenance of adult 
HSC78. Thus, it may not be surprising that the SCL transgenic mice did not 
show any abnormalities at the HSC level.
2. In cells that do not normally express SCL, such as lymphocytes, over­
expression of SCL leads to a profound disturbance of the normal differentiation 
program probably via interaction with important regulators of lymphopoiesis like 
the E proteins. This is of relevance in T cells, where ectopic SCL expression is 
seen in leukaemia.
3. Under the control of the Sca-1 promoter, SCL is expressed in T- cell 
progenitors. However, this experiment does not lead to T cell leukaemia. 
Therefore, either levels and/or the precise timing of SCL expression in T-cell 
development are critical for leukaemogenesis.
4. Additional oncogenic events are likely to be required to enhance the leukaemic 
potential of SCL and it is thus likely that SCL is involved in a molecular cross 
talk with other nuclear proteins.
5. Mice expressing the SCL DNA-binding mutant present with the same pre- 
leukaemic phenotype, further strengthening the hypothesis that, in 
lymphopoiesis, as in stem cell specification, SCL does not act through direct 
DNA-binding. Its function is therefore very likely to rely on protein-protein 
interactions through its HLH domain.
Therefore, a logical progression of this work was to try and identify protein 
partners of SCL.
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CHAPTER IV: ATTEMPTS TO IDENTIFY SCL-CONTAINING 
COMPLEXES BY CONVENTIONAL IMMUNOAFFINITY 
1 INTRODUCTION
To date, a number of laboratories have attempted to identify additional partners of 
SCL in haematopoiesis and leukaemogenesis by using expression cloning 
strategies but have not been able to characterise other informative partner proteins 
in addition to those already known. To begin my search for SCL partners we opted 
for the Far Western approach, a technique which had been successfully used, for 
example, to identify co-activators of nuclear hormone-receptors283. I made and 
screened a cDNA expression library from mRNAs extracted from a patient with a 
T-ALL carrying a s/7 deletion. As SCL is essential for erythromegakaryocytic 
differentiation (see chapter I) I also screened human megakaryocyte and erythroid 
protein expression libraries. Unfortunately, none of these screens were informative 
because of high non-specific background. Besides, this technique only detects 
binary interactions. As SCL always functions as a heterodimer, this strategy was 
certainly not the most appropriate to identify additional partners. We therefore 
decided to adopt a different approach and chose immunopurification of SCL- 
containing multiprotein complexes with subsequent mass spectrometric analysis.
In the following paragraph, I wish to delineate some of the technical considerations 
associated with this approach.
1.1 Immunopurification
The successful outcome of conventional immunopurification (IP) depends on the 
availability of specific high affinity antibodies.
Ill
The IP is commonly preceded by several steps of prepurification to reduce the 
complexity of protein lysates or nuclear extracts. This consists of an antigen 
concentration step followed by size fractionation of the protein extract and/or 
purification by ion exchange and subsequent IP. The first two steps are necessary 
to increase amount and concentration of the antigen in the input, the IP itself adds 
specificity. The IP step is performed in stringency conditions which preserve 
protein-protein interactions in multimeric complexes. The antigen-antibody 
complexes (and proteins associated to the antigen) are pulled-down with 
Sepharose beads coated with protein A or G. Affinity of protein A or G to the Fc 
fragment of antibodies is species - and IgG isotype-dependent. For example, 
protein A strongly binds to polyclonal rabbit IgG, but only weakly to murine lgG1 
and rat lgG2a and 2b whereas Protein G binds all IgGs except for chicken. It is 
important to be aware of the different characteristics of available antibodies. As a 
general rule, polyclonal antibodies have the advantage of high affinity to both 
antigen and sepharose beads. However, specificity is usually inferior to monoclonal 
antibodies. Monoclonal antibodies on the other hand can be very specific, but their 
affinity to both antigen and sepharose beads is often low.
Affinity to beads can be increased by using bridging antibodies between the 
antibody used in the IP and the beads. In order to prevent IgG heavy and light 
chain shredding, it is common practice to crosslink antibodies to beads prior to 
mass spectrometric analysis.
1.2 Mass spectrometry
Traditionally, mass spectrometry (MS) has been regarded as an indispensable yet 
expensive, complicated and time consuming tool in protein chemistry. However, in 
recent years, due to significant improvements of the technology and its ability to
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identify proteins in complex mixtures, it has become of increasing value for life 
sciences and medicine.
By forming gas-phase ions from intact, neutral molecules, MS analysis can provide 
the accurate molecular weight of proteins and peptides with masses up to 500 kD 
using only a few picomoles of material and with an accuracy of around 0.01% of 
the calculated mass. In comparison, SDS-PAGE have accuracies of only 5-10% ; 
moreover, the mobility of the protein in the gel can be grossly affected (up to 50%) 
by the presence of covalent modifications such as lipids and carbohydrates. 
Because of this accuracy, a difference between the observed and the calculated 
mass of a protein analysed by MS can give invaluable clues as to the structure of 
the protein in question.
Besides, MS also has the ability to provide amino acid (AA) sequence information 
on peptides using a methodology called tandem MS (MS/MS). With MS/MS, 
sequences of up to 25 AA can be identified.
All mass spectrometers have three essential components : an ion source, the mass 
analyzer, and a detector. Ions are produced from the sample in the ion source 
using a specific ionization method. The ions are separated in the mass analyzer 
based on their mass-to-charge (m/z) ratios and then detected by an electron 
multiplier. The data system produces a mass spectrum, which is a plot of ion 
abundance versus m/z. MS/MS consists of two stages : the first stage serves to 
isolate a peptide precursor ion of interest based on its m/z, and the second stage 
to mass analyse the product ions formed by sponaneous or induced fragmentation 
of the selected precursor ion. Interpretation of the product-ion spectrum provides 
sequence information for the peptide selected.
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Within a few years of their introduction in 1988, two different ionization methods 
called electrospray ionization (ESI) and matrix-assisted laser desorption/ionization 
(MALDI)284,285 had supplanted previous techniques. By cocrystalizing analyte 
molecules with an excess of an UV absorbing matrix, MALDI-MS produces singly 
charged peptide ions which are then analysed by a time-of-flight (TOF) analyzer. 
By contrast, in ESI, multiply charged ions are formed from peptides by spraying a 
dilute solution of the analyte into the atmosphere chamber before analysing them 
in a triple quadrupole mass filter (for review286,287).
The sensitivity of both methods is in the low-picomole range. ESI-triple quadrupole 
analyses molecules within 150 kD, MALDI-TOF achieves information on molecular 
weights of over 350kD. However, in the molecular weight range from 5-50 kD, ESI 
is much more accurate and provides better mass resolution. Generally, MALDI is 
less sensitive to contamination with buffers and salts, but intolerant of SDS. 
However, with the advent of high performance liquid chromatography (HPLC) 
combined to ESI (LC-ESI) and new desalting methods, the problem of sample 
contamination with ESI has been alleviated. In addition, LC-ESI allows the 
separation of complex protein mixtures prior to MS analysis whereas MALDI 
requires simple protein samples. LC-ESI however, takes about 70 minutes per 
sample and only one sample can be analysed at the time. In contrast, MALDI 
allows high through-put analysis. This implies that MALDI is the ideal tool when 
dealing with protein spots from two dimensional gels or with protein-protein 
interaction arrays and antibody coated arrays. LC-ESI on the other hand is used for 
the identification of proteins after one dimensional separation techniques.
The more widespread need of mass spectrometry analysis in life sciences and 
medicine has triggered the development of several new techniques and analysers.
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Importantly, the analyser in our study, called Q-TOF, is increasingly used to 
analyse complex protein mixtures (figure 4.1) (for review288). It consists of a hybrid 
between LC-ESI-triple quadrupole analyser and MALDI-time-of flight using HPLC- 
ESI or MALDI combined with a quadrupole and time-of-flight mass analyser (Q- 
TOF).
Besides, in the context of medical research and diagnostics, it is worth mentioning 
that the introduction of novel technologies such as surface-enhanced laser 
desorption/ionization MALDI already permits high through-put analysis of crude 
serum or urine samples. Finally, imaging MALDI-MS has been used to analyse 
proteins of tissue sections which were thaw-mounted on a target plate and coated 
with matrix (for review289).
2 OUTLINE OF EXPERIMENTS
A general outline of the conventional multi-step purification strategy is given in 
figure 4.2A. We decided to adopt this approach after initial unsuccessful attempts 
to immunopurify SCL in a single step from crude nuclear extracts or from extracts 
prepurified by weak anionexchange. Briefly, MEL nuclear extracts were prepared 
from 4 litres of cell culture. 25mgs were precipitated using 55% 
Ammoniumsulphate and the resuspended precipitate containing SCL protein was 
loaded on a Superose 6 H/R sizing column. Gel filtration fractions were screened 
by Western Blot for SCL and its known partners and SCL-containing fractions were 
used as the input for immunopurification. A polyclonal rabbit antiserum raised 
against the C-terminal (Ct) domain of SCL188 was affinity-purified and used in the 
IP reaction.
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3 RESULTS
3.1 Size fractionation reveals that SCL co-migrates in high-molecular weight 
fractions with known partners
In vitro analyses suggest that SCL is part of multiprotein complexes in 
erythroid cells and in vivo studies show co-occupancy of regulatory sequences of 
haematopoietic-specific genes by SCL and members of the pentameric complex 
(see Chapter I). To show that, in vivo, SCL can form multimeric protein complexes 
in erythroid cells, gel filtration analyses of nuclear extracts prepared from 
uninduced mouse erythroleukemic (MEL) cells were performed. Upon fractionation 
of the nuclear proteins on Superose 6 columns, collected fractions were subjected 
to Western Blot analysis (figure 4.2B). This revealed that SCL, as well as two 
previously characterised partners GATA-1 and Ldb1, co-elute in fractions 
corresponding to molecular weights of 670 kDa and above (fractions 6 to 10) 
thereby indicating that they are part of high molecular weight multiprotein 
complexes. A small proportion of SCL was also detected in a fraction 
corresponding to lower molecular weights (fraction 18). Very similar results were 
obtained after fractionation of nuclear extracts purified from a megakaryoblastic cell 
line (L8057, data not shown). Therefore, in erythroid cells and megakaryocytes, 
SCL and its partners GATA-1 and LDB-1, are very likely to be associated with 
nuclear proteins to form one or more high molecular weight complexes. A fraction 
of SCL may also exist as heterodimers with E-proteins or in small protein 
complexes, unless detection of SCL in fraction 18 is the result of the dissociation of 
the high molecular weight multiprotein complexes during the purification and 
fractionation processes.
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Figure 4.2
A Purification of SCL-containing multiprotein complexes: the immunopurification strategy 
B Gel-filtration analysis
Nuclear extracts were prepared from MEL cells, fractionated by a Superose 6 H/R 
gel-filtration column and analysed by W estern blotting.
The num bers over the lanes represent the eluted fraction num bers, and protein m olecu lar 
masses are indicated by arrows.
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3.2 P107 may be a partner of SCL
This initial pre-purification step allowed to reduce the complexity of the nuclear 
extracts to a great extent. Gel filtration fraction 8 was then chosen to perform pull­
down experiments using immunopurified rabbit aSCL antibodies crosslinked to 
Protein G beads. Antigen was eluted from the beads with 100 mM glycine pH 2.5 in 
six fractions. These fractions were then tested by Western Blot for presence of 
SCL. SCL and the known partners GATA-1 and E2A co-eluted in fraction three 
(figure 4.3A), thus showing that known SCL partners had been co-purified and, 
therefore, validating the technique. A typical profile of the SCL-positive eluate 3 
from MEL and L8057 nuclear extracts is presented in figure 4.3A after separation 
on a 4-12% SDS-Page gel and silverstaining. It reveals a number of discrete bands 
which are present in the IP lane with aSCL, but not in the negative control with 
rabbit polyclonal immunoglobulin (IgG). To identify additional partners of SCL, the 
precipitated proteins were subjected to mass spectrometry analysis. For this, 
silverstained bands were cut out and the proteins digested with trypsin. However, 
mass spectrometry analysis proved very difficult because of the weakness of 
some of the bands and because of structural modifications of the proteins caused 
by the silver staining process despite immediate destaining steps. To circumvent 
these problems, we scaled up the immunopurification, separated the eluate by 
SDS-PAGE and subsequently stained with Sypro Ruby gel stain. This fluorescent 
staining method does not interfere with subsequent mass spectrometry analysis 
and, as a general rule, it is less sensitive than silver-, but more sensitive than and 
colloidal Coomassie-staining. From MEL pull-downs, we visualized one band at 
around 100kD (data not shown) which was identified by mass spectrometry as
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p107, a retinoblastoma related protein. As retinoblastoma protein has been 
described as a potential partner of SCL in MEL cells226 we attempted to validate 
this result by reverse co-immunoprecipitation from MEL nuclear extracts using 
polyclonal rabbit ap107 antibodies. The results of the Western Blot with anti-SCL 
are illustrated in Figure 4.3C: p107 is able to pull down a small fraction of SCL and 
is therefore likely to be a partner of SCL.
4 DISCUSSION
This conventional immunopurification procedure was a first step towards the 
purification of SCL-containing multi-protein complexes.
1) The gel filtration data presented shows for the first time that SCL and its 
partners are part of high molecular weight complexes in vivo. 2) We were able to 
validate the purification procedure by pulling down known partners of SCL from gel 
filtration fractions. 3) After scaling-up the purification procedure and changing the 
staining technique, I could identify p107 as one potential partner of SCL in MEL 
cells.
P107 is a member of a family of three closely related mammalian proteins which 
includes p130 and the widely known tumour suppressor retinoblastoma protein 
(RB) (for review290). Together, these proteins are known as the pocket proteins 
because their main sequence similarity resides in a domain (the pocket domain) 
that mediates interactions with E2Fs and other factors including viral oncoproteins. 
Overexpression experiments have indicated functional similarities between the 
three family members in the regulation of the cell cycle. Thus, all of them cause 
arrest in the Gi phase of the cell cycle by interacting with and repressing E2F-
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mediated gene transcription. In addition, they are all phosphorylated by cyclin- 
dependent kinases (CDKs). Genetic experiments suggest that the three proteins 
have partially redundant as well as opposing functions (for review291).
The most extensively studied member of this family is RB, the first tumour- 
suppressor gene ever to be cloned292,293. RB is known for its involvement in familial 
cases of retinoblastoma. In the haematopoietic system, it is expressed in 
multipotent progenitor cells and throughout erythroid differentiation294. Rb-/- mice 
die between 13 and 15 dpc with a pronounced defect in erythroid and neuronal 
development and both intrinsic and extrinsic functions have been put forward to 
explain the haematopoietic defects observed in Rb-/- mice295,296. Interestingly, it 
has been shown in transactivation experiments that RB represses c-kit gene 
activation upon interaction with the SCL-containing pentameric complex in 
erythroblasts226. It seems that the repressive action of RB on regulating gene 
expression occurs, at least in part, via the recruitment of chromatin remodelling 
complexes to promoter regions. These complexes mediate chromatin 
condensation and subsequent inhibition of transcription297,298.
The role of the retinoblastoma related protein p107 in haematopoiesis is less clear 
in that the phenotype of the p107 single knock-out is mouse strain-dependent and 
does not have haematopoietic abnormalities. However, p107 recruits repressor 
complexes containing HDACs to E2F promoter regions similar to retinoblastoma 
protein 299-300. Thus, together with these published data, our results indicate that 
SCL may act as a repressor in erythroblasts via interaction with members of the 
pocket family of retinoblastoma related proteins.
In conclusion, we have described a potentially interesting interaction between SCL 
and p107. However, as discussed, there were clear technical limitations associated
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with the im mu noaffinity purification. We therefore decided to opt for a different 
approach to identify SCL-containing protein complexes.
CHAPTER V: THE BIOTIN-STREPTAVIDIN SYSTEM
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1 INTRODUCTION
1.1 The biotin-streptavidin purification strategy
The biotin-streptavidin purification approach I used was developed in collaboration 
with John Strouboulis262. It involves stable expression of the protein of interest 
(SCL) tagged with a 23 amino acid sequence that can be efficiently biotinylated in 
vivo, in cells that also stably express the Escherichia Coli BirA biotin ligase protein. 
Biotin is a naturally occurring cofactor of metabolic enzymes, which is active only 
when covalently attached to the enzymes through the action of specific protein- 
biotin ligases. Biotinylated substrates can be bound very tightly by the proteins 
avidin and streptavidin. This is a strong noncovalent interaction, several orders 
more avid than that of any other commonly used affinity tags and immunoaffinity 
methods. As such, this system offers advantages over conventional purification 
techniques. First, purification of the biotinylated protein is performed under more 
stringent conditions, thus reducing background binding often observed with other 
affinity tags. Second, as there are relatively few naturally biotinylated proteins, 
purification of false-positive partners is reduced compared to IP procedures using 
antibodies which may cross-react with many other unrelated proteins. The 23 
aminoacid tag was selected through multiple rounds of screening combinatorial 
peptide libraries for specific biotinylation by BirA biotin ligase301. Such tags do not 
interfere with normal protein function and localisation, and are biotinylated in vitro 
with kinetics similar to those of a natural biotin acceptor302. As such, it has been 
demonstrated that these tags serve as excellent substrates for efficient 
biotinylation in cells by co-expressed biotin-ligase.
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2 OUTLINE OF EXPERIMENTS
To set up the technique, the mouse erythroid (MEL) and megakaryoblastic (L8057) 
cell lines were first transfected with the biotin ligase BirA. Stable clones, expressing 
high levels of BirA cDNA under the control of the strong ubiquitous human EF-1a 
promoter were identified by Northern Blot (see figure 5.1 for general outline of 
experiments and figure 5.2A for Bir A constructs). They were subsequently 
transfected with an SCL cDNA tagged with a sequence coding for 23AA that can 
be biotinylated in vivo, and expressed under the control of the EF1-a promoter 
(figure 5.2B). MEL and L8057 clones expressing levels of biotinylated SCL similar 
to that of endogenous SCL in wt cells were selected. Crude nuclear extracts were 
prepared from 4 litres of cell culture (Dignam procedure) and purification of SCL- 
containing complexes performed using streptavidin beads. Complexes were eluted 
from the beads and separated by SDS- PAGE electrophoresis. Precipitated 
products were then analysed by Western Blot and mass spectrometry.
In parallel, I also set up the system in SCL-/- ES cells in order to be able to show in 
rescue assays that biotinylated SCL retained its functions in haematopoietic cells.
2.1 The SCL mutants
In addition, we used this experimental procedure to test the capacity of chosen 
SCL mutants to bind to protein partners. There were two aims to this : 1) to identify 
partners of SCL interacting with residues within the bHLH domain crucial for SCL 
function ; 2) to characterise the domains and residues of SCL mediating the 
interaction with newly identified partners. These mutants have been previously 
characterised in detailed structure-function studies188,193 (see chapter I) and are 
summarized in figure 5.3. Briefly, they consisted of three deletion mutants (ACt,
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ANt, ACtNt), three substitution mutants (RER, FL and H2F-G) and three swapped 
mutants (SMS, SNS, SES,).
The deletion mutants would help us to broadly map the domains of interaction of 
SCL with the newly identified partners. The RER mutation abrogates SCL’s ability 
to bind to DNA. The absence of interaction between this mutant and newly 
identified SCL partners could suggest that direct DNA binding of SCL is required 
for their interaction. For the FL mutant, two residues in helix 1 crucial for 
heterodimerisation with E2A were mutated into alanines. Using this mutant in pull­
down experiments would show whether heterodimerisation was absolutely required 
for protein partners to bind to SCL. The H2F-G mutant was defined in the detailed 
structure-function study of the SCL HLH protein interaction domain193. As already 
mentioned, this study was aimed at identifying some of the crucial aminoacids 
within the HLH domain of SCL indispensable for primitive and definitive 
haematopoiesis. A variety of different constructs containing point mutations within 
the SCL HLH region were assessed for their ability to rescue haematopoiesis from 
SCL-/- ES cells in vitro. In this loss-of-function study, it became apparent that a F- 
G mutation in helix two (H2F-G) was of particular interest as this mutation did not 
seem to affect SCL/E2A heterodimerization ability, but abolished rescue of 
primitive haematopoiesis. We therefore postulated that this phenylalanine in helix 
two could mediate protein-protein interaction crucial for SCL function and tested 
the interactions of the H2(F-G) mutant with known partners of SCL, as well as 
newly identified ones.
Finally, in the swapped mutants, the SCL HLH domain was substituted by the HLH 
domains of other bHLH protein family members : The muscle-specific class II 
bHLH protein MyoD, the neuronal class II bHLH protein NSCL and the ubiquitous
128
SCL wt
ACt
ANt
ACtNt
RER
H2F-G
FL
SMS
SNS
SES
QNVNGAFAELRKLI PTHPPDKKLS KNEILRLAMKYINFLAKLl 
Nt H1 L H2
RRIFTNSRERWRQ 
RRIFTNSAAAWRQ 
H1 L H2 Ct
KNEILRLAMKYINFLAKLL' 
KNEILRLAMKYINGLAKLL
H1 L H2 Ct
QNVNGAFAELRKLI 
QNVNGAAAEARKLI 
Nt H1 L
QNVNGAFAELRKLI PTHPPDKKLS KNEILRLAMKYINFLAKLL 
SKVNEAFETLKRCTSSNPNQRLPKVEILRNAIRYIEGLQALL 
Nt H1 L H2 Ct
INVNGAFAELRKLI PTHPPDKKLS KNEILRLAMKYINFLAKLL 
EAFNLAFAELRKLLPTLPPDKKLSKIEILRLAICYISYLNHVL 
Nt H1 L H2 Ct
% of EBs Dim
21.3% +
ND +
ND +
ND
ND
0%
0%
0%
0%
0%
ND
QNVNGAFAELRKLI PTHPPDKKLS KNEILRLAMKYINFLAKLL 
RDINEAFRELGRMCQMHLKSDKAQTKLLILQQAVQVILGLEQQV
Figure 5.3 Schematic presentation of SCL mutants used in this study
Deletion m utants (ACt, ANt, ACtNt), substitution m utants (RER, H2F-G, FL) and
swap m utants (SMS, SNS, SES). The table indicates the percentage of red em bryoid bodies (EB)
obtained with the respective construct in rescue experim ents and the d im erisation ability  with E2A
(Dim). Ct=C term inal; Nt=N term inal, RER=DNA binding mutant, H 2F-G =phenyla lan ine substitu tion in
helix 2, FL= phenylalanine and lysine in helix 1 replaced by alanines
SM S=SCL HLH dom ain replaced by that of MyoD
SNS=SCL HLH domain replaced by that of NSCL
SES=SCL HLH dom ain replaced by that of E47
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class I bHLH protein E2A. These swapped mutants would enable us to test the 
haematopoietic specificity of the protein interactions studied.
All mutated cDNAs were subcloned into pEF1a biotag vector in replacement of the 
wild-type SCL sequence (figure 5.2A).
3 RESULTS
3.1 Generation of SCL-/- ES cells, MEL and L8057 cells that co-express the 
biotin-ligase Bir A and biotagged wild-type or mutant SCL
After transfection of SCL-/- ES cells, MEL and L8057 cells with the pEF1-a Bir A 
constructs and selection of stable clones, total RNA was extracted from several 
independent clones and Northern blots were performed using the last 500 
nucleotides of Bir A cDNA as a probe (Figure 5.4). Bir A mRNA (1.3kb) was 
expressed at high levels in all clones compared to wild type controls.
SCL-/- ES cell clone 2, L8057 cell clone 1 and MEL cell clone 8 were subsequently 
transfected with pEF1-a biotag wild-type (wt) SCL (bio-SCL). L8057 clone 1 and 
MEL clone 8 were also transfected with the mutant SCL H2(F-G). After selection of 
stable co-transfected clones, nuclear extracts were prepared and Western Blots 
performed with aSCL antibody. Endogenous SCL was not detected in MEL and 
L8057 clones transfected with wt bio-SCL, as only the slow-migrating biotin-tagged 
protein was observed. In contrast, MEL and L8057 cells transfected with bio-SCL 
H2(F-G) retained expression of endogenous SCL, as bands corresponding to both 
tagged and untagged SCL proteins are detected (Figure 5.5, top panel). After 
stripping the membrane and incubation with a Streptavidin-HRP conjugate,
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Figure 5.4: The biotin ligase BirA is expressed in transfected clones
T ota l R N A w as ex trac ted  from  S C L-/- ES cells, L8057  and M E L ce ll c lones  
trans fec ted  w ith  the  b io tin  ligase B ir A  as w ell as from  w ild -type  ce ll con tro ls . 
T he  N orthern  B lo t ana lys is  show s express ion  o f B ir A  m R N A  (1.3 kb tran scrip t) 
in all the  tran s fe c ted  c lones  tested.
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Figure 5.5: SCL is biotinylated in vivo
Nuclear extracts were prepared from non-induced MEL, L8057 and SCL-/- embryonic stem (ES) cells 
co-expressing biotagged SCL or the H2 (F-G) mutant and the BirA biotin ligase and from wild-type MEL 
cells. Western Blots were performed using anti-SCL antibodies (top panel; note that expression of 
biotagged SCL suppresses expression of endogenous SCL in MEL and L8057 cells).
The membrane was then stripped and incubated with streptavidin-HRP to confirm that biotagged SCL 
was biotinylated in  vivo  (bottom panel). bio-SCL=biotinylated SCL, HRP= horse raddish 
peroxidase
b io -S C L wt
a S C L
aG R B 2
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. b io -S C L  
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Figure 5.6: Quantification of SCL protein expression in transfected MEL cells
Relative expression levels of SCL in nuclear extracts prepared from w ild-type MEL ce lls and 
from clones expressing bio-SCL (wild-type or H2(F-G) mutant) were analysed by W estern Blot. 
The protein GRB2 served as an internal loading control.
Triangles represent serial dilutions of the input.
Im munoblots were quantified using the Q uantity One Software from Biorad and ratios between 
levels of expression of SCL and GRB2 calculated.
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presence of biotinylated SCL was confirmed in all the clones (figure 5.5, bottom 
panel).
Down-regulation of expression of the endogenous SCL gene in MEL and L8057 
clones transfected with wt bio-SCL (and possible perturbation in clones expressing 
the bio-SCL variant), precluded any direct comparison of levels of expression of the 
transgenes versus the endogenous gene. Therefore, to select MEL and L8057 
clones with levels of bio-SCL comparable to that of endogenous SCL, levels of 
expression of bio-SCL and of a loading control (GRB2) in transfected cells, and of 
wt SCL and GRB2 in untransfected cells were compared and ratios calculated. 
Transfected clones that showed ratios comparable to that of untransfected cells 
were retained for further analyses (figure 5.6 and data not shown).
3.2 Primitive and definitive haematopoiesis from SCL-/- ES cells is restored 
upon expression of biotinylated SCL in an in vitro rescue assay
Before characterising SCL-containing complexes in MEL and L8057 cells, 
we checked that the presence of a biotinylated tag in the N-terminus of SCL did not 
perturb the function of the protein. To do this, we took advantage of the rescue 
assay of SCL-null ES cells whereby introduction of a wt SCL cDNA into these cells 
fully restores haematopoietic development89. A general description of this two step 
rescue assay89,261 is given in figure 5.7: Upon primary replating, ES cells give rise 
to three-dimensional cellular structures called embryoid bodies (EB) containing, 
amongst others, haematopoietic precursors. In contrast to wild-type ES cells, SCL- 
/- ES cells form white embryoid bodies devoid of primitive erythroid cells after 
primary replating and develop no haematopoietic activity after secondary replating. 
However, when SCL null cells are transfected with wild-type SCL cDNA, both 
primitive and definitive haematopoietic activities are restored. We have used
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Figure 5.8: Biotinylated SCL is able to rescue primitive and definitive haematopoiesis from 
SCL-/- ES cells in an in vitro differentiation assay
SCL-/- ES cells expressing BirA biotin ligase and biotagged SCL were d ifferentia ted into prim itive 
and defin itive haem atopoietic lineages. Wt ES cells and SCL-/- cells served as controls.
Levels of SCL expression were analysed in prim itive erythroid co lonies (left top panels) 
and defin itive erythroid colonies (right top panels) by sem iquantita tive RT-PCR and relative 
to levels of expression of the HPRT gene.
M orphology was assessed by phase contrast m icroscopy (left panel, prim itive erythroid colonies) 
and M ay-Grunwald-G iem sa staining (MGG panels).
M eg=m egakaryocyte
def=definitive
w t=w ild-type
MEL wt
non induced
induced
MEL
bio-SCL
MEL
bio-H2(F-G)
< 1%<1% < 1%
39% 44% 40%
Figure 5.9 Biotinylated SCL does not promote spontaneous differentiation of MEL cells
Benzidine staining of non-induced and induced wt MEL cells and M EL ce lls  expressing biotinylated 
SCL or the H2 (G-F) mutant. Percentages refer to the num ber of Benzid ine positive ce lls  counted.
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this system to assess functionality of our construct. To this, SCL-/- ES cells stably 
transfected with the biotin ligase and with pEF-1a bio-SCL were differentiated into 
primitive and definitive haematopoietic cells. Despite high levels of bio-SCL 
transcripts as judged by semi-quantitative RT-PCR of RNA isolated from 
haematopoietic colonies (7 to 8.5-fold higher than endogenous SCL, figure 5.8, top 
panels), complete rescue of primitive and definitive hematopoiesis was observed. 
Primitive erythroid colonies (figure 5.8, left panel) and definitive erythroid, 
megakaryocytic and myeloid colonies (data not shown) derived from cells 
expressing biotinylated SCL looked morphologically identical to their wt 
counterparts. May-Grunwald-Giemsa staining showed terminal cellular maturation 
of cells derived from rescued ES cells similar to that derived from wt cells (figure 
5.8, MGG panels). Moreover, the number of haematopoietic progenitors derived 
from rescued ES cells was similar to that derived from wt ES cells, as observed 
upon colony assay (data not shown). We concluded that biotinylation of SCL did 
not seem to perturb any function critical for haematopoietic specification and 
maturation of haematopoietic lineages.
3.3 Biotinylated SCL protein does not induce spontaneous differentiation of 
MEL cells and allows normal induction by HMBA or DMSO
Previous studies reported that over-expression of SCL in MEL cells induced 
spontaneous terminal maturation 210. To check whether this applied to the MEL 
clones expressing bio-SCL or bio-H2(F-G), benzidine staining was performed 
before and after exposure of the cells to an inducer of terminal differentiation. Cells 
non-exposed to the inducing agent did not show any enhanced number of 
benzidine-positive cells as compared to wt MEL cells (figure 5.9, top panel). A 
proportion of these cells was however able to undergo terminal maturation as
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shown by the substantial number of benzidine-positive cells after treatment with the 
inducing agent (figure 5.9, bottom panel).
In conclusion, we show that the function of SCL in haematopoietic cells is not 
affected by biotinylation. Moreover, we generated MEL and L8057 clones 
expressing biotinylated SCL (wt and mutant) at levels similar to that of the 
endogenous protein in wt cells, thereby preserving a normal protein stochiometry.
3.4 The known pentameric SCL complex is present in pull downs from MEL 
and L8057 cell nuclear extracts
Cells contain endogenously biotinylated proteins or peptide sequences that 
might be recognised by the biotin ligase BirA. Therefore, to be able to distinguish 
between proteins specifically pulled-down upon SCL biotinylation and background 
proteins, crude nuclear extracts were prepared from MEL and L8057 clones co­
expressing bio-SCL and BirA ligase as well as expressing BirA alone. Purification 
of SCL-containing multiprotein complexes was achieved upon pull-downs with 
streptavidin beads, under low stringency conditions (150mM NaCI, 0.3% Nonidet 
P40). After washes in more stringent conditions (250mM NaCI, 0.3% Nonidet P40), 
complexes were eluted and analysed by Western Blot. First, presence of bio-SCL 
and bio-H2(F-G) in the fraction precipitated from MEL and L8057 nuclear extracts 
was confirmed; as expected, no SCL was purified from cells expressing BirA only 
(figure 5.10, PD fractions). Most of biotinylated SCL bound to streptavidin beads as 
there was very little to no product in the unbound (UN) fractions. We next checked 
whether known partners had co-purified with wt bio-SCL. We were able to detect 
the presence of E2A, HEB, LDB-1 and LM02 in PD fractions using 250 mM NaCI 
washes, thereby validating the strategy. Importantly, none of these proteins were 
detected in the PD fraction from cells transfected with BirA only, confirming that
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Figure 5.10 Known partners of SCL co-purify with bio-SCL
Pull-downs of SCL-containing com plexes (strategy depicted at the top) were perform ed 
using nuclear extracts of MEL (bottom panel left) and L8057 (bottom  panel right) ce lls 
transfected with biotin ligase BirA only (as a negative control) or w ith Bir A and b io-SC L 
or b io-H2(F-G).
Eluates were subjected to Western Blot analysis with antibodies aga inst known partners 
of SCL (E2A, HEB, Ldb-1, LM 02, GATA-1).
IN: input; PD: pull-down; UN: unbound.
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they had been specifically pulled-down upon biotinylation of SCL. Interestingly, the 
interaction with GATA-1 could only be detected after reducing the stringency of the 
washes to 150 mM NaCI. Pull-down profiles observed from MEL and L8057 cells 
were similar with substantial enrichment for E2A(E12/47), HEB, LM02 and LDB-1. 
Enrichment of GATA-1 was not as drastic, suggesting that only a fraction of GATA- 
1 might be involved in SCL-containing protein complexes or reflecting the weak 
nature of the interaction between the two proteins.
3.5 Phenylalanine in SCL helix 2 is critical for LMO-2 and LDB-1 binding
The point mutation in helix 2 of the SCL HLH region leads to a complete absence 
of primitive haematopoiesis in the in vitro haematopoietic rescue assay from SCL- 
null ES cells, despite the fact that heterodimerization with E12/E47 is not 
impaired193. We therefore hypothesised that this mutant would no longer be able to 
bind to some of the critical partners of SCL. As shown in figure 5.10, LMO-2, LDB- 
1 and GATA-1 binding is significantly reduced in MEL cells. Interestingly, the H2F- 
G binding defect of LMO-2, LDB-1 and GATA-1 was even more pronounced in 
L8057 clones, very likely due to the impairment of heterodimerization with E12/47 
and HEB (figure 5.10, right panel, PD fractions).
3.6 Identification of potential candidate protein partners of SCL
To identify additional putative partners, SCL-containing complexes were then 
purified from 5 mg of crude nuclear extracts from MEL and L8057 cells co­
expressing BirA and bio-SCL under low stringency conditions (150mM NaCI, 0.3% 
Nonidet P40) and the nature of the precipitated products analysed by mass 
spectrometry. In order to be able to distinguish between proteins specifically pulled- 
down upon SCL biotinylation and background binding proteins, cells expressing 
BirA only were analysed in parallel. First, upon separation of the pull-down
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Figure 5.11 Coomassie stained gel of representative pull-down experiments
Nuclear extracts prepared from MEL and L8057 clones transfected with BirA only 
or co-transfected with biotagged SCL and BirA were subjected to pull-dow ns with 
streptavidin beads. Com plexes were eluted, separated by SD S-Page and stained 
with Coom assie blue.
Bands observed in the fraction pulled-down from cells expressing BirA on ly  correspond to 
endogenously biotinylated proteins or peptide sequences recognized by BirA biotin ligase. 
In the fractions pulled-down from cells expressing bio-SCL, there is enrichm ent in bands 
that do not appear in the BirA-only controls.
All lanes, including the negative controls, were cut into gel slices, d igested with trypsin 
and subject to liquid chrom atograghy mass spectrom etry (LC-MS -  service  provided by 
Functional G enom ics and Proteom ics Laboratories at the University o f B irm ingham ).
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products on SDS-PAGE, Coomassie-blue staining revealed different patterns 
between the control cells and cells expressing bio-SCL (figure 5.11). From MEL 
cells expressing bio-SCL, there was a significant enrichment in bands that did not 
appear in the BirA-only control. From L8057 cells, although the control lane 
showed more background proteins, there were also significant differences with 
cells expressing bio-SCL. The background proteins identified by mass 
spectrometry were similar to those reported previously 262. They consisted mainly 
in naturally biotinylated proteins such as carboxylases and their co-enzymes, as 
well as splicing factors, ribosomal proteins and proteins associated with the 
cytoskeleton such as actin and tubulin (table 5.1). By contrast, upon SCL 
biotinylation, we detected some of the known partners of SCL, as well as additional 
transcription factors, co-factors, chromatin remodelling proteins that were absent 
from the control BirA-only experiments (table 5.2).
SCL was the most abundant protein detected, followed by its heterodimerisation 
partners, the E-proteins (E12/E47, E2.2). Another member of the pentameric 
complex, LDB-1, was found in both MEL and L8057 cells. However, we never 
identified GATA-1 or LMO-2 by mass spectrometry (see discussion).
In addition to these known partners, a significant number of new potential 
candidates was identified (table 5.2). In an attempt to validate these results, we 
checked the interaction between SCL and selected newly identified proteins by 
Western Blot analysis from PD fractions (data not shown). Most of the proteins we 
tested were also weakly present in the PD fractions from BirA-only cells. It is 
possible that more stringent binding conditions are necessary to abolish non­
specific binding to streptavidin beads. Some of the protein interactions were not 
always reproducible even in low stringency washes. This may reflect the weakness
TABLE 5.1
background binding proteins in MEL and L8057 cells
Protein ID biological process
Carboxylases metabolism
acetyl transferases metabolism
actin cytoskeleton
myosin cytoskeleton
tubulin cytoskeleton
ribosomal proteins protein synthesis
splicing factors RNA  processing
rem arks  
require biotin as co-enzym e  
require biotin as co-enzym e
Table 5.1 Background binding proteins
These proteins were identified by mass spectrometry in pull-downs 
performed from nuclear extracts of clones transfected with BirA only.
TABLE 5.2
MEL
Protein ID No of peptides
E12/E47 10
E2.2 9
LDB-1 5
SCL 11
SSDP 5
ETO-2=MTG16 6
TIF1y+P 6
LAP2=thymopoietin 7
FACT 40 4
SSRP-1 3
RbAp 46 3
HDAC class 1 4
RUV B likel (TIP49) 2
DEAD (p68) 7
HSP70 17
EWS 4
KU 70/80 6
TCP(TRiC) 2
biological process 
transcription factor
transcription factor
transcription factor
transcription factor
transcription factor
co-repressor
chromatin remodelling
nuclear architecture
basal transcription
basal transcription
co-repressor
chromatin remodelling
chromatin remodelling
ATP dependent RNA helicase
chaperone
transcription co-factor 
DNA repair 
chaperone
remarks 
known partner
known partner
known partner
interacts with Ldb-1
interacts with Rb 
nucleosome shifting 
nucleosome shifting 
interacts with Rb 
co-repressor 
co-activator
interacts with CBP and p300 
interacts with basal machinery 
HD AC-3 priming
L8057
Protein ID No of peptides biological process remarks
E12/E47 17 transcription factor known partner
HEB 2 transcription factor known partner
LDB-1 8 transcription factor known partner
SCL 21 transcription factor
SSDP 2 transcription factor interacts with Ldb-1
ETO-2 5 co-repressor
KAISO 2 co-repressor
LCP-1 2 unknown
DEAD (p68) 3 ATP dependent RNA helicase interacts with CBP and p300
HSP70 16 chaperone
Table 5.2 SCL candidate partners
These proteins were identified by mass spectrometry as potential candidate partners of SCL. 
They were not identified in the pull-downs performed from clones transfected with BirA only.
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of binding to SCL. Therefore, further analysis will be required to confirm the reality 
of most of these interactions.
However, two proteins, single-stranded DNA binding protein 2 (SSDP2) and Eight- 
Twenty-One 2 (ETO-2), consistently came up in mass spectrometric analysis with 
multiple hits, and were chosen for further analysis.
4 DISCUSSION
Strengths and weaknesses of the technique
The biotin-streptavidin approach allowed us to successfully and robustly pull-down 
SCL containing multiprotein complexes. In comparison to the conventional 
immunoaffinity purification technique this approach had several major advantages:
1) Due to the high affinity between biotin and streptavidin, it permits purification 
of protein complexes from crude nuclear extracts in a single step, and
2) achieves protein yields high enough for easy analysis by mass 
spectrometry.
3) It allowed us to analyse the protein-binding characteristics of SCL mutants. 
However, a major downside of this approach could be the perturbation of the 
composition of SCL-containing complexes by expression of exogenous, 
biotinylated protein. It is therefore critical to set up the system carefully: 
Importantly, we first showed by rescue experiments from SCL-/- ES cells that the 
function of SCL in haematopoietic cells is not affected by biotinylation. We then 
generated MEL and L8057 clones expressing biotinylated SCL (wt and mutant) at 
levels similar to that of the endogenous protein in wt cells, thereby preserving a 
normal protein stochiometry. It was therefore likely that the protein-protein
144
interactions involving bio-SCL would reflect the interactions observed with 
endogenous SCL.
The composition of SCL-containing complexes may be different in MEL and 
L8057 cells
We first validated the pull-down strategy by showing that the SCL pentameric 
complex can be isolated from MEL and L8057 cells upon biotinylation of wild-type 
SCL. Moreover, this technique helped us test one of the SCL mutants 
characterised in a recent structure-function study193 for its ability to bind to SCL 
protein partners in MEL and L8057 cells. Thus, we identified the phenylalanine in 
helix 2 of SCL as critical for binding to LMO-2 in MEL cells, whereas 
heterodimerisation with E2A was not affected. It has been described previously, 
that LMO-2 physically interacts with SCL, whereas LDB-1 links LMO-2 to GATA- 
1219. It is therefore not surprising that we also saw a reduction in LDB-1 and GATA- 
1 binding in the H2 mutant cells.
In L8057 cells, however, this mutant led to almost complete absence of all protein 
interactions studied, thereby indicating that, although the same core complex 
(comprising SCL, E2A or HEB, LM02, LDB1 and GATA-1) is present in the two cell 
types, there may be differences in the overall composition of the SCL-containing 
complexes or in the strength of the interactions between proteins. Mutation of a 
critical residue in SCL could therefore destabilise the complexes differently. 
Furthermore, the results from the mass spectrometry analysis of streptavidin pull- 
downs show that, in MEL cells, SCL is a partner of multiple other proteins, whereas 
in L8057 cells only few candidates were identified. If these results are validated, 
this further supports the idea that SCL-containing complexes are indeed different in 
these cell types.
Discussion of mass spectrometry results 
Known partners
Upon mass spectrometric analysis of the pull-down products we were able to 
identify known partners of the pentameric complex, thus validating the technique. 
However, neither GATA-1 nor LM02 were identified. For GATA-1, this is perhaps 
not surprising as Western Blot analysis of material isolated from cells expressing 
biotinylated SCL showed that the SCL/GATA-1 interaction was salt-sensitive and 
only a fraction of GATA-1 interacts with SCL, thus making its detection by mass 
spectrometry difficult. LM02 is a small protein (20 kDa) and, therefore, the peptides 
resulting from trypsin digestion are likely to be under-represented in the mass 
spectrometry analysis as opposed to larger proteins.
The majority of interactions found involve repressor complexes 
In addition to these known partners, the biotin-streptavidin approach allowed us to 
identify a number of novel interesting candidate partners of SCL, although the 
interaction between the majority of them and SCL remains to be validated.
Amongst them is the co-activator and ATP-dependent RNA helicase p68 known to 
interact with CBP/p300303. Interestingly, CBP/p300 was shown to be a protein 
partner of SCL198.
Perhaps surprisingly, the majority of the proteins identified are part of repressor 
complexes. Interestingly, two of them, Lamin A/C binding protein LAP2 and the 
retinoblastoma associated protein 46 (RbAp46) have been shown to interact with 
retinoblastoma protein304 and are implicated in gene repression. As mentioned in 
chapter IV, SCL was shown to repress c-kit gene expression by recruiting 
retinoblastoma protein226, and our results from the immunopurification experiments 
suggest that SCL might also interact with p107.
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Besides, several of these putative partners involved in transcriptional repression 
have also been identified by quantitative mass spectrometry using isotope-coded 
affinity tag (ICAT) as partners of NF-E2p18/MafK during erythroid differentiation 
(TIFy, RbAp46, HDAC1)117. This might indicate that, in erythroid cells, these 
proteins are part of general multi-protein complexes that bind to sequence-specific 
transcription factors such as NF-E2 or SCL.
The reasons why the majority of putative partners we identified are involved in 
repression of gene transcription remain speculative. However, we have to consider 
that the purification strategy using salt extraction for nuclear extract preparation is 
biased towards the isolation of repressor complexes. This is in accordance to the 
results obtained from the purification of GATA-1 complexes in MEL cells by the 
same technique (John Strouboulis, unpublished data). Besides, it might be that 
repressor complexes are more abundant in the nucleoplasm or that they come off 
DNA more easily than activating complexes.
In conclusion, we show that the biotin-streptavidin purification technique can be 
used successfully to pull-down SCL-containing multiprotein complexes from two 
different haematopoietic cell lines. As presented in the next chapter, this has 
opened up a new area of investigation regarding SCL function in erythrocytes and 
megakaryocytes.
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CHAPTER VI: CHARACTERISATION OF PREVIOUSLY
UNIDENTIFIED SCL PARTNERS 
1 INTRODUCTION
After successfully setting up and validating the biotin-streptavidin purification 
strategy, I further analysed the results obtained by mass spectrometry.
Possible SCL protein partners identified by MS with more than one peptide hit and 
not present in MS results from biotin ligase only clones were chosen for validation 
experiments comprising several different steps.
As already mentioned in chapter V, we tested the interaction between newly 
identified candidate protein partners in biotin pull-downs by Western Blot. Western 
blotting is sensitive up to the femtomole detection level, whereas MS requires 
picomoles of protein. This approach therefore helped us to exclude false positive 
candidate partners that had not appeared in the MS results of Bir A only pull-downs 
and to verify the mass spectrometry results.
We then chose two proteins, SSDP2 and ETO-2 for further analysis.
1.1 SSDP2
SSDP2 was originally cloned from a chick embryo fibroblast cDNA expression 
library305. It specifically binds to a pyrimidine-rich DNA region within the a2 
collagen gene. This region is unusual in that it forms single strands and is 
hypersensitive only when the promoter is active thus implying that it may be 
important for transcriptional regulation of the collagen gene. SSDP2 is highly 
conserved throughout all species. Importantly, a complex comprising SSDP2,
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LDB1/Chip and the LIM-homeodomain protein Apterous was described in the wing 
in Drosophila 263, In Xenopus, SSDP enhances axis induction by LDB-1 in 
conjunction with the LMO-2 ortholog Xlim-1306. Together, these studies reveal 
SSDP as a co-factor of LDB-1 in invertebrate and vertebrate development. 
However, nothing is known so far about its role in adult haematopoiesis.
1.2 ETO-2
ETO-2 is a member of the ETO family of co-repressor proteins whose founding 
member (ETO, MTG8) was originally identified upon characterisation of the t(8;21) 
chromosomal breakpoint, involved in 12-15% of acute myeloid leukaemia (AML) 
(for review, 307). In mouse, ETO-2 is expressed during embryogenesis, in most 
adult tissues and in myeloid and erythroid cell lines 264. MTG16, the human 
homolog of ETO-2, was identified by molecular characterisation of the t(16;21) 
associated with therapy-related AML. It is highly expressed in various 
haematopoietic organs such as spleen, thymus and peripheral blood leukocytes 
308. Gene targeting experiments of ETO with whom it shares a 75% homology, 
have shown its vital role in the development of the gastrointestinal system. Apart 
from this, most functional data on ETO and ETO-2 stems from the assignment of 
their interacting protein partners309. The first direct evidence supporting the co­
repressor model came from the isolation of the human nuclear receptor co­
repressor NCoR in a yeast two-hybrid assay using full length ETO as bait130,131. 
Subsequently, other partners were identified such as SMRT128 and mSin3A131, all 
of which interact with HDACs.
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2 OUTLINE OF EXPERIMENTS
To further validate the interaction between SSDP2 and SCL, as there are no 
aSSDP2 antibodies available, we subcloned SSDP2 cDNA into the 
pEF1 a-biotag vector and expressed biotinylated SSDP2 in MEL cells. This allowed 
us to perform pull-downs using the biotinylated protein and subsequent Western 
Blot with aSCL antibodies. We are now planning to generate antibodies against 
SSDP2. We then focused on the characterisation of the SCL/ETO-2 interaction. To 
do this, we have set up a series of experiments that are described below:
1) We confirmed the interaction between SCL and ETO-2 by reverse co- 
immunoprecipitation from untransfected cell lines to document interactions 
between the endogenous proteins.
2) To exclude the possibility that ETO-2 was pulled-down non-specifically 
because of contamination with DNA in the input fraction, we repeated the 
co-IP on DNAase-treated nuclear extracts.
3) We validated the interactions in co-localisation experiments in MEL and 
L8057 nuclei.
4) Next, we documented the ETO-2/SCL interaction in mouse primary erythroid 
cells and megakaryocytes.
5) We then mapped the domain of SCL necessary for the interaction with ETO- 
2 and tested chosen SCL mutants (see Chapter V), for their ability to bind 
ETO-2.
6) In order to further characterise the nature of the complexes containing SCL 
and ETO-2, we performed immunodepletion experiments and further co- 
immunoprecipitations from MEL and L8057 nuclear extracts.
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7) As a first step towards the functional characterisation of the new interaction, 
we used transactivation assays in a heterologeous cell line to assess the 
effect of ETO-2 on reporter gene activation by SCL and the pentameric 
complex.
8) Finally, we examined changes in the composition of SCL complexes during 
erythroid differentiation using an in vitro differentiation assay of day 12.5 
fetal liver cells.
3 RESULTS
3.1 Validation of interesting candidate partners
In a first attempt to validate the mass spectrometry results, we confirmed the 
interaction between SCL and SSDP2 or ETO-2 by Western Blot analysis from the 
pulled-down fractions used for MS analysis (data not shown).
3.1.1 SSDP2 is a partner of SCL in erythroid cells
To further validate these results, we then expressed biotinylated SSDP2 in MEL 
cells and isolated co-purifying proteins with streptavidin beads. We show that 
SSDP2 interacts with SCL and its partners (the E2A proteins, Ldb1 and LM02) by 
Western Blot (figure 6.1).
3.1.2 SCL interacts with ETO-2 in erythroid cells and megakaryocytes
Reverse co-immunoprecipitation
We next validated the interaction between endogenous SCL and ETO-2 by co- 
immunoprecipitation (colP) of ETO-2 with SCL antibodies (data not shown) and 
reverse colP from MEL cell nuclear extracts (figure 6.2 A). Increasing amounts of 
ETO-2 antibodies precipitate increasing amounts of SCL, thereby showing the 
specificity of the interaction. We also confirmed the interaction in L8057 cells
MEL
bio-SSDP2
SSDP2 
E12/E47
SCL
Ldb1
LM 02
IN PD UN
Figure 6.1: The SCL7SSDP2 interaction is confirmed using biotinylated SSDP2
N uclear ex trac ts  w ere  p repa red  from  M EL ce lls  tran s fe c ted  w ith  b io tin  ligase  and b io -S S D P 2 . 
W este rn  B lo t ana lys is  o f s trep tav id in  pu ll-dow ns  show ed  tha t S S D P 2  in te ra c ts  w ith  S C L  and 
its know n pa rtne rs  E12/47, Ldb1 and L M 0 2 .
IN = inpu t o f c rude  n uc lea r extract, PD = s trep tav id in  pu ll-dow n , U N = unbound
A IP: ETO-2
Ab amount 
SCL
1 jLlI 2jllI 4jliI UN IgG
MEL
B
IN
IP: ETO-2 
IP UN IgG
SCL
Figure 6.2: The SCL/ETO-2 interaction is confirmed by reverse co-immunoprecipitation  
of endogenous proteins
A Im m unop rec ip ita tion  (IP) of SC L from  w ild -type  M EL n uc lea r e x tra c ts  w ith  a E T O -2  
a n tib od ie s  con firm s  the  in te raction  be tw een  the  tw o  p ro te in s  in an e ry th ro id  ce ll line  
Increas ing  am oun ts  o f a E T O -2  a n tib od y  rep resen ted  by the  tr iang le , p re c ip ita te  increas ing  
am oun ts  o f SCL, thus  ind ica ting  the  sp ec ific ity  o f the  b ind ing .
B Im m unop rec ip ita tion  (IP) of SC L from  w ild -type  L8057  nuc lea r e x tra c ts  w ith  a E T O -2  
a n tib od ie s  con firm s  the  in te raction  be tw een  the  tw o  p ro te in s  in a m e g a k a ry o b la s tic  ce ll line. 
A b=antibody, IN = inpu t o f c rude  nuc lea r ex tract, U N =unbound , lg G = n e g a tive  co n tro l
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(figure 6.2 B). Then, we show by reverse colP that the SCL/ETO-2 interaction is 
conserved in induced MEL cells (figure 6.3). Finally, to exclude the possibility that 
ETO-2 could have been purified because of non-specific binding to nucleic acids, 
nuclear extracts were treated with DNase before col P. SCL was still detected in the 
immunoprecipitated fraction, confirming the interaction of ETO-2 and SCL (figure 
6.3).
Gel filtration
Upon gel filtration of MEL nuclear extracts, Western Blot analysis of gel 
filtration fractions shows that ETO-2 elutes in the same high molecular weight 
fractions as SCL (figure 6.4). MTG16, the human homolog of ETO-2, was found to 
interact with the zinc finger oncoproteins Gfi-1 and Gfi-1 b in in vitro assays 310. As 
this latter is crucial for erythropoiesis and megakaryopoiesis 311, we reasoned that it 
could interact with ETO-2 in mouse haematopoietic cells and, as a first indication of 
this, checked its fractionation profile. We found that Gfi-1 b elutes in the same high 
molecular weight fractions as ETO-2 and SCL.
Co-localisation
Finally, to further document the interaction between SCL and ETO-2, we have 
performed co-localisation experiments. These experiments were kindly performed 
by Dr Franscisco Iborra (MHU). MEL and L8057 cells were fixed and 
immunolabelled with anti-SCL and anti-ETO-2 antibodies. For both proteins and in 
both cell types, the staining appeared nuclear when compared with DAPI staining 
(data not shown) and punctate, as previously reported in other cell types 156-264 
(figure 6.5, top panel and data not shown). In a first attempt to demonstrate co­
localisation of the proteins, we have undertaken a conventional analysis. Dual 
staining of the cells showed that a substantial amount of SCL and ETO-2 co-
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IP: ETO-2
uninduced +DMSO DNAase treatec
IN IP UN IgG IN IP UN IgG IN IP UN IgG
ETO-2
SCL --- .— ,
Figure 6.3 The SCL/ETO-2 interaction is present in induced MEL cells and in DNAase 
treated nuclear extracts
Nuclear extracts were prepared from uninduced and DM SO -induced M EL cells. A fraction of 
the nuclear extract from uninduced cells was treated with DNAase. All nuclear extracts were 
subjected to co-im m unoprecip itation using anti-ETO-2 antibody.
W estern Blots were probed with aETO -2 antibody (upper panel) and aS C L  (lower panel) 
antibodies.
670 kD 158kD 
Gel Filtration Fractions 6 8 10 1214 16 18 20
SCL
ETO-2
GFI-1 B
Figure 6.4 Gelfiltration of wild-type MEL nuclear extracts
Nuclear extracts prepared from w ild-type MEL cells were fractionated on a Superose 6 H/R 
column.
W estern blots of fractions 6 to 20 were probed with the antibodies as indicated. This 
revealed that SCL co-m igrates with ETO-2 and GFI-1 B in the high m olecu lar w eight fractions. 
Molecular weights in kD are indicated at the top.
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Figure 6.5 Colocalisation
N uc le a r co -loca lisa tio n  o f SC L w ith  ETO -2 (uppe r pane l, firs t row ) w a s  d e te c te d  by 
im m u no fluo re scen ce  using a E T O -2  and a -S C L  an tibod ies . aLD B 1 and a S C 3 5  a n tib o d y  
se rved  as a pos itive  con tro l (second row) o r nega tive  con tro l (th ird  row ), respective ly .
In an a ttem p t to  fu rthe r va lida te  these  resu lts , da ta  o f op tica l in te n s itie s  o ve r the  
n uc leo p la sm  o f M EL (low er panel, left) and L8057  ce lls  ( lo w e r pane l, righ t) w e re  e xpo rted  
to  Exce l fo r backg round  substrac tion  and ana lys is .
*=  p -va lu e <  0 .05
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localise in the nuclei of both MEL (figure 6.5, top panel) and L8057 (data not 
shown) cells. As controls, we also show co-localisation of SCL and known partner 
Ldb1, but not of an abundant unrelated nuclear protein (splicing factor SC35210,312) 
with a component of the SCL complex such as Ldb1 (Figure 6.5, top panel). Dr 
Iborra then analysed the results in a different way and used a high resolution 
approach that takes advantage of the ability of an antibody to block access of 
another antibody to its antigen (although blocking is incomplete as we 
demonstrated co-localisation in the merged images, figure 6.5, top panel). In 
contrast to the conventional analysis indicating that two targets lie within 200nm, 
this approach reveals targets that lie within a few nanometers 266-313. in the 
absence of blocking antibodies, the intensity of the fluorescence detected in MEL 
and L8057 nuclei upon incubation with anti-SCL, -ET02, -Ldb1 and -SC35 
antibodies was arbitrarily set to 100 (figure 6.5, bottom panels). The intensity of the 
signal from SCL antibodies was significantly reduced when co-incubated with ETO- 
2 or Ldb1 Abs. So were those from anti-ETO-2 and -Ldb1 Abs when incubated with 
anti-SCL Abs, confirming, at a very high resolution, that these proteins do interact 
with each other. No interaction could be detected between Ldb1 and SC35. 
Validation in primary erythroid cells and megakaryocytes
To confirm these results in primary cells, we isolated Ter119+ cells from spleen of 
phenylhydrazine-treated mice and megakaryocytes from adult mouse bone 
marrows (figure 6.6), and prepared nuclear extracts. From both cell types, colP 
with SCL Abs under stringent conditions confirmed presence of the SCL core 
complex (including SCL, E2A, LDB-1 and LM02), but failed to detect interaction 
with GATA-1. Interaction with ETO-2 was confirmed. Reverse co-
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Figure 6.6 ETO-2 interacts with the SCL core complex in primary erythroid cells and 
megakaryocytes
Nuclear extracts prepared from Ter 119+ mouse splenocytes (upper panel) and prim ary 
m egakaryocytes (lower panel) were subjected to co-im m unoprecip ita tion with anti-SC L or 
anti-ETO-2 antibodies (splenocytes only).
The m orphology of cells used for nuclear extract preparation was assessed by 
May Grunwald G iemsa Staining (shown next to each panel).
Ter119+ cells represent proerythroblasts to m ature erythrocyte and enucleated stages. 
P rim ary m egakaryocytes=im m ature m egakaryocyte precursors (dark cytoplasm ) to m ature 
m egakaryocytes (large cells with granular cytoplasm  and polyplo id nuclei).
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immunoprecipitation with ETO-2 antibodies from Ter119+ extracts confirmed 
interaction with the SCL core complex (E2A, SCL and LM02, Figure 6.6).
Taken together, these results validate the interaction between SCL and 
ETO-2 in wt non-transfected MEL and L8057 cells and reveal the presence of an in 
vivo multiprotein complex comprising the SCL core complex and ETO-2 in primary 
erythrocytes and megakaryocytes.
3.2 Composition of SCL- and ETO-2-containing complexes differs in 
erythroid cells and megakaryocytes
In an attempt to finely characterise the nature of SCL-and ETO-2-containing 
protein complexes, we performed immunodepletion experiments (see scheme 
figure 6.7A). To do this, nuclear extracts from MEL and L8057 cells were first 
subjected to immunoprecipitation with antibodies against ETO-2 and GATA-1. After 
characterisation of the nature of the complexes pulled-down by Western Blot, the 
depleted supernatants were then subjected to another IP with antibodies against 
SCL to identify the remaining complexes (figure 6.7B and C).
Immunoprecipitation with ETO-2 antibodies from L8057 and MEL nuclear extracts 
confirms the interaction of ETO-2 with the SCL core complex observed in primary 
erythroid cells and megakaryocytes (figure 6.7B, top panel, IP lanes). In MEL cells, 
ETO-2 was also found to interact with GATA-1. Binding of GFI-1 B was also 
confirmed. Importantly, IP with GFI-1 b Abs precipitated SCL from MEL nuclear 
extracts (figure 6.7D, upper panel) indicating that GFI-1 b is also likely to be part of 
the SCL core complex. It was shown previously that the ETO-2 homolog ETO 
binds to mSin3A and other co-repressors upon co-expression in heterologous 
cells131. Besides, mSin3A has also been known to interact with SCL220. Therefore, 
we tested whether we could detect mSin3A in co-immunoprecipitations using
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Figure 6.7 Depletion Experiments and further Co-immunoprecipitations
A S chem e  o f the  im m unodep le tion  e xpe rim en ts  
B,C Im m unopep le tion  e xpe rim en ts
W ild -typ e  M EL and L8057 ce ll nuc lea r ex trac ts  w ere  im m u no de p le ted  o f E T O -2  (B) o r 
GATA-1 (C). Im m unop rec ip ita ted  co m p le xe s  w ere  ana lysed  by  W e ste rn  B lo t (B and  C, 
uppe r pane ls). A  second  co -IP  w as pe rfo rm ed  on the  d ep le ted  su p e rn a ta n t us ing  a S C L  
a n tib od ie s  to ana lyse  the  nature  o f the  rem a in ing  co m p le xe s  (B and C, low e r pane ls ).
T he  e x ten t o f the  dep le tion  w as assessed  by W este rn  B lo t w ith  a E T O -2  (B) o r GATA-1 (C). 
Note, th a t all d ep le tion s  apa rt from  GATA-1 dep le tion  in M E L ce lls  w e re  co m p le te  as no 
p roduc ts  w ere  de tec ted  in the  unbound  (UN) frac tions .
D C o-im m un o p rec ip ita tio n  from  M EL and L8057 ce lls  w ith  aG F I-1  b (top) o r a S C L  
a n tib od ie s  (bo ttom ).
IN = inpu t o f c rude  nuc lea r extract, IP = im m unoprec ip ia tion , U N = un bo u nd , 
lgG = ne ga tive  contro l.
159
aETO-2 (figure 6.7B) and aSCL (figure 6.7D, lower panel). We found that mSin3A 
interacts with ETO-2 and SCL, but not N-CoR although described previously as a 
partner of ETO-2134(data not shown).
The second IP with SCL antibodies, after depletion of ETO-2, showed that 
the core SCL complex (SCL, LMO-2, LDB-1) was present in the absence of ETO- 
2, and that there was no interaction with Gfi-1 B, suggesting that Gfi-1 B binds SCL 
through ETO-2 (figure 6.7B, bottom panel).
Turning to the IP with GATA-1 antibodies under stringent conditions, SCL 
(data not shown), Ldb1 and LMO-2 were undetectable in the IP fractions (figure 
6.7C), confirming the weakness of the interaction between GATA-1 and the SCL 
core complex. In contrast, there was enrichment of ETO-2, GFI-1 B and mSin3A in 
the precipitated products. The colP on the depleted supernatant with SCL 
antibodies shows presence of the core complex comprising ETO-2 (figure 6.7C, 
lower panel). This complements the data obtained upon colP with ETO-2 Abs and 
shows that the SCL/ETO-2 binding is independent of GATA-1 and that the ETO-2 
complex comprising the co-repressor proteins mSin3A and Gfl-1 b also involves 
GATA-1.
In L8057 cells, surprisingly, ETO-2 does not interact with GATA-1 or GFI-1 B (figure 
6.7B and data confirmed by reverse colP, figure 6.7C (GATA-1 )and 6.7D (GFI-1 b)) 
or mSin3A (figure 6.7B), but only with the SCL core complex. The second IP with 
aSCL shows, as in MEL cells, presence of the SCL core complex in absence of 
ETO-2. A second IP with SCL Abs from GATA-1 depleted supernatant confirms the 
presence of the core SCL complex and ETO-2 in the absence of GATA-1 (figure 
6.7C, lower panel). In order to exclude that the absence of the SCL/GFI-1b 
interaction was due to a mechanism specific to the L8057 cell line, we performed
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co-immunoprecipitations from nuclear extracts of primary megakaryocytes with 
aSCL This confirmed that, in primary megakaryocytes, SCL does not interact with 
GFI-1 b.
The data presented here are summarised in figure 6.8. The model shows a 
possible representation of the nature of the complexes according to the results 
obtained from the depletion experiments with the limitations associated to this 
technique. We cannot exclude the existence of additional complexes and suspect 
that the proteins represented in a given complex may not always interact 
altogether.
Taken together, these results led us to the conclusion, that the nature of the 
SCL and ETO-2 complexes is fundamentally different in erythroid cells versus 
megakaryocytes.
3.3 Class II bHLH proteins heterodimerise with E2A to bind ETO-2
To map the domain of SCL involved in the interaction with ETO-2, we 
expressed truncated, biotinylated forms of SCL: (ANt, ACt and ANt-ACt) in MEL 
cells (figure 5.3). Upon nuclear extract preparation, protein complexes were pulled- 
down with streptavidin beads and presence of ETO-2 analysed by Western Blot. 
The bHLH domain of SCL alone was sufficient for interaction with ETO-2 (data not 
shown). We then analysed binding of ETO-2 to SCL variants that were defective in 
DNA-binding (SCL-RER)188 or impaired for interaction with LM02 (SCL H2(F-G)). 
SCL-RER was able to bind ETO-2 in both MEL and L8057 cells (figure 6.9 A), 
suggesting that SCL and ETO-2 may reside in a complex that does not bind DNA, 
or that binds through the DNA-binding domain of other transcription factors. In MEL 
cells, interaction between bio-H2(F-G) and ETO-2 are preserved, suggesting that 
ETO-2 is not recruited to the SCL complex through LMQ2/LDB-1. In L8057 cells
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Figure 6.8 Hypothetical model of SCL and ETO-2 containing complexes in erythroid cells 
and megakaryocytes
This model represents the possible nature of the com plexes according to the resu lts obta ined 
from the depletion experim ents with the lim itations associated to th is technique.
We assum ed that SCL binds to its heterodim erisation partner E2A.
F=phenylalanine
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Figure 6.9 SCL mutant analysis
A N uclea r ex trac ts  w ere  prepared  from  M EL (uppe r panel) and L8057  ( lo w e r pane l) 
ce lls  tran s fe c ted  w ith  B ir A on ly  o r b io -S C L  (w ild -type), b io -R E R  o r b io -H 2 (F -G ) 
and sub jec ted  to  s trep tav id in  pu ll-dow ns. W este rn  B lo ts w ere  p robed  w ith  a S C L  o r 
a E T O -2  an tibod ies .
B N uclear ex trac ts  p repared  from  M EL cell tran s fe c ted  w ith  b io -S E S , b io -S M S ,
b io -S N S  and b io -F L  w ere  sub jected  to  s trep ta v id in  pu ll-dow ns. W e s te rn  B lo ts
w ere  p robed w ith  s trep ta v id in -H R P  to revea l the  m u tan t S C L  o r w ith  a E T O -2  and aE 2A .
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however, H2(F-G) fails to bind to ETO-2 (figure 6.9 A), but also to any of the 
SCL partners tested, including the heterodimerisation partners E2A and HEB 
(figure 5.10).
We also generated swapped mutants whereby SCL HLH domain was 
substituted by the corresponding region of other bHLH proteins (MyoD, E47 and 
NSCL to produce bio-SMS, bio-SES and bio-SNS, respectively). These variants 
were able to heterodimerise with E12/E47 as we previously reported 193 (figure 6.9 
B). Interestingly, whereas substantial amounts of ETO-2 co-purified with the bio- 
SMS and bio-SNS, interaction with the bio-SES was much weaker (figure 6.9 B). 
Finally, no interaction between heterodimerisation-defective SCL (SCL-FL) and 
ETO-2 was detected.
3.4 ETO-2 represses the activator function of the pentameric complex in 
heterologous cells
To get insight into the possible function of the SCL/ETO-2 complex, we 
performed transactivation studies of human GATA-1 regulatory sequences in a 
reporter assay. We recently showed by chromatin immunoprecipitation (ChIP) 
assay that the DNasel hypersensitive sites situated 3.5 kb upstream of GATA-1 
promoter (hHS-3.5) and 14 kb downstream of GATA-1 promoter (hHS+14) bind the 
SCL pentameric complex in MEL cells231. These sequences together with human 
GATA-1 promoter (IE) were used to drive expression of the luciferase gene 
(construct hHS-3.5-IE-hHS+14) in NIH3T3 cells upon co-transfection with various 
combinations of vectors expressing members of the pentameric complex (SCL, 
E47, LM02, LDB-1 and GATA-1). We show a 7-fold increase in luciferase levels 
upon co-expression of the five proteins (figure 6.10). In accordance with the ChIP 
data showing co-occupancy of GATA-1 regulatory regions by these proteins231,
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Figure 6.10 ETO-2 represses the activator function of the pentameric complex 
in transactivation assays
T he  h e te ro log ou s  ce ll line N IH 3T3 w as  tra n s ie n tly  co -tra n s fe c te d  w ith  lu c ife ra se  rep o rte r 
g enes  (see sch em a tic  p resen ta tion  at the  top) and ve c to rs  e xp ress in g  th e  ind ica ted  
tran sc rip tion  fac to rs : SCL, E2A, Ldb1, L M 0 2 , Gata-1 and ETO -2.
T riang le  rep resen ts  increas ing  conce n tra tion s  o f E TO -2 e xp ress io n  vecto r.
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each of these factors was found necessary to achieve maximum activation, 
as expression levels decreased when they were individually omitted. We then co­
transfected increasing concentrations of an ETO-2 expression plasmid together 
with the five components of the pentameric complex. We observed a significant 
reduction of the levels of activation of the reporter gene and concluded that ETO-2 
represses the activator function of the SCL complex in this setting.
3.5 The SCL/ETO-2/GFMb interaction is lost during terminal erythroid 
differentiation
Taken together, these results led us to the hypothesis that ETO-2 might mediate 
repression of SCL target genes which have to be silenced for differentiation to 
proceed normally. In a first attempt to test this hypothesis, we established an 
expression profile of proteins involved in the SCL/ETO-2 interaction in non-induced 
and induced MEL cells (figure 6.11 A). This revealed that expression of ETO-2 is 
significantly reduced in induced MEL cells, whereas protein levels of the other 
proteins remain stable or increase slightly. This suggests that the repressor 
function of SCL may be alleviated upon silencing of ETO-2 expression during 
erythroid differentiation. As induction of MEL cells might not precisely mirror 
erythroid differentiation, we decided to test our hypothesis in a different system and 
performed in vitro differentiation of day 12.5 primary fetal liver cells314(figure 
6.11B).
To examine how a decrease in ETO-2 protein levels during erythroid differentiation 
could impact on the SCL-containing complexes, we analysed their composition 
during in vitro erythroid differentiation of fetal liver cells. We isolated a pure 
population of undifferentiated, benzidine-negative, c-kit+, Ter119- erythroid
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Figure 6.11
A: Expression levels of indicated proteins in non-induced and induced M EL cells 
W estern Blot analysis of nuclear extracts prepared from non-induced=NI and induced= l M EL 
cells. (Decrease of levels of expression of PU.1 serves as a control o f induction of M EL cell 
term inal maturation).
B: In v itro  erythroid differentiation of day 12.5 w ild-type prim ary fetal liver cells.
Benzidine staining (left upper panel) and FACS analysis (left lower panel) o f ce lls after 
0,1 and 2 days of differentiation.
Right panel: Expression profile (left) and co-im m unoprecip itation (right) o f p ro te ins as indicated 
using nuclear extracts prepared from fetal liver cells on day 0 and day 2 of d ifferentia tion.
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precursors (Day 0) that were subjected to differentiation to obtain terminally 
differentiated, benzidine-positive CD71+, Ter119+ erythrocytes (Day 2). Western 
blot analysis of these populations showed a decrease in levels of all the proteins 
we tested upon differentiation (figure 6.11, right panel, INPUT). In erythroid 
precursors (Day 0), SCL interacted with all of its known partners including GATA-1 
and with ETO-2, GFI-1 b and mSin3A. However, in terminally differentiated 
erythrocytes (Day 2) the interaction with ETO-2 and GFI-1 b was lost although SCL 
still bound to the members of the core complex (except for LDB-1). Interestingly, 
aSCL also co-immunoprecipitated mSin3A, suggesting that mSin3A binds to SCL 
independently of ETO-2 and GFI-1 b.
The co-activator and intrinsic histone-acetylase CBP/p300 was previously 
shown to interact with SCL198. Besides, supporting the idea of a co-factor 
exchange, recent work by Zhang et al139 suggests that in HeLa cells, E2A can act 
both as a repressor or activator by exchanging members of the ETO family for the 
co-activator CBP/p300. We therefore tested the hypothesis that CBP/p300 binding 
to SCL might increase in terminal differentiation. However, in our system in primary 
erythoid cells, SCL/CBP/p300 containing complexes decreased with differentiation.
In summary, we therefore conclude that SCL binds to ETO-2 and GFI-1 b 
primarily in erythroid precursors and that this interaction is lost in terminal 
differentiation whereas mSin3A continues to bind to SCL. Furthermore, we show 
that in terminal erythroid differentiation, the mechanism underlying ETO-2 directed 
repression is not the inhibition of co-factor exchange with CBP/p300.
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4 DISCUSSION
Using a novel protein purification approach, we have identified previously unknown 
partners of SCL and show that SCL interacts with SSDP2 and the co-repressor 
ETO-2 in erythroid cells and megakaryocytes.
SSDP2 has been described as a co-factor of LDB-1 and LMO-2 orthologs in the 
early development of drosophila and xenopus (see above). Here, we show for the 
first time that SSDP proteins are also involved in the formation of haematopoietic 
multiprotein complexes in vertebrates. This is of particular interest as genes of the 
ssdp family have been localised to translocation breakpoints and deletions in 
myeloid malignancies315.
ETO-2 came up consistently in our mass spectrometry analysis as a partner of 
SCL and the interaction between the two endogenous proteins was characterised 
using a variety of different approaches.
Co-localisation
Due to its low resolution of several hundred nanometres, the use of conventional 
co-localisation for transcription factors and other small molecules has been 
questioned. Therefore, we opted for an additional and previously validated 
technique to analyse optical intensities from co-localisation experiments266, and 
show that SCL and ETO-2 co-localise within only a few nanometers from each 
other.
Immunodepletions and co-immunoprecipitations
In order to further characterise the nature of the SCL/ETO-2 containing complexes, 
we performed depletion experiments and further co-immunoprecipitations. These
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experiments allowed us to start to define the composition of the complexes and to
identify other previously unknown partners.
mSin3A
ETO-2 interacts with mSin3A in MEL cells. This is in contrast to recently published 
data, showing that ETO, but not ETO-2 could interact with mSin3A upon co­
expression in heterologous cells134. This difference may reflect the difference in cell 
types used in this study and ours (erythroid cell line versus Cos 7 cells) and/or in 
the levels of expression between endogenous and overexpressed proteins. 
Alternatively, ETO-2 may be in the same complex with mSin3A, but not physically 
binding to it.
It is of note that, in accordance to previously published data220, we, too, show that 
mSin3A binds to SCL. Thus, mSin3A might also interact with SCL independently of 
ETO-2. This idea is consistent with our preliminary data from immunodepletion 
experiments using nuclear extracts prepared from the T-cell leukaemia cell line 
Jurkat. These experiments reveal the presence of a complex containing SCL and 
mSin3A after immunodepleting with aETO-2.
GFI-1 b
Our data indicate that SCL and ETO-2 co-migrate with GFI-1 b and that the three 
proteins co-immunoprecipitate in MEL cells and primary erythroid precursors, but 
not in megakaryocytes. Although it was recently shown that GFI, a GFI-1 b 
homolog, interacts with ETO310, we show here for the first time that GFI-1 b and 
ETO-2 bind to an essential sequence specific transcription factor (SCL) in 
erythropoiesis.
The gene locus encoding for the growth independence 1 (Gfi) protein was first 
discovered in a screen for Moloney murine leukaemia virus proviral integration
sites in T cell lymphoma316. Gfi-1 zinc finger protein and its homologs have been 
implicated in processes as diverse as oncogenesis317, apoptosis316,318,319, 
proliferation320, cell fate specification and differentiation102,311. Studies in 
vertebrates have focused mostly on haematopoietic lineages whereas research 
with C elegans and Drosophila has centred on the nervous system. Given their 
structural similarities, it is reasonable to think that the two proteins might perform 
redundant functions, although growing evidence suggests that they are not always 
interchangeable321,322. Gain-of-function studies have indicated a role for GFI-1 b in 
terminal erythropoiesis323 Besides, loss-of-funotion studies have established that 
Gfi-1 B plays an essential role in the generation of red blood cells and platelets311. 
Gfi-1 B mutant embryos form immature primitive erythrocytes, but definitive 
erythropoiesis is disrupted, leading to death at dpc 15. Hence, in the absence of 
Gfi-1 B, haematopoietic progenitors commit to the erythroid lineage but fail to 
mature. Similarily, there is a block in megakaryocytopoiesis. Lack of Gfi-1 on the 
other hand severely affects lymphoid and granulocyte development102,318.
Gfi-1 and its vertebrate homolog Gfi-1 B act as transcriptional repressors via their 
Snail/Gfi-1 (SNAG) domain320 and can bind directly to DNA. Besides, Gfi-1 can 
function as a transcriptional repressor even in the absence of the SNAG domain310. 
In this case, Gfi-1 requires protein-protein interaction with HDACs and the co­
repressor ETO. Interestingly, recent data suggests that GFI-1 b also acts as a 
repressor during human erythroid differentiation323. Moreover, Gfi-1 and Gfi-1 B can 
activate transcription in an erythroid cell line324, hence implying that they affect 
target promoters differentially depending on the cellular context.
Importantly, Gfi-1 and its homologs seem to cooperate with bHLH transcription 
factors in different tissues, including T cells325 and T cell lymphoma319, although a
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direct physical interaction has not been described so far. In view of their similar 
expression profiles and knock-out phenotypes a possible interaction between SCL 
and GFI-1 b seemed plausible, but had not been formally demonstrated so far. 
GATA-1
Interestingly, in erythroid cells, we found a complex consisting of ETO-2, Gfi-1 b, 
mSin3A and GATA-1, but without the SCL core complex. This is consistent with 
results obtained in primary splenocytes and megakaryocytes, where we were 
unable to show SCL/GATA-1 binding. The reasons for this may be threefold
1. The importance of stringency conditions when performing affinity 
purifications and co-immunoprecipitations has been stressed before. 
A fine balance between preserving protein-protein interactions, but 
eliminating non-specific background binding has to be kept. 
Immundepletions and co-IPs on primary cells were performed under 
stringent conditions. As mentioned previously, this may explain why 
the GATA-1/SCL interaction could not be revealed in these 
experiments.
2. Besides, the SCL/GATA-1 complex may be less abundant then the 
SCL core and the GATA-1/Gfi-1b/mSin3A/ETO-2 complex.
3. Alternatively, if there is indeed a bias towards preferentially purifying 
repressor complexes with this technique, this may also indicate that 
the SCL/GATA-1 interaction is part of an activating complex.
Taken together, although incomplete, the immunodepletion experiments allowed us 
to conceive a hypothetical model of the nature of the complexes within the 
limitations associated to this technique. The principle problem we encountered in 
interpreting the results was directly related to the complexity of the cellular protein
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network. When performing co-immunoprecipitations of transcription factors, results 
obtained always derive from a pool of different cells at different stages of their cell 
cycle and different genes in repressed or active states. Hence, at any one time, a 
whole spectrum of protein complexes may be present in the nuclear extracts used. 
Besides, we cannot exclude the existence of additional complexes and suspect 
that the proteins represented in a given complex may not always interact 
altogether. However, from these experiments and the subsequent validations in 
primary erythroid cells and megakaryocytes, it has become apparent, that the 
SCL/ETO-2 complexes in these two cell types are fundamentally different. In red 
cells, the SCL core complex interacts with ETO-2, GFI-1 b and mSin3A, whereas in 
megakaryocytes, the SCL core only binds to ETO-2.
SCL mutants
Analysis of the SCL mutants revealed that the DNA binding activity of SCL is 
dispensable for the interaction with ETO-2, indicating that the complex could either 
form off DNA or via DNA binding of other members of the complex. Mapping of the 
interaction domain confirmed that the bHLH domain of SCL is sufficient for ETO-2 
binding. This is not unexpected, as it was shown previously that the bHLH domain 
is sufficient for all of SCL’s functions188 including heterodimerisation with its partner 
E2A, and that ETO-2 binds to E2A via a short aminoacid sequence at the N 
terminus of E2A139. In the same study, E2A homo- and heterodimers transfected 
into HeLa cells bound ETO-2 equally well. Our data from MEL cells reveals that, 
although all SCL swapped mutants heterodimerise with E2A, only SMS, containing 
the MyoD HLH domain and SNS (for NeuroSCL HLH domain) but not SES (for 
E2A HLH domain) bind to ETO-2. This may indicate that bHLH heterodimers have 
a stronger affinity to ETO-2 than E2A homodimers and that the tissue specific class
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II bHLH protein is necessary to recruit the repressor complex to specific target 
genes, whereas E2A serves as the ubiquitous anchor protein.
ETO-2/SCL may act as a repressors of gene expression in early erythroid 
differentiation
Previous data have shown that ETO proteins can act as co-repressors of gene 
expression. We performed transactivation studies, which confirmed the repressive 
effect of ETO-2 on the activator function of the pentameric complex. Moreover, 
using in vitro differentiation of fetal liver cells, we could show, that the SCL/ETO- 
2/GFI-1b interaction is lost with erythroid differentiation, whereas the SCL core 
complex also comprising GATA-1 remains intact. Interestingly, we did not see a 
decrease in SCL/mSin3A containing complexes, further indicating, that mSin3A 
may bind to SCL independently of ETO-2 and Gfi-1 b.
Taken together, it is possible that ETO-2 is required in the early stages of erythroid 
differentiation to repress expression of target genes of SCL. Down-regulation of its 
expression then leads to the release of the repressive status and to gene 
activation, therefore allowing terminal erythroid maturation.
This repression may be mediated by recruitment of HDACs. Our preliminary data 
suggests, that ETO-2 and SCL indeed interact with HDAC-3 in MEL cells (data not 
shown). On the other hand, ETO-2 could prevent interaction of SCL with a co­
activator. Co-factors exchange is a commonly used mechanism to regulate levels 
of transcriptional activation. Different classes of transcription factors can recruit 
both co-repressors and co-activators 115 116 as recently exemplified by NF- 
E2p18/MafK whose dimerisation partner switches from co-repressor to co-activator 
during MEL cell differentiation 117.
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Moreover, recent data also suggests that binding of ETO to E2A might lead to 
dissociation of the E2A/p300 interaction139. However, we could not confirm that 
SCL/CBP/p300 containing complexes increased with terminal erythroid 
differentiation and concluded that co-factor exchange involving CBP/p300 was not 
the mechanism underlying ETO-2 mediated repression of gene activation in this 
setting. Finally, ETO-2 could sequester the SCL core complex and prevent its 
binding to DNA.
In order to pursue the functional characterisation of the SCL/ETO-2 interaction in 
haematopoiesis, we have taken both gain-of-function and loss-of-function 
approaches. Thus, we are currently investigating the effects of over-expression of 
ETO-2 or E2A mutants that are unable to bind ETO-2139 on the in vitro 
haematopoietic differentiation of wild-type ES cells.
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FINAL DISCUSSION AND FUTURE DIRECTIONS
The aim of this work was to further define the role of the bHLH transcription factor 
SCL in definitive haematopoiesis and leukaemogenesis. We began with the 
phenotypic characterisation of a transgenic mouse model over-expressing SCL 
under the control of the sca-1 promoter sequences. Ectopic expression of SCL in 
thymocytes and B-lymphocytes led to a profound disturbance of the normal 
differentiation program in these cells although no leukaemia was observed. These 
findings led us to the conclusion that SCL sequestered E2A proteins essential for 
lymphocyte development and that SCL on its own was only weakly oncogenic. 
This, together with other lines of evidence already mentioned above, led us to 
investigate the importance of protein-protein interactions for SCL’s functions, and 
we were able to identify novel SCL partners in erythropoiesis and 
megakaryocytopoiesis. It now seems likely, that SCL can exert both activating and 
repressive function on its target genes depending on the cell type and the stage of 
differentiation examined. We established that the repressor effect in early erythroid 
differentiation is mediated by a co-repressor complex containing ETO-2 and GFI- 
1b and that the underlying mechanism is probably not co-factor exchange involving 
CBP/p300.
We now plan to further characterise the role and mechanism of this interaction in 
erythroid differentiation and leukaemogenesis. We have generated MEL cell clones 
containing biotinylated SSDP2, E2A and ETO-2. These will allow us to further 
elucidate the multi-protein network surrounding SCL. Besides, we will attempt to 
generate transgenic mice expressing a biotinylated version of SCL. This will enable
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us to perform pull-downs on specific cell populations after cell sorting. Moreover, it 
will be critical to find new SCL target genes that might also recruit ETO-2. 
However, one of the principle questions to be addressed remains the exact role 
and mechanism of the ETO-2/SCL interaction in haematopoiesis. To this aim, loss- 
of-function studies of ETO-2 such as siRNA or morpholino will address the role of 
this widely expressed protein in general. In addition, in order to specifically target 
the SCL/ETO-2 complex, it will therefore be essential to identify small molecules or 
peptides inhibiting this interaction. Several publications have recently successfully 
attempted this approach to characterise protein-protein interactions. Using the 
information obtained from the crystal structure of the respective proteins, it has 
been possible to engineer stable peptides that mimic BAD326 or interfere with the 
BCL 6 interaction327. The design of such molecules will not only allow us to answer 
the fundamental questions surrounding protein-protein interactions, but may also 
represent a new approach for future therapeutic drug targeting.
As far as leukaemogenesis is concerned, our preliminary data suggests that ETO-2 
is expressed in the SCL expressing acute T-cell lymphoblastic leukaemia cell line 
Jurkat and that it binds to SCL in this cell type.
Hence, in addition to sequestering E proteins, SCL could recruit repressor 
complexes to genes normally switched on in differentiating T cells. Two papers 
now suggest that both these mechanisms may be operative. Herblot et al 
demonstrated that SCL and LMO-2 overexpression in mice leads to inhibition of 
E2A/HEB function and repression of the pre-Tagene expression, essential for 
normal T cell development149. Consistent with this, O’Neil et al showed that 
expression of an SCL transgene in an E2A or HEB heterozygous background 
promotes development of leukaemia. Using ChIP assays, they demonstrated that
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the SCL/E2A heterodimer recruits the co-repressor complex mSin3A/HDAC1 to 
enhancer elements of genes important for thymocyte differentiation, such as CD4 
and pre-Ta256.
Taken together, these data indicate that, in T-ALL, SCL may form aberrant 
protein complexes, therefore perturbing expression of genes essential for normal 
T-cell differentiation.
However, these aberrant SCL-containing complexes remain to be fully 
characterised and their exact molecular mechanism of action elucidated. Moreover, 
their relevance in human leukaemogenesis needs to be investigated.
In conclusion, we are only beginning to understand how the cross-talk between 
sequence-specific transcription factors and their co-factors regulates gene 
transcription. After the discoveries of genetic code and histone code, study of the 
composition and dynamics of multimeric transcription factor complexes and their 
effects on gene regulation may lead us to the identification of a « transcription 
factor complex code ». Decrypting this code will shed further light on the 
fundamental questions of how gene transcription is controlled and will enable us to 
envisage novel therapeutics for our patients.
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